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Metabolomics aims to identify and quantify all of the small molecules within a cell. The 
relative concentrations of metabolites within cells grown under different experimental 
conditions, or different species, can be compared using pool size data. Exposing cellular cultures 
to isotopically labeled compounds allows the progress of metabolites through metabolic 
pathways to be tracked, known as flux.  In the first experiment, the metabolic effects of exposure 
to lower than optimal temperatures in wild type Salmonella enterica, i.e. cold shock, were 
determined. The metabolites involved in glycolysis, the citric acid cycle, and the pentose 
phosphate pathway had less efficient labeling and smaller pool sizes at lower temperatures. Most 
of the amino acids detected showed less efficient labeling and larger pool sizes at lower 
temperatures, perhaps indicating that proteins were being broken down into amino acids. 
Alternatively, the less efficient labeling may be due to enzymes denaturing reducing the catalytic 
abilities of the cells, a slowdown in the rate of transcription or in the rate of translation. It is 
important to study cold shock in Salmonella enterica, at three temperatures in which 
contamination with the pathogen occurs, in order to see if there is a way to kill the pathogenic 
species more efficiently and limit the people who get ill from consuming Salmonella enterica 
from food contamination.  
The second experiment compared the purH mutant and the wild type strain of Salmonella 
enterica. The purH mutant had the gene that codes for the enzyme AICAR transformylase/IMP 
cyclohydrolase removed. AICAR is important to study since it is involved in many pathways in 
diverse organisms, activates AMP-activated protein kinase in mammals, which affects energy 
balance and the response to metabolic stress, and AICAR accumulation has been linked to an 
inhibition of the proliferation of cancer cells. Metabolites in glycolysis and the citric acid cycle 
were found to label less efficiently or have smaller pool sizes in the purH mutant, with the 
exceptions of those compounds involved in other pathways. The pentose phosphate pathway 
showed similar labeling patterns and larger pool sizes in the purH mutant, indicating that sugars 
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Systems biology attempts to understand how each and every component interacts in the 
system being studied as a whole i.e. the system is more than simply the sum of its components. 
The system is studied by examining the system structures, the system dynamics, and the control 
method. The system structures encompass the actual biochemical pathways, the gene networks, 
and the ways in which the gene network and biochemical pathways regulate phenotypes. The 
system dynamics encompasses the changes that occur due to a disturbance. The control method 
involves looking at regulatory portions of the system.
1
 It is important to study metabolomics on a 
systems biology level, because the genes, metabolites, and phenotypes are all interconnected in a 
vast web that is not fully understood. Changing one gene theoretically may only remove the 
ability to make one protein, enzyme, or metabolite; however, the changes seen on a systems level 




Metabolomics is the study of all of the small molecules (molecules with molecular 
masses less than 1000 atomic mass units) produced by a cell (metabolites).
3, 4
 Metabolomics 
allows a snapshot of cellular biochemistry, showing the concentrations of various metabolites, as 
well as the flow of these metabolites into, out of, and within a cell.
3, 4, 5
   Metabolomics can be 
used not only to determine what a natural state of homeostasis means in terms of metabolite 
concentration and flow (metabolism), but also how metabolite concentrations and flows can 
change under various experimental conditions.
4
 Metabolomics can even determine how 
metabolism changes as a result of a genetic mutation.
4, 6
  In short, metabolomics allows the 
metabolism, the deconstruction and construction of molecules, of an organism to be studied in 
both native and altered states and conditions. Metabolomics is already enhancing the 
understanding of cellular metabolism, the effects of genetic mutations, and the role diseases, 
drugs, and bacterial communication have played.
3,7 ,8, 9, 10
  
Metabolites can be divided into two groups, lipids or water-soluble metabolites.
3
 Lipids 
are the nonpolar and amphiphilic molecules produced by a cell or organism, such as fats, waxes, 




and maintenance of the cellular membranes.
11, 12
 The goal of lipidomics is to identify and 
quantitate lipids found in a given system. Water soluble metabolomics studies, as one would 
expect, all of the water soluble metabolites within a cell. The water-soluble metabolites exist 
transiently, often in very low concentrations, and can play well established metabolic roles 
within the cells or tissues.  Water-soluble metabolites include sugars, cofactors, molecules 
involved in the transfer of electrons, and many other compounds.
3
  
Metabolomics can be studied in one of two ways, in a targeted fashion or in an untargeted 
fashion.
4
 In targeted metabolomics, only a specific set of metabolites is searched for and 
quantitated; whereas in untargeted metabolomics, as many compounds as possible are searched 
for and detected.
 4, 13, 14
 Identification of all unknown compounds in untargeted metabolomics 
studies can be very cumbersome and has not been done fully as of yet.
15
 Targeted metabolomics 
allows screening for biomarkers of disease, illicit drugs, as well as the determination of the 
concentrations of specific metabolites of interest in routine analysis.
16, 17
 Untargeted 
metabolomics allows a broader screening of metabolism. For instance using untargeted 
metabolomics, the determination of the metabolic changes due to differing environmental 
conditions, global changes in metabolism due to disease and drug treatments, or genetic 





    
Metabolomics studies can be done for a wide range of organisms: adherent and non-
adherent bacterial cultures, single-cellular organisms such as yeast or plankton, plants, animal 
tissues or organs, and biological fluids.
20, 7, 19, 21, 16
 In the case of bacterial cultures and single-
celled organisms, cells are grown in liquid media or on agarose or agar plates.
5
 In the case of 
plants, tissues, and organs, experiments may be performed on the entire organism, and samples 
may be removed during the experiment or after the organism has been sacrificed.
22
 Biological 
fluids may be removed from organisms in a fairly non-invasive manner after the entire organism 
has been exposed to the experimental conditions.
16




experiments presented in this thesis, the rest of this introduction to metabolomics methodology 
will be based on working with them.  
Using bacterial cellular cultures as a model, cells may be grown in liquid media or on 
media plates. The bacterial cellular cultures may be exposed to the condition during the initial 
growth phase or after a certain density, or concentration, of cells has been reached.
20
 
Experimental conditions can vary widely, depending on both the questions being asked by the 
study and the optimal conditions of the system (organisms or cells) being studied. Cells grown 
under different conditions may incorporate the components of the media differently into their 
metabolism, indicating that the cellular metabolism under the new conditions has changed.
20
  If 
the media includes an isotopically labeled compound, such as 
13
C labeled glucose, its flux can be 
tracked through various pathways in order to try to determine what changes to metabolism may 
have occurred due to the experimental conditions.
20
  Graphs of the relative percentage of labeled 
metabolite to unlabeled metabolite over time are known as flux graphs and show the 
incorporation of labeled nutrient over time.
5, 23, 24, 25
  For a given pathway of interest, multiple 
metabolites are examined to see how the incorporations of the labeled forms are changing, either 
in pattern or rate.
5, 24, 25
  For instance, if the concentration of unlabeled metabolite is decreasing 
and the concentration of labeled is not increasing, it indicates that there may a chemical reaction 
somewhere in the pathway that is not able to occur causing the metabolite not to be produced. 
To complement this information, data on pool size, which is the concentration of the 
individual metabolites within a cell, can also be gathered.
24
  Pool size can also be thought of as a 
measure of the intracellular concentration of the metabolites before 
13
C incorporation, which can 
help explain the observation of slower labeling.  If an experimental group has a larger pool size 
than the control, then there may be some blockage in the pathway causing it to build up or the 
metabolite may not be used as quickly under the experimental condition.   
In addition, heat maps can be used to compare the effect of conditions.
26
  A heat map 
details the ratio of the relative change in the concentration of a metabolite (pool size data only) in 
the experimental group to the relative change of a metabolite in the control, or another 
experimental group.
26
  If metabolite has a larger concentration in comparison, then it will appear 








In order to get the information needed to construct flux graphs, pool size plots, and heat 
maps, the metabolites must be extracted from the cells.
27
 In this step it is important to stop 
metabolism as quickly as possible (quenching), so that the process of extracting the metabolites 
does not itself affect metabolism.
27
 Often the process for quenching metabolism is the same 
process used to extract the metabolites. Depending on what types of metabolites are being 
studied, different extraction protocols are used targeting either specific classes of metabolites or 
as many metabolites as possible. Once metabolism has been quenched and the metabolites have 
been extracted, they may be detected through  gas chromatography-mass spectrometry (GC-MS) 
or liquid chromatography-mass spectrometry (LC-MS).
28
 GC-MS and LC-MS may be used to 




The instrumental methods gather the raw data that may then be processed and analyzed in 
order to construct flux graphs, pool size plots, and heat maps. The raw data must be processed 
using software such as MAVEN, XCMS, or Xcaliber in order to match metabolites to peaks on 
the spectra by mass to charge ratio (m/z) and retention time by comparison with known standards 
or information from data bases.
29,30
 Exact concentrations of metabolites can be determined 
through the use of internal standards or the relative concentrations between experimental 
conditions, over time, or among isopomers can be calculated.
25
 Once the raw data has been 
processed and the flux graphs, pool size plots, and heat maps have been generated, the analysis 
of the metabolic pathways can begin.
31
 
Flux graphs and pool size plots can be overlaid onto metabolic pathways to determine 
locations where metabolism is not functioning optimally or functioning at all.  Indications of 
suboptimal metabolism include if the unlabeled metabolite disappears and labeled metabolite is 
not present, or if there is a buildup of metabolites further down the metabolic pathway. 
Suboptimal performance may also be indicated by slower labeling or less complete labeling of a 
metabolite as compared to the control conditions. If one imagines that metabolic pathways are 




the items before the blockage will build up, while the items after the blockage will disappear. If 
there is a slow worker on the assembly line, the effect will be similar to the effect of a blockage, 
but to a lesser extent (some items will make it down the assembly line). If there is a very fast 
worker on an assembly line, the items before the worker will be used up quickly and passed 
along the assembly line to the next step just as quickly. After that, the items may reach a more 
normal speed of movement. Flux can be thought of as the speed at which metabolites (items) are 
moving through a metabolic pathway (the assembly line). Pool size can be thought of as the 
amount of items at each station at the beginning of a shift, when there is no movement through 
the assembly line.  
Analytical Instrumentation 
 
Metabolites are largely detected through chromatography-mass spectrometry, due to the 
ability to detect many metabolites simultaneously and the flexibility that the instrumental method 
affords.
24
  Chromatography is used first to separate compounds based on the retention of the 
compound (the time it takes for the compound of interest to travel through the column, the time it 
takes for the compound reaches the mass analyzer in the mass spectrometry portion of the 
method, or the time it takes for the compound of interest to reach the detector in other analytical 
methods). Once the compounds have been separated temporally, they are usually injected 
directly into the ion source of a mass spectrometer. From there, the compounds are ionized and 
separated based on m/z in the mass analyzer portion of the mass spectrometer. The compounds 




Chromatography is used to separate metabolites based on size, charge, or affinity for 
certain ligands. Chromatography separates molecules based upon how much the compounds 
interact with the coating on the column (stationary phase). The mobile phase carries the 
compounds through the column. The competing forces on compounds caused by the stationary 




mobile phase, which moves compounds through the column at different speeds, and therefore 
causes compounds to elute after different amounts of time spent in the column.
32
  
There are two highly used ways chromatography can be done, via normal phase or 
reverse phase chromatography. Normal phase chromatography was used first and consists of a 
polar stationary phase and a nonpolar mobile phase. Normal phase stationary phases include 
polar compounds such as silica based polymers and zirconia, and best separates polar 
compounds. Reverse phase was invented after normal phase and consists of a polar mobile phase 
and a nonpolar stationary phase. Reverse phase stationary phases include hydrocarbon chains, 
such as C-18 or C-10, and best separates nonpolar compounds.  Within these two ways, there are 
also various types of chromatography that can be done. Gas chromatography, liquid 
chromatography, ultra high performance liquid chromatography, and affinity chromatography 
are common forms of chromatography.  
In gas chromatography, volatile and semi-volatile substances are aerosolized and injected 
into the column. These compounds are then carried through the column by a carrier gas and have 
the ability to interact with the coating on the column. The compounds are then eluted in an order 
determined by the boiling point of the compound, the interaction of the compound with the 
column, and the length of the column. An oven can be used in gas chromatography contains the 
column and may be heated in a gradient manner in order to expedite the flow of compounds 
through the column. Compounds that are smaller or have a lower boiling point elute faster in gas 
chromatography.  Gas chromatography is not compatible with nonvolatile substances, 
compounds with boiling points above 450 °C. Suitable compounds for analysis with gas 
chromatography have a relatively low molecular weight (usually below 1000 atomic mass units), 
are thermally stable, have a low boiling point, and are unable to react with the stationary phase or 
mobile phase. Some nonvolatile compounds can be analyzed using gas chromatography after 
derivatization.
33
 Derivatization may be a long process though and may not work with all 
molecules, but allows nonvolatile compounds to be volatilized for analysis via gas 
chromatography. 
Liquid chromatography can be used to separate nonvolatile compounds, semi-volatile 




(UPLC), affinity chromatography, and ion exchange chromatography are types of the broader 
category of liquid chromatography. In liquid chromatography a sample is injected into the 
column, dissolved in the mobile phase, and carried by the mobile phase through the column. One 
or more solutions may be used as the mobile phase in liquid chromatography. As in gas 
chromatography, the compounds are partitioned between the mobile phase and the stationary 
phase. Compounds are eluted from the column based on their size, affinity for the mobile phase 
and stationary phase, and the length and diameter of the column. Typically, in HPLC typically 
particle diameters are 5 µm, while in UPLC particle diameters are less than 2 µm.
34
 UPLC 
differs from HPLC due to the ability of the instrumentation to withstand higher back pressures. 
UPLC allows higher back pressures to be withstood due to the better instrumentation used. This 
allows a small column packed with small particles (diameters smaller than 2 µm) to be used as 
the stationary phase, which leads to be a better separation due to van Deemter forces. Due to the 
small particles size, uniform packing of the particles, and high flow rates sometimes used, the 
sample is moved through the column at a very high pressure. This allows fast and reproducible 
separations.  
Affinity chromatography works by injecting a sample into a column coated with a 
compound that will only bind to the compounds of interest. The compounds coating the column 
attach to a portion of or the entire molecule of interest. The compounds of interest are retained 
and everything else in the sample is washed through the column. The components coating the 
column can then be forced to release the molecules of interest by adding a reagent, known as 
salting the column. Affinity chromatography is very expensive due to the need for ligands 
capable of binding to the compound of interest, and this method is not flexible as compared to 
those methods not requiring ligands. 
In ion exchange chromatography, the stationary phase consists of a coating of charged 
particles. A solution of compounds, dissolved in the mobile phase, goes through the column and 
oppositely charged particles interact with the charged particles in the stationary phase. This 
allows oppositely charged particles to be retained in the column longer than similarly charged 
particles, leading to better separation. A type of ion interaction chromatography is ion pairing 




the components of the sample are dissolved in the mobile phase those of opposite charge interact 
with the ion pairing reagent. The addition of the ion pairing reagent allows the analyte molecules 
to interact with the coating on the column. The interactions between the ion pairing reagents and 
the oppositely charged particles slow down the movement of the compounds through the column 
and allow the compounds to have a longer retention time, which leads to better separation. 
Mass spectrometry 
Gas phase mass spectrometry works by injecting compounds, ionizing the compounds 
using an ionization source, separating mass to charge ratios (m/z), and then detecting the mass to 
charge.
35
 When mass spectrometry is paired to a chromatographic technique, the injection of the 
compounds into the ionization source is based on their elution from the chromatographic column 
used. There are a number of ion sources used in mass spectrometry whose purpose is to ionize 
compounds. Ionization sources include electron ionization (EI), chemical ionization (CI), 
electron spray ionization (ESI), and matrix assisted laser desorption (MALDI).
35
 Some ion 
sources, such as ESI, accomplish ionization by adding protons (positive mode mass 
spectrometry) or removing protons (negative mode mass spectrometry).
36
 Other ion sources 
accomplish ionization by bombarding a molecule with a stream of electrons, such as EI.
37
 Once 
ions have been made they are collected and moved into the mass analyzer either once a certain 
number of ions have been collected or after a certain amount of time has passed.
38
 Having two 
methods of moving ions into the mass spectrometer helps prevents too many ions from getting 
into the mass analyzer and introducing molecular repulsion, diffusion of the ion band, or ion 
suppression.
38
 The separation by m/z is accomplished by utilizing electrical and magnetic fields 
to guide the ions to the desired location within the mass analyzer.
35
 The ions organized by m/z 
are then sent to the mass detector. Detectors also vary widely and can include Faraday cups, 
electron multiplier tubes, and micro channel plate detectors.
35
 Mass spectrometry is one method 
used for metabolomics analysis since it requires a small samples size, it is relatively easy to 
manipulate and detect charged particles, it enables accurate identification via m/z mass 
fragmentation patterns, and retention times when paired with chromatography, and has the ability 




Electron ionization sources have a filament that is heated until electrons are ejected from 
the surface of the metal.
39
 The electrons are attracted to an anode set up on the opposite end of 
the ion source. The sample is vaporized and injected into the ion source perpendicular to the 
filament and between the filament and the anode.
39
 As the electron beam generated by the 
filament moves towards the anode, the electron beam hits the sample, causing ionization and 
often fragmentation.
39
 The fragmentation caused by electron ionization can be extensive, and less 
destructive ionization sources are desirable.
39
 A schematic for an electron ionization source is 
shown in Figure 1.1.  
 Figure 1-1. Electron ionization sources work through colliding the analyte molecules with a beam of 















Electrospray ionization sources work by first injecting the sample into a usually heated 
capillary or needle.
36
 A voltage is applied to the tip of the needle, and an electrode is place across 
from the needle.
36
 The sample forms a Taylor cone as it moves towards the electrode. The Taylor 
cone eventually gets so small that droplets of the sample form. The solvent evaporates from the 
droplets due to the heat, sheath gas, and the continuing dispersion of sample drops into smaller 
drops until single ionized, analyte molecules are produced.
36
 As the solvent evaporates from the 
sample droplets, the charge from the solvent is transferred to the sample droplets. At some 
critical point, the charges on the sample overcome columbic interactions forcing the droplet to 
break into two or more droplets. The breaking apart of the droplets theoretically continues until 
all of the solvent has been removed and only the analytes remain. Electrospray ionization is 
another soft ionization technique, where fragmentation of the analytes is unlikely to occur.
36
 Due 
to the mechanism of ionization used in electrospray ionization, larger molecules may become 
multiply charged, allowing their detection with common mass analyzers.
36
 Figure 1.2 shows a 
schematic of an electrospray ionization source.  
. 
Figure 1-2.  An electrospray ionization source produces a fine spray of charged particles via the formation of a 














Figure 1-3. A MALDI ion source consists of the sample imbedded in the matrix, a pulsed laser, and 
an electrostatic field. 
  
MALDI works by first inserting the sample into a matrix of some sort.
40
 The matrix is 
usually chosen so that the matrix strongly absorbs at the wavelength of laser excitation, the 
analyte should be soluble in the matrix, and the matrix should be stable in a vacuum. Matrices 
absorb energy from the pulsed laser into the matrix and then transfer the energy to the analyte 
molecules embedded within the matrix. A laser is then razed across the surface of the matrix- 
analyte  mixture in short bursts, generating plasmas.
40
 The plasmas generate ions, often by taking 
protons away from the matrix and adding them to the analyte molecules.
40
 The ions are then 
carried into the mass analyzer where separation can occur, followed by detection. MALDI is able 
to ionize compounds that otherwise do not ionize very well, very large or non-volatile 
compounds, including polymers and proteins.
40
 Fragmentation is minimized since the matrix 
largely absorbs the energy of the laser pulses and transfers the energy to the analyte molecules.
40
 
Unfortunately reproducibility between laser bursts is poor, finding an appropriate matrix for the 
sample may be difficult, and quantification is not possible.
40














Figure 1-4. Triple quadrupole mass analyzers consist of three quadrupoles. The first and third 
quadrupoles select ions with the desired range of m/z. The second quadrupole collides the ions passed from the first 
quadrupole with a collision gas, fragmenting the ions further.  
 
Mass analyzers are responsible for separating ions into bands of m/z. Some mass 
analyzers use electromagnetic fields to accomplish the separation, such as the traditional 
magnetic sector mass analyzer; others use the velocity difference due to mass, such as time-of-
flight  (TOF) mass analyzers. The types of mass analyzers vary widely, and a few mass analyzers 
of note are triple quadrupoles (electromagnetic field), time of flight (velocity), reflectron mass 
analyzers (velocity), and ion traps (electromagnetic field). Triple quadrupole mass analyzers, 
when used in selected reaction monitoring mode, consist of a series of quadrupoles. The first 
quadrupole selects ions with a parent m/z. The second quadrupole allows fragmentation of the 
parent ion though collision with an inert gas such as nitrogen. The third quadrupole selects the 
fragmented ions with the desired m/z. The ions are then detected, and a mass spectrum is 



















Figure 1-5. Quadrupoles separate ions based on the stability of their flight through the quadrupole. Ions of 
interest can be selected by changing the voltage and radio frequency applied to the rods.  
 
 
Quadrupoles consist of four parallel metal rods. A direct current voltage is applied to 
each of the rods along with a radiofrequency potential. Ions are injected into the quadrupole and 
will orbit in between the four metal rods with orbits forming based on m/z. Ions orbiting closer to 
the center of the four metal rods will have more stable orbits than ions orbiting further from the 
center of the rods.  Ions with a stable orbit pass through the quadrupole, and the ions selected to 
pass through the quadrupole can be changed by altering the applied voltage and radiofrequency 
potential applied to the four rods. If the ions have a m/z different than the desired one, the ions 
crash into the walls of the quadrupole and are not transmitted through the quadrupole.
41
  
Quadrupole mass analyzers have a mass accuracy of greater than 100 ppm. A quadrupole is 
shown in Figure 1.5. 
Using a triple quadrupole mass analyzer in multiple reactions monitoring mode for 
targeted metabolomics allows the reliable and reproducible quantitation of metabolites and the 
ability to absolutely quantify metabolites.
13
 The triple quadrupole is also highly robust and 






 This method may require optimization, and a standard calibration curve 
for an internal standard in order for absolute quantitation of metabolites.
3
  Unfortunately since 




TOF mass analyzers separate ions by applying an electric field to all of the ions at the 
same instant in time. The ions are accelerated towards the detector. Larger ions will take longer 
to reach the detector than smaller ions, thus accomplishing the separation of ions into bands of 
m/z. Ions may be accelerated at different points within the mass analyzer leading to a larger than 
desirable spread, known as initial spacing distribution, in the bands of m/z until the focal point is 
reached.
42
 After the focal point has been reached, all ions of the same m/z are moving together. 
Reflectron mass analyzers work very similarly to time of flight mass analyzers; except that a 
magnetic field curves the ions back towards the region of acceleration. The reflection of ions is 
accomplished by a series of reflectrons, which are regions with differential voltages applied. The 
differential voltages interact with the charges on the ions and turn the ions around. Ions that were 
accelerated earlier are in effect moving faster and so get turned around in a later series of 
differential voltage plates. This allows the ions with similar m/z to reach the detector in a shorter 
band of time. TOF mass analyzers have a 2-5 ppm mass accuracy, as do reflectron mass 







Figure 1-6. A time of flight mass analyzer applies the same acceleration to all ions. Ions with a heavier mass to 







Figure 1-7. Reflectron mass analyzers accelerate ions in the same manner as time of flight mass analyzers, but 
due to the reflectron of ions back to the detector eliminate the spread of ions due to differential acceleration. 
The faster the ion is moving the further into the electromagnetic fields the ion will travel before being turned around 


















Figure 1-8. Orbitrap mass spectrometers often consist of an ion source, an s-lens, a c-trap, a collision cell, and 




Orbitrap mass spectrometers use an ion trap as a mass analyzer that traps ions using 
purely electrostatic forces. The Exactive Orbitrap Plus mass spectrometer, used in all of the 
studies in this thesis, works by first ionizing compounds and the ions are then moved to a c-trap, 
where they can be transported to either a collision cell for fragmentation or directly to an 
Orbitrap mass analyzer. Figure 1.8 shows the set up for a typical orbitrap mass spectrometer.  
 The important distinction between Orbitrap mass spectrometers and other types of mass 
spectrometers is the specific use of the orbitrap as an ion trap. The Orbitrap ion trap consists of a 
small central electrode and a large outer electrode.
38
 A direct current voltage is applied between 
the two electrodes, generating an electrostatic field.
38
 The ions are injected and consequently 
trapped in this electrostatic field.
38
 Due to the interaction of the charge on the ions and the 
electrostatic field in which the ions are placed, the ions orbit around the central electrode while 
also oscillating.
38
 The frequency of the oscillations is based only on the m/z of the ions and the 
potential between the electrodes.
38
 Since a direct current voltage is applied between the 
electrodes, the m/z actually determines the frequency of oscillations.
38
 A series of orbits are 
Ion source
C-trap









formed around the central electrode, with each orbit having a unique m/z and frequency of 
oscillation.
38
 As the ions orbit around the central electrode and pass near the outer electrode, an 
image charge is generated in the outer electrode.
38
 The image charges are Fourier transformed to 
produce a spectrum of the oscillation frequencies, which can then be transformed into a mass 
spectrum using available computer software.
38
 
The Orbitrap mass spectrometer’s main advantage is its high resolution (up to 150,000), 
which allows metabolites with very small differences in m/z to be separated into different 
peaks.
45
 The Orbitrap mass spectrometer is extremely accurate in finding m/z (2-5 ppm).
45
 Due to 










CHAPTER 2  FINDING THE METABOLIC CHANGES IN SALMONELLA 
























Wild type Salmonella enterica was grown at three different temperatures in order to 
determine the metabolic changes associated with cold shock (the condition resulting from 
exposure to less than ideal temperatures). On three separate days, cultures of S. enterica were 
grown at their optimal temperature of 37 °C until they reached mid-exponential phase.  The 
bacterial cultures were then filtered onto nylon filters and exposed to one of three temperatures, 
37 °C, 25 °C, or 3 °C for thirty minutes. The bacterial cultures were switched to 
13
C labeled 
glucose media, and the metabolism of the cells was quenched while their contents were 
simultaneously extracted after the appropriate amount of exposure (0, 2, 5, 15, 30, 60, or 120 
min) to isotopically labeled glucose. The cellular extracts were then analyzed using UPLC-MS, 
and the results analyzed with the use of MAVEN, cluster, and Java Treeview. Metabolites that 
were detected in glycolysis and the citric acid cycle showed slower or less complete labeling and 
smaller pool sizes at lower temperatures. Metabolites that were detected in the pentose phosphate 
pathway showed slower or less complete labeling and smaller pool sizes. Glutamate, glutamine, 
leucine/ isoleucine, aspartate, and valine showed less complete or slower labeling and larger pool 
sizes indicating the possible breakdown of proteins into amino acids. Alanine showed slower or 
less complete labeling and larger pool sizes at lower temperatures. Alternatively, the less 
efficient labeling may be due to enzymes denaturing, reducing the catalysis abilities of the cells, 
a slowdown in the rate of transcription of DNA into RNA, or a slowdown in the rate of 
translation of RNA into proteins. It is important to study the cold shock of S. enterica at these 
three temperatures (body temperature, the temperature of a kitchen countertop, and the 
temperature of a fridge) in order to see if there is a weakness in the pathogenic bacteria at these 










Stress metabolomics studies the metabolic effects stress has on metabolism.
46
 In essence, 
organisms are placed in unusual conditions in order to determine how those unusual conditions 
affect metabolic rates, metabolic pathways, and the concentrations of metabolites. Stress can be 
caused by a number of different conditions. Heat stress is caused by the placement of organisms, 
or cells, in an environment with a higher than usual temperature.
47
 Cold stress, or cold shock, 
results from the placement of organisms in lower than usual temperatures.
48
 Oxidative stress is 
caused by the addition of an oxidizing agent, such as hydrogen peroxide, to an environment in 
which the organism resides.
49
 Stress can also be caused by placing organisms in environments 
with little (hypoxic) or no (anaerobic) oxygen environments when the organism requires oxygen 
for normal metabolic functions.
50
 Osmotic stress can be caused by adding higher than normal 
concentrations of solutes to an environment, for instance placing a freshwater organism into salt 
water.
51
 Although the responses of organisms to stressors change from species to species and are 
dependent on the type of stressor, the organisms will alter their metabolism in order to mitigate 
any damaging effects the stressor may have.
52
 Organisms may also alter their metabolism to try 
to adept to the new circumstances in which they find themselves.
46
 
It is generally thought that exposure to a stressor of some sort (abnormal temperatures, 
low oxygen levels, exposure to higher solute concentrations, and so on) will cause two types of 
responses from the organism. The first response from the organism is to repair any damage to the 
cells, or organism as a whole, caused by exposure to the stressor.
46, 53
 The second response is 
generally to slow down the rate of growth and cease or drastically reduce reproduction until 
more optimal conditions arrive.
46, 53
 
Many studies have been done on how cold shock affects organisms such as insects and 
plants, but all of the metabolic effects of cold shock have not been elucidated for even these 
groups of organisms.
54,55, 50, 56, 57
 A few studies have looked at how cold shock affects model 
single celled organisms, such as Escherchia coli and yeast, and these studies seem to be making 
headway towards understanding how cold shock affects these two model organisms.
58, 46
 




One study of note was done by the Willmitzer group, and studied the effect of heat stress, 
cold shock, oxidative stress, and nutrient starvation in E. coli on the metabolome and the 
transcriptome. The study looked at how the pool sizes of 93 different metabolites changed after 
the addition of stress as time passed. The concentrations of 15 metabolites changed significantly 
after 10 minutes of stress application, as determined by a p value less than or equal to 0.05 and a 
minimum ratio of 2 between the pool size before stress addition and pool size after stress 
addition. The pool sizes of 5 more metabolites changed significantly after 40 minutes of stress 
application. There was a general decrease in pool size after the application of cold shock for the 
metabolites involved in central carbon metabolism (glycolysis and the citric acid cycle).  The 
pool sizes of many amino acids increased after stress application, any stress application studied, 
during the course of this study as well. E. coli and S. enterica are rather similar organisms, based 
on the size of the genome and the characterization into classes based on physical characteristics. 
Similar results for the S. enterica study to the E. coli study are expected due to the similar 
physical characteristics and genome. The effects of cold shock on some proteins and the 
transcriptome of S. enterica have been studied. The effects of cold shock on the metabolome of 





The wild type strain LT2 of S. enterica, provided by the Down’s lab at the University of 
Georgia, were revived from freezer glycerol stocks and streaked onto rich Diffco, agar media 
plates.
59
  The plates were inoculated at 37 °C until single, isolated colonies appeared. The 
bacterial colonies were removed from the plates and inoculated in rich media for approximately 
six hours. The bacterial cultures were then centrifuged at 3 °C and 13,200 RPM for one minute. 
The media was removed, and the S. enterica cells were suspended in 2 mL of 8.5% NaCl in 
sterile water.  100 µL of the cells in NaCl solution was used to inoculate 5 mL of minimal no 





















to minimize the chance of mutations occurring in the strains due to longer incubation periods.
59
 
The minimal NCE media components are listed in Table 2.1. The growth and extraction of 
metabolites from cells is based on the findings of the Rabinowitz lab.
60
 The cells were allowed to 
grow overnight at 37 °C with continual shaking at 200 RPM; and the next morning, 1 mL of the 
overnight minimal NCE media culture was used to inoculate 50 mL of minimal NCE media, in 
biological triplicate. Once the bacterial cultures reached mid-exponential phase as determined by 
the optical density at 600 nm (OD600 equal to approximately 0.8), 5 mL aliquots of the cultures 
were filtered onto 47 mm nylon filters (manufactured by Fischer Scientific) and placed on 
minimal NCE media agarose plates. Growth curves for each strain were done in a previous 
experiment in order to determine the OD650 correlating to mid-exponential phase, the exact 









Nitrilotriacetic acid    5.3 µM 
MgSO
4
 (anhydrous) 3.75 µM 
MnSO4 *1H2O 1.25 µM 
NaCl 17.1 µM 
FeSO
4
*7H2O 0.4 µM 
CoCl2 0.4 µM 
CaCl2 *2H2O 0.7 µM 
ZnSO4 0.035 µM 
CuSO4 *5H2O 0.04 µM 
Al2(SO4)3 0.039 µM 
H3BO3 0.2 µM 
Na2MoO4 *2H2O 1.2 µM 
Potassium phosphate dibasic crystals 0.021 M 
Potassium phosphate monobasic crystals 0.027 M 




Table 2-2. The average optical densities for each experiment are reported. 
 
 
5, 15, 30, 60, and 120 min of exposure to 7 mM 
13
C glucose plates. The cultures were allowed to 
grow on the filters; nutrients are able to diffuse through the filters and into the cells, for a half 
hour at the desired temperature, 37 °C, 25 °C, or 3 °C. Once that time passed, all but one set of 
filters were placed onto minimal NCE media agarose plates, containing 
13
C labeled glucose. The 
plates were then placed back at the desired temperature until the appropriate amount of exposure 
to the isotopically labeled plates had passed. The cells then had their metabolisms quenched and 
the water soluble metabolites were extracted. 
The quenching and extracting process is started by scraping any media on the bottom of 
the filters off and placing the filters cell side down into petri dishes containing 1.3 mL of 
extraction solvent (40:40:20 HPLC grade methanol: HPLC grade acetonitrile: HPLC grade water 
with 0.1 M formic acid kept at -20 °C). The filters were placed on ice at -20 °C for fifteen min. 
The filters were then taken on ice to the cold room, kept at 3 °C, where the filters were flipped 
over using a serological pipette tip, and the filters were washed with the extraction solvent in the 
petri dish 15 times while rotating the filter in order to remove the cells from the filter. The 
extraction solvent was removed from the petri dish and placed in a microcentrifuge tube. 300 µL 
of chilled extraction solvent was added to the filters, and the filters were washed another 15 
times. This extraction solvent was added to the same microcentrifuge tube containing the first 
round of extraction solvent. The filters were disposed of, and the microcentrifuge tubes were 
centrifuged at 13,200 RPM at 3 °C for five min. The supernatant was placed in a 1 dram vial and 
kept at 3 °C, while the cellular pellet was suspended in 50 µL of chilled extraction solvent. The 
microcentrifuge tubes containing the lysed cells were transported on ice to a -20 °C freezer 
where they remained for another fifteen min. The microcentrifuge tubes were then transferred on 







ice back to the cold room and centrifuged for five min at 3 °C and 13,200 RPM. The supernatant 
was added to the corresponding 1 dram vial, and the cell pellet was suspended in 50 µL of 
chilled extraction solvent. The lysed cells were transferred on ice back to the -20 °C freezer and 
left there for a final fifteen min. The microcentrifuge tubes were then taken back to the cold 
room on ice, and centrifuged for a final five min at 3 °C and 13,200 RPM. The supernatant was 
placed in the corresponding 1 dram vial, and the cell pellet was disposed of. The 1 dram vials 
were then placed in a nitrogen drying apparatus until the contents of the vials were dry. The 
residues in the vials were suspended at 3 °C with 300 µL of chilled sterile water and the contents 
were transferred to an autosampler vial. The samples were then ready for detection on the UPLC-
MS system. This entire procedure was done on three different days, one day was assigned for 
each temperature. All three experiments were completed within the same week, and all of the 
UPLC-MS detection was also accomplished within that week. 
The UPLC-MS system was controlled by Xcalibur (Thermo Scientific), and the methods 
used for separation and detection are those reported by the Rabinowitz lab.
61
 The MS was 
calibrated and tuned by direct injection before use with the use of Thermo Scientific’s negative 
mode ESI standard calibration mix as well as with a mixture of polytyrosine-1,3,6, 1 µM 
glutamic acid, and 3 µM aspartic acid in HPLC grade water with 0.1 percent formic acid.  The 
separation was accomplished using a Synergy Hydro-RP column (100 mm x 2 mm with 2.5 µm 
sized particles) and a reverse-phase gradient using tributylamine (TBA) as an ion-pairing 
reagent. The mobile phase gradient uses varying mixtures of two mobile phases: solvent A 
consists of 97:3 HPLC grade water: HPLC grade methanol with 10 mM tributylamine and 15 
mM acetic acid; while, solvent B is HPLC grade methanol. The gradient lasts 25 min and is: 0.0 
min, 0% B; 2.5 min, 0% B; 5.0 min, 20% B; 7.5 min, 20% B; 13 min, 55% B; 15.5 min, 95% B; 
18.5 min, 95% B; 19 min, 0% B; 25 min, 0% B. The gradient is summarized in the Figure 2.1 
below. The flow rate through the column is held at a constant 200 µL per minute and the 
temperature of the column is kept at 25°C. The autosampler tray is kept at 4°C, and 10 µL of 









As compounds are eluted from the column they are injected directly into an ESI source. 
Nitrogen acted as the sheath gas, auxiliary gas, and sweep gas. The flow rates were 25 arbitrary 
units, 8 arbitrary units, and 3 arbitrary units for the three types of gas, respectively. The spray 
voltage in the ion source was set to 3 kV, the capillary temperature was set at 325 °C, the 
capillary voltage was set at -50 V, and the tube lens voltage was set at -100 V. 
The MS was set to scan in the following m/z at the following times: from 0.0 to 5.0 min, 
the range of 85 to 800 m/z units, from 5.0 to 6.7 min, the range of 100 to 800 m/z units, from 6.7 
to 6.9 min, the range of 85 to 800 m/z units, from 9.0 to 16 min, the range of 110 to 1000 m/z 
units, and from 16 to 24 min, the range of 220 to 1000 m/z units. The m/z scanning range was 
raised from 85 to 110 between 9 to 16 minutes in order to allow sulfates and phosphates to elute 
without entering the mass analyzer and causing space charge effects. The scanning ranges are 
summarized in the Table 2.3. 
The raw data , displayed as a total ion chromatogram in Figure 2.2, was converted to the 
format of MZML files, using msconvert.
62
 The MZML files were then loaded in software 
program MAVEN, where all peak detection and integration was performed on the data, including 
the blanks analyzed during the experiments.
63
 MAVEN allows large amounts of data to be 
processed together with visualization of the peaks given by ion count versus retention time for a 
Figure 2-1.The mobile phase gradient is shown. Solvent A (blue) consists of 97:3 water: 




given m/z windows, an example of which is shown in Figure 2.3.
63
 The MZML files were loaded 
into MAVEN. The peaks were then aligned using the parameters shown in Table 2.4. Automatic 
peak detection was then performed using the parameters shown in Figure 2.4. The chromatogram 
is searched for peaks for each metabolite of interest. The correct peaks are chosen  by hand based 
on labeling patterns, pool size information, consistency between replicates, peak shape, and 





Figure 2-2.The total ion chromatogram can be viewed using Xcaliber. The time point 0 









Table 2-3. The scanning ranges for each range of retention times are summarized below. The 
scanning ranges for the mass spectrometer can be set up so as to scan only the relevant mass to charge ratio ranges 








Time (min) Scanning range (m/z) 
0.0 to 5.0 85.0 to 800 
5.0 to 6.7 100 to 800 
6.7 to 6.9 85.0 to 800 
9.0 to 16 110 to 1000 
16 to 24 220 to 1000 
Figure 2-3. The extracted ion chromatogram for glutamine is shown here. MAVEN allows the extraction of a 



















All of the samples were analyzed with a 20 ppm m/z window surrounding the theoretical 
m/z for each metabolite and their isotope labeled partners for flux analysis (theoretical m/z ± 20 
ppm). The samples taken before the addition of 
13
C labeled glucose were also analyzed with a 5 
ppm window surrounding the theoretical m/z of each metabolite in order to generate a heat map.  
 
Parameter value 
Group must contain at least [X] good peaks 2 peaks 
Limit total number of groups in alignment 
to 
1000 groups 
Peak grouping window 20 scans 
Minimum peak intensity 5000.00 
Minimum peak S/N  5 
Minimum peak width 5 scans 
Maximum number of iterations 10 





Figure 2-4. The parameters used for automatic peak detection by MAVEN are shown above. Multiple peaks 
are detected for each metabolite with this method and the best group of peaks for each metabolite is chosen by hand 




A spreadsheet of the integrated peaks, m/zs and retention times of the peaks, as well as 
the peak identities were exported into Microsoft Excel where further analysis was done. The flux 
data was used to make flux graphs showing the relative percentage of the parent compound 
(unlabeled) and each labeled form of the metabolite versus time of exposure to the isotope for 
each metabolite. Pool size graphs were also made using the total ion counts from the mass 
spectra within the m/z window at the appropriate retention time for each metabolite, allowing the 
comparison of the pool sizes of each metabolite between the cultures grown at 37, 25, and 3 °C. 
P values for the pool size data were determined for all of the metabolites detected. P values are a 
measure of statistical significance. A p value of 0.01 is considered very significant and correlates 




comparing the log transformed relative changes between the cultures was made by first log 
transforming and clustering the information with the program Cluster 3.0.
64
 Java Treeview then 
used the information generated by Cluster 3.0 to make a heat map showing the relative changes 
in concentration before the addition of isotope labeled compound for each metabolite detected.
65
 
The flux graphs, pool size plots, and heat map were all compared to metabolic pathways using 
the KEGG database in order to find the differences in the metabolic pathways between the 
differences between the cultures grown at the three different temperatures. 
Results and Discussion 
 
Flux graphs, pool size information, and heat maps have been generated and overlaid onto 
a number of pathways. The heat map for all of the known metabolites detected is shown in 
Figure 2.5. In the glycolysis pathway, the lower temperatures show less complete labeling and 
slower labeling than the warmer temperatures. The colder temperatures also show smaller pool 
sizes. Glucose-6-phosphate, fructose-6-phosphate, fructose-1,6-bisphophate, 1,3-
disphoglycerate, and pyruvate all showed slower or less complete labeling and smaller pool sizes 
at the lower temperatures. Glyceraldehyde-3-phosphate, dihydroxyacetone (DHA), 3-phospho-
glycerate, 2-phosphoglycerate, and phosphoenolpyruvate were not detected in this series of 
experiments. Metabolites may not be detected if they are at too low of a concentration within the 
cell, if they are not extracted efficiently with the water soluble extraction procedure, or if the 
metabolites degrade quickly during extraction or before analysis with the UPLC-MS set up. 
Glucose/fructose-6-phosphate showed full labeling occurring in only 50% of the molecules 
detected at 2 min for the 3 °C bacterial cultures, but full labeling occurred for 80% of the 
molecules detected at 2 min for the two higher temperatures. The pool sizes have a fold change 
of 0.77 for 37 vs. 25 °C (p value= 0.36) and 0.73 for 37 vs. 3 °C (p value= 0.18). P values are a 
measure of statistical significance. Fructose-1,6-bisphosphate showed a dramatic decrease in the 
percentage of molecules detected that showed full labeling in the 3 °C cultures, 50% labeled as 
opposed to 90% labeling at the higher temperatures. The pool sizes have a fold change of 1.53 




follows the same pattern as fructose-1,6-bisphosphate; the 3 °C time point of 2 min shows 50% 
of the molecules detected fully labeling, while at the higher temperatures 90% of the molecules 
detected at the 2 min time point show full labeling. The pool sizes have a fold change of 1.31 for 
37 vs. 25 °C (p value= 0.41) and 39.2 for 37 vs. 3 °C (p value= 0.03).  Pyruvate showed 60% of 
molecules fully labeling at the 20 min time point for the 3 °C bacterial cultures. The 25 °C 
bacterial cultures showed 80% of the molecules labeling at 5 min, while the 37 °C showed 90% 
of the molecules detected at the 2 min time point. The pool sizes have a fold change of 0.73 for 
37 vs. 25 °C (p value= 0.66) and 7.17 x 10-4 for 37 vs. 3 °C (p value= 0.18).  Metabolites are 
moving less efficiently through the glycolysis at lower temperatures. Figure 2.6 summarizes the 
results for glycolysis, Figure 2.7 displays the flux graphs, and Figure 2.8 displays the pool size 






Figure 2-5. Heat map of metabolites detected for the experiment testing cold shock in S. enterica. The relative 
pool sizes for each metabolite is visualized as a heat map, where relative increases in concentration are shown in red 
and relative decreases in concentration are shown in blue. Metabolites are organized by metabolic pathway through 







Figure 2-6. The glycolysis pathway is shown. Grey boxes in the cycle indicate metabolites that were not detected. 
























Figure 2-7. The flux graphs for the metabolites involved in glycolysis are shown. C0 refers to the unlabeled 
metabolite. C1 refers to the metabolite containing 1 
13










Figure 2-8. The pool size plots for the metabolites involved in glycolysis are shown. *** refers to a comparison with a p 
value ≤ 0.01. ** refers to a comparison with a p value ≤ 0.05. * refers to a p value ≤ 0.1. 
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Every metabolite that is detected in the citric acid cycle also shows slower or less 
efficient labeling and smaller pool sizes. Alpha-ketoglutarate, succinyl-coA, succinate, fumarate, 
and malate were detected. Citrate, cis-aconitate, isocitrate, and oxaloacetate were not detected in 
this series of experiments. Alpha-ketoglutarate showed essentially no labeling in the 25 °C 
bacterial cultures; while the 3 °C bacterial cultures showed 30% of the molecules detected being 
labeled with 2 
13
C after 120 min. The 37 °C bacterial cultures showed 30% full labeling after 5 
min and nearly 80% full labeling after 120 min. The pool sizes have a fold change of 6.09 x 10
4
 
for 37 vs. 25 °C (p value= 0.13) and 3.25 for 37 vs. 3 °C (p value= 0.23).  Succinyl-coA did not 
show any labeling. The pool sizes have a fold change of 0.34 for 37 vs. 25 °C (p value= 0.15) 
and 3.57 for 37 vs. 3 °C (p value= 0.34). Labeling with different numbers of 13C indicates that 
different routes are being utilized to make the metabolites in question. 80% of the succinate 
molecules detected displayed full labeling after 20 min at 37 °C; while only 5% of the succinate 
molecules detected display full labeling at 3 °C. The 25 °C bacterial cultures show 70% labeling 
with 2 
13
C at 20 min. The pool sizes have a fold change of 4.10 x 10
5
 for 37 vs. 25 °C (p value= 
0.16) and 31.1 for 37 vs. 3 °C (p value= 0.17).  Fumarate shows 80% of the molecules detected 
fully labeled after 20 min at 37 °C. Fumarate was in the noise range in the 25 °C bacterial 
cultures.  In the 3 °C bacterial cultures, 60% of the molecules detected labeled with 3 13C after 60 
min. The pool sizes have a fold change of 13.9 for 37 vs. 3 °C (p value= 0.04).  Malate showed 
60% of the molecules detected fully labeling after 2 min at 37 °C, but only 40% of the molecules 
detected labeled with 3 
13
C after 20 min at 3 °C. Malate was not detected in the 25 °C bacterial 
cultures. The pool sizes have a fold change of 2.58 x 10
5
 for 37 vs. 25 °C (p value= 9.09 x 10-4) 
and 15.5 for 37 vs. 3 °C (p value= 3.49 x 10-5).   Compounds may not be detected in the case of 
the 25 °C cultures due to a problem with the extraction or UPLC-MS method, since the three 
experiments were performed on three different days. Figure 2.9 shows a summary of the 
metabolites in the citric acid cycle overlaid with colored boxes denoting the less efficient 
labeling and the smaller pool sizes at lower temperatures, Figure 2.10 displays the flux graphs, 







Figure 2-9. The citric acid cycle is shown. White boxes in the cycle indicate metabolites that were not detected. 
Blue boxes indicate metabolites with slower or less complete labeling and smaller pool size at lower temperature 




































detected at 25 °C. 
Compound not 
detected at 25 °C. 
Fumarate 
Compound not 






  Figure 2-11. The pool size graphs for the metabolites involved in the citric acid cycle are shown. *** refers to a comparison with 
a p value ≤ 0.01. ** refers to a comparison with a p value ≤ 0.05. * refers to a p value ≤ 0.1. 
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The pentose phosphate pathway shows smaller pool sizes or less efficient labeling for all 
compounds detected for the 3 °C cultures, compared to the 37 °C. Glucose-6-phosphate, 
ribulose-5-phosphate, ribose-5-phosphate, xyulose-5-phosphate, 6-phosphogluconate, 
sedoheptulose-7-phosphate, and fructose-6-phosphate all show less complete or slower labeling 
patterns with smaller pool sizes at lower temperatures. Glyceraldehyde-3-phosphate and 
erythose-4-phosphate were not detected in this series of experiments. 6-phosphogluconate 
showed full labeling of 90% of the molecules detected after 2 min in the 37 °C and 25 °C 
bacterial cultures. The 3 °C bacterial cultures were not detected. The pool sizes have a fold 
change of 0.45 for 37 vs. 25 °C (p value= 0.10) and 157 for 37 vs. 3 °C (p value= 0.17).  Ribose/ 
ribulose/ xyulose-5-phosphate showed full labeling of 90% of the molecules detected after 2 min 
at 37 °C, but only 30% of the molecules detected showed full labeling after 15 min in the 3 °C 
bacterial cultures. The 25 °C bacterial cultures for ribose/ribulose/xyulose-5-phosphate were not 
detected.  The pool sizes have a fold change of 4.28 x 10
13
 for 37 vs. 3 °C (p value= 0.30).  
Sedoheptulose-1/7-phosphate shows full labeling of 90% of the molecules detected at 37 °C after 
2 min and 80% of the molecules detected show full labeling after 2 min at 25 °C. Only 20% of 
the molecules detected show full labeling at 3 °C after 15 min. The pool sizes have a fold change 
of 0.45 for 37 vs. 25 °C (p value= 0.23) and 0.53 for 37 vs. 3 °C (p value= 0.19).   Figure 2.10 
shows the pentose phosphate pathway with colored blocks indicating whether the warmer or 
colder temperatures had faster or more complete labeling and larger pool size, Figure 2.11 shows 










 Figure 2-12. The pentose phosphate pathway is shown. Grey boxes in the pathway indicate metabolites that were 
not detected. Blue boxes indicate metabolites with slower or less complete labeling and smaller pool size in the 


















Figure 2-13. The flux graphs for the metabolites involved in the pentose phosphate pathway, excepting those 
that have already been shown, are shown here. *** refers to a comparison with a p value ≤ 0.01. ** refers to a 









The amino acids that are detected largely show slower or less complete labeling and 
larger pool size at lower temperatures, indicating that perhaps more amino acids are being 
produced by the breakdown of proteins. Alternatively, the less efficient labeling may be due to 
enzymes denaturing, reducing the catalytic ability of the cells, a slowdown in the rate of 
transcription, or a slowdown in the rate of translation. Glutamate, glutamine, aspartate, leucine/ 
isoleucine, and valine all show less complete or slower labeling and larger pool sizes at lower 
temperatures, indicating that perhaps proteins are being degraded into their amino acids. Alanine 
showed less complete or slower labeling and smaller pool sizes at lower temperatures. None of 
the other amino acids were detected in this series of experiments. 70% of the glutamate 
molecules detected show full labeling after 20 min at 37 °C, while only 15% of the glutamate 
molecules show labeling with 2 
13
C after 20 min at 3 °C. Glutamate was not detected at 25 °C. 
The pool sizes have a fold change of 0.47 for 37 vs. 3 °C (p value= 0.08).  90% of the glutamine 
molecules detected showed full labeling after 20 min at 37 °C. 40% of all glutamine molecules 
showed labeling with 2 
13
C after 120 min at 3 °C. Glutamine was not detected at 25 °C. The pool 
sizes have a fold change of 1.38 x 10
14
 for 37 vs. 3 °C (p value= 0.20).   60% of the aspartate 
molecules detected showed full labeling after 2 min at 37 °C. 50% of the aspartate molecules 
detected showed labeling with 3 
13
C after 20 min at 3 °C. Aspartate was not detected at 25 °C. 
The pool sizes have a fold change of 0.43 for 37 vs. 3 °C (p value= 0.06).  90% of the alanine 
molecules detected showed full labeling after 2 min at 37 °C, while 80% of the alanine 
molecules detected showed labeling with 2 
13
C after 2 min at 3 °C. Alanine was not detected at 
37 or 25 °C, but was detected at 3 °C. 80% of the valine molecules detected showed full labeling 
after 2 min at 37 °C, while only 60% of the valine molecules detected showed full labeling after 
120 min at 3 °C. Valine was not detected at 25 °C. The pool sizes have a fold change of 0.53 for 
37 vs. 3 °C (p value= 0.05).  Full labeling of 60% of the molecules of leucine/ isoleucine was 
detected after 5 min at 37 °C and only 10% of the molecules detected fully labeling after 120 min 
at 3 °C. Leucine/ isoleucine was not detected at 25 °C. The pool sizes have a fold change of 1.08 




Figure 2.15 shows the pool size graphs. The labeling and pool size information about the amino 




Table 2-5. The amino acids are grouped according to their labeling efficiencies and their pools sizes. The fold 
changes and p values shown here are for the 37 to 3 °C. 
Amino acid Fold change P value 
Glutamate 0.465 0.077 
Glutamine 1.38 x 10
14
 0.195 
Aspartate 0.429 0.0585 
Leucine/ Isoleucine 1.08 0.878 





















Figure 2-15. The flux graphs for leucine/isoleucine and valine, as well as the pool size graphs for all of the 
amino acids are shown. *** refers to a comparison with a p value ≤ 0.01. ** refers to a comparison with a p value 
≤ 0.05. * refers to a p value ≤ 0.1. 
 Alanine 
Compound not 
detected at 25 °C. 
Leucine/ isoleucine 
*37, 3 °C; 
**37, 3 °C 
*37, 3 °C; 
***37, 3 °C  
**37, 3 °C 
***37, 3 °C; 
**37, 3 °C  
*37, 25 °C; **37, 3 °C; 





There are metabolic differences between S. enterica cultures grown at 37 °C and the 
cultures grown at 25 and 3 °C. Metabolites that were detected in glycolysis and the citric acid 
cycle show less efficient labeling and smaller pool sizes at lower temperatures, in agreement 
with the E. coli study done by the Willmitzer lab.
46
 Metabolites that were detected in the pentose 
phosphate pathway show less efficient labeling and smaller pool sizes. Five of the six amino 
acids detected showed less efficient labeling and larger pool sizes indicating that those amino 
acids might be produced by the breakdown of proteins, in agreement with the E. coli study done 
by the Willmitzer lab.
46
 Conversely, the less efficient labeling may be due to enzymes 
denaturing, reducing the catalytic ability of the cells, a slowdown in the rate of transcription, or a 
slowdown in the rate of translation. The remaining amino acid showed less efficient labeling and 
smaller pool sizes at lower temperatures, indicating the possible conversion into other 
metabolites. It is important to study cold shock in S. enterica in order to kill the pathogenic 
species more effectively at the three temperatures studied so that contaminated food or surfaces 















CHAPTER 3  
FINDING THE DIFFERENCES DUE TO THE PURH GENETIC 




























In this set of experiments, the purH355 mutant, strain DM2, and the LT2 wild type strain 
of Salmonella enterica were compared metabolically via metabolomics and kinetic flux 
profiling
59
. The purH mutant has the genome sequence coding for the production of the enzyme 
AICAR transformylase/IMP cyclohydrolase changed via the insertion of a thymidine into 
position 716. The insertion leads to a frame shift mutation that leads to the improper formation of 
ACIAR transformylase/IMP cyclohydrolase. AICAR transformylase/IMP cyclohydrolas 
catalyzes the reaction needed to convert aminoimidazole carboxamide ribotide (AICAR) into 
FICAR. It is important to study AICAR since it is involved in many pathways in diverse 
organisms, is involved in energy balance and the stress response of the metabolome in mammals, 
and has been linked to an inhibition in the proliferation of cancer cells. Due to the lack of 
AICAR transformylase/IMP cyclohydrolase, the purH mutant cannot make purines and so can 
act as a model for humans taking sulfa drugs. Humans taking sulfa drugs as well as the purH 
mutant show the buildup of amino-carboxamide ribonucleotide (AICAR) and the inhibition of 
purine metabolism.
59
 The cellular strains were grown under the same conditions, and their 
contents were extracted before analysis with UPLC-MS.  Metabolites involved in glycolysis and 
the citric acid cycle were largely found to label slower or have smaller pool sizes in the purH 
mutant. Notable exceptions in the citric acid cycle include those compounds involved in other 
pathways. The non-oxidative portion of the pentose phosphate pathway shows comparable 
labeling patterns and larger pool sizes in the purH mutant, indicating that sugars may be 
preferentially traveling through the pentose phosphate pathway instead of glycolysis and the 
citric acid cycle.  
Introduction 
Untargeted metabolomics can be used in order to compare different types of organisms, 
either different species, mutations of species, or the mutated species to the wild type may be 
compared. Untargeted metabolomics is needed in this type of analysis, since a genomic mutation 
may affect metabolites that are involved in metabolic pathways intersecting the pathway affected 
by the mutation.
66




identified, they may be grown under similar conditions, and their metabolic contents extracted 
for metabolomic analysis. The relative concentrations of metabolites may be compared to see if 
one species or mutant produces more of any given metabolite than another. Some metabolites 
may be found in one species or mutant, but not detected in another. The pathways with which or 
efficiencies in which species or mutants move compounds through their catabolic or anabolic 
pathways may also differ. Metabolomics is a useful tool for identifying changes in species and 
mutants, because metabolites are the second to end result of any differences in the genome, with 
the phenotypes of the organism being the end result.
66
   
Experimental Procedures 
 
The wild type and purH mutant strains, provided by the Down’s lab at the University of 
Georgia, were revived from freezer glycerol stocks and streaked onto rich Diffco, agar media 
plates.
59
  The experimental procedure detailed in chapter two was followed for each of the 
strains, with a few changes. Instead of performing the experiments at three different 
temperatures, only the optimal temperature for S. enterica, 37 °C, was used. The wild time strain 
of S. enterica was moved onto unlabeled minimal NCE media plates at an average OD650 of 
0.518 and the purH mutant was moved onto unlabeled minimal media plates at an OD650 of 
0.540. During the analysis phase of the experimentation, automatic peak detection was not 
utilized using MAVEN. Instead peaks were picked manually using labeling, peak shape, 
closeness of retention time to the expected retention time, and consistency between replicates. 
The rest of the experimental procedure and analysis was performed in a similar manner as 
explained in chapter two.  
Results and Discussion 
 
A heat map showing the relative changes in all of the known metabolites detected is 
shown in Figure 3.1. In the glycolysis pathway, glucose-6-phosphate, fructose-6-phosphate, and 




however, pool size in the purH strain is higher than in the wild type strain. Glucose/fructose-6-
phosphate showed full labeling occurring in 70% of the molecules detected after 2 min in the 
wild type strain and in the purH mutant. The pool sizes have a fold change of 0.66 (p value= 
0.04). Approximately 80% of the fructose-1,6-bisphosphate molecules detected showed full 
labeling after 2 min in both  the wild type and the purH mutant strains. The pool sizes have a 
fold change of 1.96 (p value= 6.74 x 10
-3
). 1,3-diphosphoglycerate was not detected. In 3-
phosphoglycerate and 2-phosphoglycerate (not differentiable in the methods used, so this is 
probably a combination of the two metabolites), isotopic labeling did not occur in the purH 
mutant. The pool sizes have a fold change of 0.33 (p value= 4.45 x 10
-4
). This may indicate that 
3-phosphoglycerate and 2-phosphoglycerate are not being synthesized or entirely used in further 
reactions. Very little isotopic labeling occurred in the wild type strain in the case of 3-
phosphoglycerate and 2-phosphoglycerate as well; however, after this point in the glycolysis 
pathway, the purH shows consistently smaller pool sizes. Phosphoenolpyruvate was not detected 
in this analysis due to the unstable nature of the compound. Pyruvate showed full isotopic 
labeling in both strains, but was not detected within the 5 ppm window used to look at pool size. 
This indicated that the flux of pyruvate was slower in the purH mutant than in the wild type 
strain. 80% of the pyruvate molecules detected were fully labeled after 5 min in the wild type 
strain, while only 60% of the pyruvate molecules detected were fully labeled after 5 min in the 
purH mutant strain. In Figure 3.2, the glycolysis pathway is shown with colored boxes indicating 
which strain had faster or more complete labeling and larger pool size and Figure 3.3 displays 







Figure 3-1. The heat map shows the log base 2 concentrations of all known metabolites detected in the purH 
mutant relative to the concentrations of the metabolites found in the wild type strain. The color bar on the 
lower right hand side shows the colors associated with the relative change in metabolite concentration between the 










Figure 3-2. The glycolysis pathway is shown. Grey boxes in the cycle indicate metabolites that were not detected. 
Blue boxes indicate metabolites with slower or less complete labeling and smaller pool size in the purH mutant. Red 
boxes indicate metabolites with faster or more complete labeling and larger pool size in the purH mutant. A red “X” 
denotes the location where the larger relative rates of metabolic flux and pool size change from the purH mutant 






















Labeling not detected 






Figure 3-3. The flux and pool size graphs for the metabolites involved in glycolysis 
are shown. *** refers to a comparison with a p value ≤ 0.01. ** refers to a comparison 




In the citric acid cycle, the pool sizes for the metabolites are smaller in the purH strain 
than in the mutant strain, except where metabolites are involved in multiple pathways. Entering 
into the citric acid cycle, pyruvate showed a smaller pool size in the purH mutant. Cis-asconitate 
and isocitrate were not detected in these experiments. Alpha-ketoglutarate and succinate also 
showed full isotopic labeling in the wild type and the purH mutant, as well as a smaller pool size 
in the case of the purH mutant. Only 40% of the alpha-ketoglutarate molecules detected show 
full labeling after 5 min in the wild type strain and 60% of the alpha-ketoglutarate molecules 
detected show full labeling after 15 min in the purH mutant.  The pool sizes have a fold change 
of 0.66 (p value= 1.04 x 10
-3
). Succinate molecules showed full labeling in 80% of the molecules 
detected in the wild type strain and in the mutant strain after 20 min. The pool sizes have a fold 
change of 0.43 (p value= 3.30 x 10
-5
).  Succinyl-coA did not show labeling in the case of the 
purH mutant or in the wild type strain. Succinyl-coA was not detected within the 5 ppm error 
range used for pool size analysis. Fumarate did not display any labeling in the wild type strain, 
but 70% of the fumarate molecules detected showed full labeling after 20 min in the purH 
mutant strain. The pool sizes have a fold change of 0.28 (p value= 0.27). Fumarate is involved in 
the urea cycle. Malate shows isotopic labeling in both the wild type and the purH mutant strains 
and shows a larger pool size in the purH mutant. Malate showed full labeling in 70% of the 
molecules detected after 20 min in the wild type strain and the purH mutant strain The pool sizes 
have a fold change of 3.17 (p value= 0.14).  Malate is also involved in other metabolic pathways 
Figure 3.13 shows the citric acid cycle with colors indicating relative increase, decrease, or no 
change in metabolic flux for each metabolite and Figure 3.14 shows the flux and pool size graphs 







Figure 3-5. The citric acid cycle is shown above. White boxes in the cycle indicate metabolites that were not 
detected. Blue boxes indicate metabolites with slower or less complete labeling and smaller pool size in the purH 
mutant. Red boxes indicate metabolites with faster or more complete labeling and larger pool size in the purH 




































Figure 3-6. The flux graphs for the metabolites involved in the citric acid cycle are shown. *** refers 





Labeling not detected 







In the oxidative part of the pentose phosphate pathway, glucose-6-phosphate and 6-
phospho-D-gluconate show comparable labeling patterns and a larger pool size in the purH 
mutant. 6-phosphogluconate showed full labeling in 90% of the molecules detected after 2 min 
in the wild type and the purH mutant strains. The pool sizes have a fold change of 1.64 x 10
3
 (p 
value= 0.07). 6-phosphogluconolactone was not detected in this experiment. In the non-oxidative 
part of the pentose phosphate pathway, for every metabolite that was detected, except erthyrose-
4-phosphate, full isotopic labeling was found in the wild type and purH mutant, with larger pool 
sizes being found in the purH mutant strain. Ribose/ ribulose/ xyulose-5-phosphate showed full 
labeling in 90% of the molecules detected after 2 min in the purH mutant, but labeling was 
detected for the wild type strain. Ribose/ ribulose/ xyulose-5-phosphate was not detected within 
the 5 ppm error window used for the pool size analysis. Sedoheptulose-1/7-phosphate showed 
full labeling in 95% of the molecules detected after 2 min in the wild type and the purH mutant 
strains. The pool sizes have a fold change of1.20 (p value= 0.56). Erythrose-4-phosphate showed 
no isotopic labeling in the wild type or the purH mutant strains. The pool sizes have a fold 
change of 0.87 (p value= 0.80). This data shows that the pentose phosphate pathway is being 
unregulated in the purH mutant strain of S. enterica. The pentose phosphate pathway may be 
allowing the purH mutant to continue to function without the presence of fructose-1,6-
bisphosphatase. The pentose phosphate pathway is shown in Figure 3.18 with colored boxes 
indicating which metabolite had faster or more complete labeling, as well as a larger pool size 










Figure 3-9. The pentose phosphate pathway is shown above. Red boxes indicate metabolites with faster or more 
complete labeling and larger pool size in the purH mutant. Grey boxes in the pathway indicate metabolites that were 


















Figure 3-10. The flux graphs for the metabolites involved in the pentose phosphate pathway that 
were not already shown are shown here. *** refers to a comparison with a p value ≤ 0.01. ** refers to a 
comparison with a p value ≤ 0.05. * refers to a p value ≤ 0.1. 
 6-phosphogluconate 
Ribose/ ribulose/ xyulose-5-phosphate 
Labeling not detected 
in purH strain 
Sedoheptulose-1/7-phosphate 
Not detected within 
the 5 ppm error 






Due to the mutation found in the purH mutant, the mutant is unable to synthesize purines 
and so purine metabolism was also studied in this experiment. 5-phosphoribosyl-1-
pyrophosphate showed slower or less complete labeling or smaller pool sizes in the purH mutant 
as compared to the wild type strain. 5-phosphoribosyl-1-pyrophosphate, phosphoribosylamine, 
glycinamide ribonucleotide, N-formylglycinamide ribonucleotide, N-formylglycinamidine 
ribonucleotide, carboxyaminoimidazole ribonucleotide, N-succinocarboxyamide-5-
aminoimidazole ribonucleotide and FICAR were not detected in this series of experiments. 
AICAR molecules showed labeling with 6 
13
Cin 80% of the molecules detected in the wild type 
strain after 2 min. AICAR molecules showed labeling with 5 
13
C in 60% of the molecules 
detected after 60 min. AICAR was not detected within the 5 ppm error window used in the pool 
size analysis. IMP did not display a significant difference between the wild type and purH 
mutant strains. Labeling of IMP was not detected in the wild type or the purH mutant strains; 
IMP was not detected within the 5 ppm error window used for the pool size analysis. In the 
experiments done here, purine and thiamine were added to the media containing the cells, since 
that should provide the cells with the end product for the pathway affected by the mutation. Even 
with the end products added to the media, phenotypic and metabolic differences are seen 
between the wild type and purH mutant strains. The purine pathway is involved in making the 
purine nucleic acids, guanine and adenine. Thiamine also intersects the purine metabolic 
pathway and so the cell has no reason to make thiamine since the media was supplemented. This 
probably explains why most of the metabolites involved in the purine metabolic pathway do not 
show any labeling with 
13
C. AICAR is involved in a number of other pathways and so the 
labeling pattern is explainable. Figure 3.22 summarizes the metabolites involved in purine 











Figure 3-11. A schematic of purine metabolism is shown. Red boxes indicate that there was faster or more 
complete labeling or a larger pool size in the purH mutant. Blue boxes indicate that there was slower or less 
complete labeling or smaller pool sizes in the purH mutant. White boxes indicate that the compound was not 
detected in this experiment. Grey boxes indicate that there was no significant difference in the labeling patterns or 

















Figure 3-12. The flux graphs for AICAR are shown. 
 AICAR 
Not detected within 
the 5 ppm error 










, ATP, and ADP. Acetyl-CoA shows labeling in the purH mutant, but not in the wild type 
strain. Approximately 80% of the acetyl-CoA molecules detected showed labeling with 2 or 3 
13
C after 20 min in the purH mutant. This labeling pattern makes sense since the acetyl group is 
relatively easy to label, while the 21 carbons involved in the Coenzyme A molecules are more 
difficult to label. The pool sizes have a fold change of 4.57 x 10
-3
 (p value= 0.78). NADH 
molecules showed labeling with 16 
13
C in the 30% of the molecules detected after 120 min in the 
wild type strain, while 40% of the NADH molecules detected showed labeling with 14 
13
C after 
120 min in the purH mutant strain. The pool sizes have a fold change of 0.75 (p value= 0.07). No 
labeling of NADPH occurred in the wild type strain, while 15% of the NADPH molecules 
detected showed labeling with 16 
13
C after 120 min. The pool sizes have a fold change of 3.85 (p 




 shows isotopic labeling in the wild type and the purH mutant. NAD
+
 
molecules show labeling with 16 
13
C in 20% of the molecules detected after 120 min in the wild 
type strain; while 30% of the NAD
+
 molecules detected show labeling with 16 
13
C after 120 min. 
The pool sizes have a fold change of 0.95 (p value= 0.04). NADP
+
 molecules showed labeling 
with 1 
13
C in 15% of the molecules detected after 120 min in the wild type strain, while 20% of 
the NADP
+
 molecules detected showed labeling with 16 
13
C after 120 min in the purH mutant 
strain. The pool sizes have a fold change of 3.83 (p value= 0.12). ATP molecules showed 
labeling with 5 
13
C in 30% of the molecules detected after 30 min in the wild type strain, while 
40% of the ATP molecules detected showed labeling with 5 
13
C after 30 min in the purH mutant 
strain. ATP was not detected within the 5 ppm error window used for pool size analysis.  ADP 
was not detected in this set of experiments. Half of the flux and pool size graphs for the 
metabolites of interest listed here are shown in Figure 3. 13 and the second half of the flux and 





Figure 3-13. The flux graphs for acetyl coenzyme A, NADH, and NAD+ are shown. *** refers to 
a comparison with a p value ≤ 0.01. ** refers to a comparison with a p value ≤ 0.05. * refers to a p 









Figure 3-14.  Flux graphs for NADPH, NADP
+
, ATP, and ADP. *** refers to a 
comparison with a p value ≤ 0.01. ** refers to a comparison with a p value ≤ 0.05. * refers to 
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The purH mutant differs from the WT strain of S. enterica due to the removal of the gene 
coding for the production of AICAR transformylase/IMP cyclohydrolase. Glycolysis showed a 
slowdown in the purH mutant after the production of 1,3-diphosphoglycerate. The slowdown in 
the purH mutant strain continued through the citric acid cycle, except in some cases where the 
metabolites were involved in more than one pathway or between two metabolites that were 
involved in more than one pathway. Acetyl-CoA, succinyl-CoA, fumarate, and malate all show a 
larger pool size in the purH mutant strain and comparable labeling patterns to the wild type 
strain.  The pentose phosphate pathway shows larger pool sizes and comparable labeling patterns 
to the wild type strain, indicating that perhaps sugars are moving through the pentose phosphate 
pathway instead of glycolysis and the citric acid cycle in the purH mutant strain. AICAR labels 
to a lesser degree in the purH mutant, which is expected since AICAR transformylase/ IMP 







































Cold shock metabolomics showed that the wild type strain of S. enterica had less 
efficient labeling and smaller pool sizes at lower temperatures in central carbon metabolism. 
Metabolites that were detected in the pentose phosphate pathway show less efficient labeling and 
smaller pool sizes. Proteins may also be degrading into amino acids. Conversely enzymes may 
be denaturing leading to slower rates of enzymatic turnover. Transcription and translation may 
also be occurring at slower rates due to the change in temperature. Further work could be done in 
order to determine the effect of cold shock on lipids, fatty acids, and proteins in the wild type 
strain of S. enterica. The effect of cold shock on macromolecule synthesis rates could also be 
studied. Other organisms may also be exposed to cold shock and their metabolites quantified in 
order to see if the metabolic changes due to cold shock are fairly universal or if they differ 
between species, classes, or families of organisms. 
The purH mutant had the gene coding for AICAR transformylase/IMP cyclohydrolase 
altered. The purH mutant showed a slowdown in the glycolysis pathway and throughout the 
citric acid cycle after the production of 1, 3-diphosphoglycerate. Sugars may be broken down in 
the mutant strain through the use of the pentose phosphate pathway, as demonstrated by the 
larger pool sizes and similar labeling patterns in the purH mutant strain. In future studies, other 
strains of S. enterica may be studied in order to determine the metabolic differences caused by 
other mutations to the genome or the accumulation of AICAR caused by the purH mutation 
could be harnessed into an anti-cancer drug with differential lowering of body areas in areas 
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Table A-1. The pool size data and p values for the metabolites detected in the temperature experiment are shown. 
Metabolite median m/z 37 °C/25 °C 37 °C/3 °C 25 °C/3 °C 
37 °C/25 °C p 
value 
37 °C/3 °C p 
value 
25 °C/3 °C p 
value 
Pyruvate 870 0.729 0.000717 0.000983 0.658 0.183 0.183 
Sarcosine 880 1 4.39 x 10
-14
 4.39 x 10
-14
 1 0.00253 0.00253 
alanine 88 1 4.39 x 10
-14
 4.39 x 10
-14
 1 0.00253 0.00253 
lactate 89 2.74 x 10
-11
 8.71 x 10
-16
 0.0000318 0.198 0.13 0.13 
acetoacetate 101 4.32 x 10
-10
 3.22 x 10
-15
 7.44 x 10
-06
 0.423 0.0111 0.0111 
4-aminobutyrate 102 6.54 x 10
-11
 4.55 x 10
-15
 0.0000697 0.0658 0.0139 0.0139 
L-Serine 104 4.35 x 10
11
 0.193 4.44 x 10
-13
 0.423 0.0706 0.06 
Uracil 111 2.92 x 10
13
 511 1.75 x 10
-11
 0.225 0.226 0.0715 
L-Proline 114 236 1.32 0.00557 0.424 0.833 0.0215 
fumarate 115 2.96 x 10
14
 13.9 4.71 x 10
-14
 0.0345 0.0396 0.011 
2-ketoisovalerate 115 17000 1.38 0.0000811 0.0344 0.281 0.00667 
L-Valine 116 68900 0.534 7.74 x 10
-06
 0.0532 0.0473 0.00836 
Succinate 117 410000 31.1 0.0000759 0.161 0.169 0.0382 
Methylmalonic acid 117 410000 31.1 0.0000759 0.161 0.169 0.0382 
L-Threonine 118 2.23 x 10
13
 0.35 1.57 x 10
-14
 0.263 0.084 0.0171 
homoserine 118 2.23 x 10
13
 0.35 1.57 x 10
-14
 0.263 0.084 0.0171 
purine 119 1 4.77 x 10
-15
 4.77 x 10
-15
 1 0.423 0.423 
Nicotinate 122 6.74 x 10
13
 0.196 2.92 x 10
-15
 0.0788 0.00369 0.00873 
Thymine 125 1.65 x 10
13
 16.9 1.03 x 10
-12
 0.00626 0.00429 0.124 
Citraconic acid 129 42500 4.39 0.000103 0.0074 0.00396 0.0393 
N-Acetyl-L-alanine 130 11800 730 0.0618 0.376 0.377 0.0647 
leucine/isoleucine 130 11200 1.08 0.0000963 0.119 0.878 0.046 
asparagine 131 0.0215 0.188 8.74 0.0216 0.00426 0.0265 






Table A-1 continued. 
Metabolite median m/z 37 °C/25 °C 37 °C/3 °C 25 °C/3 °C 
37 °C/25 °C p 
value 
37 °C/3 °C p 
value 
25 °C/3 °C p 
value 
aspartate 132 103000 0.429 4.16 x 10
-6
 0.117 0.0585 0.00313 
malate 133 258000 15.5 6.02 x 10
-5
 0.000909 3.49 x 10
-5
 0.0943 
Methylcysteine 134 93 1.95 0.021 0.37 0.63 0.0536 
hypoxanthine 135 7290 159 0.0218 0.24 0.242 0.165 
4-Aminobenzoate 136 6.51 x 10
-12
 5.29 x 10-
12
 0.814 0.186 0.21 0.8 
p-hydroxybenzoate 137 3.07 x 10
13
 14.7 4.80 x 10
-13
 0.00154 0.000969 0.0223 
acetylphosphate 139 0.305 18.9 62 0.0228 0.0271 0.0172 
Carbamoyl phosphate 140 0.483 0.0111 0.0229 0.675 0.0897 0.091 
alpha-ketoglutarate 145 60900 3.25 5.34 x 10
-5
 0.133 0.225 0.185 
glutamine 145 1.38 x 10
14
 1.38 x 10
14
 1 0.195 0.195 1 
O-Acetyl-L-serine 146 33 0.463 0.014 0.111 0.158 0.058 
glutamate 146 33200 0.465 0.000014 0.122 0.0768 0.0101 
2-Hydroxy-2-methylbutanedioic acid 147 570 4.45 0.0078 0.00892 0.0088 0.0202 
methionine 148 2.55 x 10
12
 0.178 6.98 x 10
-14
 0.02 0.0492 0.0356 
3-methylphenylacetic acid 149 2.3 x 10
12
 35.5 1.54 x 10
-11
 0.00138 0.000489 0.164 
guanine 150 4930 9180 1.86 0.255 0.255 0.563 
Xanthine 151 233 3.77 x 10
11
 1.62 x 10
9
 0.306 0.304 0.423 
Hydroxyphenylacetic acid 151 331 966 2.92 0.0016 0.00161 0.379 
2,3-dihydroxybenzoic acid 153 4 x 10
13
 4 x 10
13
 1 0.0387 0.0387 1 
Orotate 155 186 33200 178 0.0438 0.0434 0.139 
allantoin 157 3.66 x 10
-10
 1.63 x 10
-12
 0.00445 0.423 0.039 0.0393 
Phenylpyruvate 163 0.0000555 0.2 3600 0.00146 0.354 0.00146 
Methionine sulfoxide 164 21200 7.7 x 10
13
 3.64 x 10
9
 0.0631 0.0631 0.423 
Phosphoenolpyruvate 167 1 6.63 x 10
-13
 6.63 x 10
-13
 1 0.241 0.241 
D-glyceraldehdye-3-phosphate 169 1 2.13 x 10
-13
 2.13 x 10
-13
 1 0.0268 0.0268 




Table A-1 continued. 
Metabolite median m/z 37 °C/25 °C 37 °C/3 °C 25 °C/3 °C 
37 °C/25 °C p 
value 
37 °C/3 °C p 
value 
25 °C/3 °C p 
value 
Diphosphate 177 0.932 2.63 2.82 0.61 0.00354 0.00908 
L-Tyrosine 180 4780 4460 0.933 0.00108 0.00108 0.957 
3-phosphoglycerate 185 2 x 10
11
 0.257 1.29 x 10
-12
 0.41 0.117 0.0688 
D-erythrose-4-phosphate 199 3.2 x 10
12
 0.672 2.1 x 10
-13
 0.153 0.474 0.0739 
D-glucarate 209 1.35 x 10
11
 0.0695 5.16 x 10
-13
 0.177 0.0944 0.0848 
deoxyribose-phosphate 213 1.15 x 10
11
 0.0807 7.04 x 10
-13
 0.423 0.00514 0.0145 
Chorismate 225 905 3.27 x 10
12
 3.62 x 10
9
 0.003 0.00301 0.423 
D-Ribose 5-phosphate 229 4.28 x 10
13
 4.28 x 10
13
 1 0.302 0.302 1 
Uridine 243 9.28 x 10
11
 12.4 1.34 x 10
-11
 0.00834 0.00795 0.0467 
Shikimate 3-phosphate 253 1.14 x 10
13
 161 1.41 x 10
-11
 0.197 0.199 0.349 
D-glucosamine-1-phosphate 258 2.75 x 10
12
 2.76 1 x 10
-12
 0.00331 0.00169 0.0281 
D-glucosamine-6-phosphate 258 3.09 x 10
12
 31.2 1.01 x 10
-11
 0.0631 0.0664 0.192 
glucose-6-phosphate 259 0.703 0.77 1.1 0.179 0.359 0.596 
2,3-Diphosphoglyceric acid 265 1.31 39.2 29.9 0.411 0.0332 0.0548 
S-Ribosyl-L-homocysteine 266 1.62 13.4 8.27 0.427 0.135 0.0527 
inosine 267 0.805 1.89 2.35 0.655 0.17 0.238 
6-phospho-D-gluconate 275 0.449 157 350 0.11 0.174 0.0186 
Xanthosine 283 1.75 0.598 0.341 0.232 0.218 0.0813 
D-sedoheptulose-1/7-phosphate 289 0.452 0.525 1.16 0.0659 0.185 0.607 
N-acetyl-glucosamine-1/6-phosphate 300 5.95 21.8 3.66 0.0507 0.0426 0.0831 
glutathione 306 1.44 1.58 1.1 0.641 0.563 0.855 
Octoluse 8/1P 319 0.112 0.136 1.21 0.181 0.158 0.764 
dTMP 321 0.165 0.62 3.76 0.0766 0.704 0.104 
CMP 322 0.985 2.26 2.29 0.981 0.387 0.158 
UMP 323 1.14 1.87 1.64 0.893 0.615 0.201 




Table A-1 continued. 
Metabolite median m/z 37 °C/25 °C 37 °C/3 °C 25 °C/3 °C 
37 °C/25 °C p 
value 
37 °C/3 °C p 
value 
25 °C/3 °C p 
value 
aminoimidazole carboxamide ribonucleotide 337 0.548 38 69.3 0.393 0.291 0.072 
fructose-1,6-bisphosphate 339 1.53 24.9 16.2 0.375 0.0822 0.0505 
Sucrose 341 1 0.953 0.952 0.997 0.889 0.71 
Cellobiose 341 1 0.953 0.952 0.997 0.889 0.71 
dGMP 346 2.53 29.5 11.7 0.136 0.0673 0.095 
IMP 347 0.413 55.4 134 0.0139 0.0542 0.00227 
S-Adenosylmethioninamine 354 0.491 27.9 56.8 0.239 0.244 0.0453 
GMP 362 0.234 0.757 3.24 0.22 0.793 0.259 
Xanthosine 5--phosphate 363 0.65 0.164 0.252 0.439 0.352 0.394 
Orotidine 5-phosphate 367 0.528 26.1 49.4 0.358 0.202 0.112 
Sedoheptoluse bisphosphate 369 0.565 50.4 89.3 0.504 0.297 0.154 
Riboflavin 375 4.06 8.36 2.06 0.00155 0.00122 0.215 
dCDP 386 1.79 83.6 46.7 0.391 0.127 0.121 
Octoluse Bisphosphate 399 0.267 8.42 31.5 0.281 0.312 0.195 
dTDP 401 3.92 37.6 9.61 0.318 0.228 0.179 
CDP 402 2.46 1.5 0.61 0.0898 0.264 0.189 
UDP 403 1.76 127 72.2 0.348 0.108 0.0291 
adenosine 5-phosphosulfate 426 0.43 2 4.65 0.159 0.507 0.00275 
ADP 426 3.12 118 37.8 0.0498 0.0311 0.0403 
GDP 442 1.94 16.6 8.57 0.384 0.163 0.0843 
FMN 455 1.76 29.9 17 0.471 0.165 0.205 
dCTP 466 2.55 15.8 6.21 0.577 0.413 0.217 
dTTP 481 3.33 12.9 3.89 0.491 0.381 0.45 
CTP 482 6.76 21.3 3.16 0.127 0.109 0.249 
UTP 483 1.33 23.7 17.8 0.665 0.133 0.184 




Table A-1. continued. 
Metabolite median m/z 37 °C/25 °C 37 °C/3 °C 25 °C/3 °C 
37 °C/25 °C p 
value 
37 °C/3 °C p 
value 
25 °C/3 °C p 
value 
ATP 506 1.24 36.4 29.3 0.677 0.103 0.0996 
UDP-glucose 565 0.878 0.407 0.464 0.608 0.00863 0.0128 
UDP-glucuronate 579 0.971 0.685 0.705 0.906 0.212 0.184 
ADP-D-glucose 588 71.8 25.8 0.36 0.0743 0.0777 0.0645 
guanosine 5-diphosphate-3-diphosphate 596 8.92 x 10
10
 8.92 x 10
10
 1 0.423 0.423 1 
UDP-N-acetyl-D-glucosamine 606 0.805 1.12 1.39 0.488 0.762 0.109 
glutathione disulfide 611 7.42 2.79 0.375 0.356 0.473 0.331 
NAD+ 662 1.26 1.63 1.29 0.434 0.204 0.0622 
NADH 664 1.26 11.7 9.32 0.262 0.0205 0.00784 
NADP+ 742 2.06 16.3 7.91 0.109 0.0357 0.00121 
NADPH 744 0.646 54.2 83.9 0.451 0.23 0.0231 
FAD 784 1.42 1.54 1.09 0.0365 0.0533 0.671 
acetyl-CoA 808 1.11 145 130 0.776 0.0871 0.00285 







Table A-2. The fold changes and p values for the metabolites in the heat map for the purH vs wild type study 
are shown. 
Metabolite median m/z purH/WT p value 
S-methyl-5-thioadenosine 296.0818 0.865 0.669 
L-arginino-succinate 289.1147 1.09 0.717 
D-sedoheptulose-1/7-phosphate 289.0321 1.2 0.555 
xanthosine 283.0676 2.88 0.0199 
6-phospho-D-gluconate 275.0171 1640 0.067 
inosine 267.0729 6.25 0.00644 
adenosine 241.8991 0.0281 0.00254 
S-ribosyl-L-homocysteine 266.0699 0.607 0.0159 
1,3-diphopshateglycerate 264.9514 0.529 0.127 
2,3-Diphosphoglyceric acid 264.9514 0.529 0.127 
glutathione 306.0758 0.747 0.0211 
dUMP 307.0331 51.9 0.0396 
Geranyl-PP 313.0603 1.09 0.836 
cyclic-AMP 328.0446 0.0675 0.0266 
trehalose/sucrose 341.1082 0.978 0.887 
Cellobiose 341.1082 0.978 0.887 
D-erythrose-4-phosphate 199.0012 0.868 0.801 
Acetylcarnitine 203.1172 1.4 0.196 
Kynurenine 207.0775 0.831 0.0145 
D-glucarate 209.0301 0.865 0.439 
deoxyadenosine 250.095 3.49 0.089 
deoxyinosine 251.0789 0.126 0.323 
glucose-1/6-phosphate 259.0215 0.655 0.0428 
NAD+ 259.0215 0.949 0.0428 
Taurodeoxycholic acid 662.1006 3.04 0.227 
UDP-D-glucose 498.2883 1.14 0.215 
UDP-D-glucuronate 565.0467 1.05 0.268 
ADP-D-glucose 579.0261 0.131 0.448 
UDP-N-acetyl-glucosamine 588.0737 1.14 0.00103 
glutathione disulfide 606.0734 2.84 0.076 
NADH 611.1442 0.748 0.199 
cyclic bis(3-->5-) dimeric GMP 664.1169 1.67 0.0581 
NADP+ 689.0862 3.83 0.121 
NADPH 742.0673 3.85 0.000105 
FAD 744.0826 0.982 0.0147 
acetyl-CoA 784.1494 0.00457 0.779 




Table A-2 continued. 
Metabolite median m/z purH/WT p value 
GMP 836.1508 21.5 0.413 
xanthosine-5-phosphate 362.051 3.95 0.363 
orotidine-5-phosphate 363.0341 1.78 0.05 
riboflavin 367.0177 0.514 0.104 
S-adenosyl-L-homoCysteine 375.1302 0.42 0.00266 
UDP 383.1131 1.4 0.0954 
Cholic acid 402.994 3.55 0.125 
adenosine 5-phosphosulfate 407.2802 0.446 0.212 
Deoxycholic acid 426.0125 1.1 0.00608 
cholesteryl sulfate 448.3061 0.395 0.0781 
ornithine 465.3043 1.78 0.387 
nicotinamide 131.0823 0.715 0.0657 
nicotinate 121.0404 1.71 0.189 
taurine 122.0246 0.108 0.0191 
thymine 93.00521 0.298 0.338 
Pyroglutamic acid 125.0352 0.257 0.319 
Citraconic acid 128.0352 0.0795 0.424 
N-Acetyl-L-alanine 129.0193 0.0026 0.000107 
leucine/isoleucine 130.0507 3.29 0.207 
asparagine 130.0873 0.743 0.0000287 
Hydroxyisocaproic acid 131.0459 0.645 0.499 
aspartate 131.0713 0.692 0.134 
malate 132.0302 3.17 0.14 
anthranilate 133.0143 0.638 0.00313 
p-aminobenzoate 136.04 0.638 0.0000973 
p-hydroxybenzoate 136.04 0.368 0.0000973 
acetylphosphate 137.0243 0.581 0.0298 
Carbamoyl phosphate 138.9799 0.239 0.145 
histidinol 139.9753 0.312 0.211 
a-ketoglutarate 140.0827 0.661 0.00104 
2-oxobutanoate 145.0141 0.647 0.0113 
acetoacetate 101.024 0.647 0.598 
dimethylglycine 101.024 0.387 0.598 
4-aminobutyrate 102.0557 0.387 0.0617 
serine 102.0557 0.00192 0.0617 
glycerate 104.035 0.943 0.365 
uracil 105.0189 7.35 0.878 




Table A-2 continued. 
Metabolite median m/z purH/WT p value 
fumarate 114.0556 0.284 0.271 
2-keto-isovalerate 115.0034 3.13 0.00174 
indole 115.0398 1.86 0.00311 
betaine 116.0502 15.1 0.185 
valine 116.0714 15.1 0.0000321 
Methylmalonic acid 116.0714 0.433 0.0000321 
succinate 117.0191 0.433 0.000033 
threonine 117.0191 4.31 0.000033 
homoserine 118.0505 4.31 0.0000959 
D-glyceraldehdye-3-phosphate 118.0505 0.118 0.0000959 
arginine 168.9901 0.392 0.000333 
Ascorbic acid 173.1045 0.764 0.0262 
N-carbamoyl-L-aspartate 175.0249 0.623 0.00465 
allantoate 175.0364 1.21 0.436 
glucono-Î´-lactone 175.0479 0.0411 0.369 
hydroxyphenylpyruvate 177.0408 1.05 0.235 
dihydroxy-acetone-phosphate 179.0348 0.118 0.836 
3-phosphoglycerate 168.9901 0.325 0.000445 
Acetyllysine 184.9865 0.478 0.196 
allantoin 187.1085 0.948 0.116 
glutamine 157.0368 1.18 0.854 
glutamate 145.0616 0.836 0.0981 
O-acetyl-L-serine 146.0456 0.931 0.386 
2-Hydroxy-2-methylbutanedioic acid 146.0456 0.317 0.46 
methionine 147.0298 0.169 0.000000457 
xanthine 148.0435 0.87 0.00292 
2,3-dihydroxybenzoic acid 137.297 0.663 0.797 
dihydroorotate 153.019 1.06 0.0241 
Uric acid 157.0252 0.0125 0.792 
Pyridoxamine 167.0208 0.00501 0.0177 
fructose-1,6-bisphosphate 167.0823 1.96 0.00674 
sedoheptulose-bisphosphate 338.9886 8.15 0.107 










Table A-3. The average ion counts plus or minus the standard deviation counts for each metabolite discussed 




0 min  2 min 5 min 15 min 
glucose/fructose-6-phosphate 12C 1.28 ± 0.55 x 106 1.28 ± 0.8 x 105 1.54 ± 0.6 x 105 9.37 ± 4.0 x 104 
glucose/fructose-6-phosphate 13C1 7.09 ±  3.4 x 10
4 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
glucose/fructose-6-phosphate 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
glucose/fructose-6-phosphate 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
glucose/fructose-6-phosphate 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
glucose/fructose-6-phosphate 13C5 0 ±  0.0 x 10
0 2.79 ±  4.8 x 104 6.15 ±2.0 x 104 4.41 ± 3.8 x 104 
glucose/fructose-6-phosphate 13C6 0 ±  0.0 x 10
0 9.47 ±  8.9 x 10 5 1.52 ± 0.6 x 106 1.07 ± 0.9 x 106 
fructose-1-6-bisphosphate 12C 2.52 ±  1.2 x 106 4.40 ±  2.2 x 104 4.88 ± 2.4 x 104 5.59 ± 3.4 x 104 
fructose-1-6-bisphosphate 13C1 1.37 ± 0.69 x 10
5 2.70 ±  2.3 x 103 1.72 ± 1.0 x 103 2.52 ± 1.8 x 103 
fructose-1-6-bisphosphate 13C2 4.39 ± 2.0 x 10
4 1.88 ±  1.5 x 103 1.86 ± 1.0 x 103 1.09 ± 0.2 x 103 
fructose-1-6-bisphosphate 13C3 1.62 ± 0.9 x 10
3 5.18 ±  2.5 x 104 4.28 ± 2.0 x 104 1.48 ± 0.2 x 104 
fructose-1-6-bisphosphate 13C4 3.08 ± 4.3 x 10
2 1.24 ±  0.8 x 104 1.29 ± 0.6 x 104 4.55 ± 2.5 x 103 
fructose-1-6-bisphosphate 13C5 9.21 ± 1.3 x 10
3 1.79 ±  0.5 x 105 2.07 ± 0.5 x 105 1.33 ± 0.2 x 105 
fructose-1-6-bisphosphate 13C6 1.86 ± 0.04 x10
5 3.60 ±  0.9 x 106 4.44 ± 1.1 x 106 2.96 ± 0.5 x 106 
1,3-Diphosphoglyceric acid 12C 5.44 ± 1.1 x104 8.24 ±  1.8 x 102 1.52 ± 1.0 x 103 1.80 ± 1.0 x 103 
1,3-Diphosphoglyceric acid 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
1,3-Diphosphoglyceric acid 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
1,3-Diphosphoglyceric acid 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
Pyruvate 12C 6.06 ± 5.4 x 107 7.35 ±  3.2 x 106 5.50 ± 2.3 x 106 1.10 ± 0.6 x 106 
Pyruvate 13C1 1.57 ± 1.1 x 10
6 2.79 ±  1.4 x 105 1.37 ± 1.5 x 105 0 ±  0.0 x 100 
Pyruvate 13C2 0 ±  0.0 x 10
0 2.03 ±  0.4 x 106 2.26 ± 0.7 x 106 7.59 ±3.1 x 105 
Pyruvate 13C3 0 ±  0.0 x 10
0 4.23 ±  3.8 x 107 7.38 ± 3.1 x 107 2.80 ± 1.2 x 107 
alpha-ketoglutarate 12C 8.36 ±  5.5 x 106 4.35 ± 0.5 x 106 4.35 ± 0.9 x 106 1.09 ± 0.1 x 106 
alpha-ketoglutarate 13C1 4.42 ±  3.4 x 10
5 3.45 ±  0.9 x 105 2.47 ± 1.0 x 105 4.04 ± 0.5 x 104 
alpha-ketoglutarate 13C2 1.52 ±  1.5 x 10
3 1.15 ±  0.4 x 106 1.13 ± 0.3 x 106 4.03± 1.2 x 105 
alpha-ketoglutarate 13C3 0 ±  0.0 x 10
0 1.35 ±  0.6 x 106 1.60 ± 0.4 x 106 8.29 ± 0.3 x 105 
alpha-ketoglutarate 13C4 5.45 ± 4.7 x 10
2 7.80 ±  3.6 x 105 1.36 ± 0.3 x 106 1.19 ± 0.1 x 106 
alpha-ketoglutarate 13C5 2.32 ± 2.0 x 10
2 1.86 ±  1.1 x 106 4.33 ± 1.0 x 106 6.65 ± 0.5 x 106 
succinyl-CoA 12C 3.25 ± 0.9 x 104 1.95 ±  0.4 x 104 9.56 ± 5.3 x 103 9.22 ± 16.0 x 102 
succinyl-CoA 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C5 0 ±  0.0 x 10










0 min  2 min 5 min 15 min 
succinyl-CoA 13C6 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C7 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C8 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C9 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C10 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C11 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C12 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C13 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C14 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C15 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C16 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C17 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C18 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C19 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C20 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C21 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C22 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C23 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C24 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C25 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
Succinate 12C 1.44 ±  1.0 x 108 6.86 ±  3.0 x 106 3.24 ± 0.8 x 106 1.67 ± 1.0 x 106 
Succinate 13C1 6.71 ±  5.0 x 10
6 7.34 ±  2.2 x 105 5.03 ± 0.7 x 105 2.48 ± 2.0 x 105 
Succinate 13C2 3.81 ±  3.3 x 10
4 3.77 ±  1.8 x 106 3.39 ± 1.1 x 106 1.81 ± 0.2 x 106 
Succinate 13C3 0 ±  0.0 x 10
0 2.20 ±  1.8 x 106 2.10 ± 0.3 x 106 2.86 ± 1.5 x 106 
Succinate 13C4 0 ±  0.0 x 10
0 9.00 ±  4.9 x 106 1.20 ± 0.1 x 107 2.88 ± 1.1 x 107 
fumarate 12C 3.57 ±  1.6 x 106 4.16 ±  1.2 x 105 1.61 ± 0.6 x 105 5.72 ± 5.5 x 104 
fumarate 13C1 1.42 ±  0.9 x 10
5 3.61 ±  1.9 x 104 2.04 ± 0.8 x 104 8.72 ± 1.8 x 103 
fumarate 13C2 0 ±  0.0 x 10
0 3.05 ±  1.6 x 105 2.45 ± 1.1 x 105 1.03 ± 0.2 x 105 
fumarate 13C3 0 ±  0.0 x 10
0 4.74 ±  0.7 x 105 3.78 ± 0.8 x 105 4.80 ± 1.5 x 105 
fumarate 13C4 0 ±  0.0 x 10
0 1.37 ±  0.5 x 106 1.55 ± 0.4 ± 106 2.93 ± 0.5 x 106 
malate 12C 3.99 ±  0.3 x 107 6.24 ±  1.9 x 106 2.87 ± 0.6 x 106 1.03 ± 0.4 x 106 
malate 13C1 1.74 ±  0.2 x 10
6 9.64 ±  2.2 x 105 6.53 ± 1.61 x 105 2.20 ± 0.5 x 105 
malate 13C2 8.86 ±  2.1 x 10
3 7.74 ±  1.0 x 106 6.67 ± 1.2 x 106 5.97 ± 0.5 x 106 
malate 13C3 1.32 ±  0.2 x 10
5 2.21 ±  0.6 x 107 2.71 ± 0.6 x 107 5.56 ± 0.4 x 107 
6-phospho-D-gluconate 12C 9.17 ±  6.4 x 105 3.56 ±  0.4 x 104 3.41 ± 0.7 x 104 2.50 ± 0.4 x 104 
6-phospho-D-gluconate 13C1 4.29 ±  3.1 x 10










0 min  2 min 5 min 15 min 
6-phospho-D-gluconate 13C2 6.36 ±  11.0 x 10
3 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
6-phospho-D-gluconate 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
6-phospho-D-gluconate 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
6-phospho-D-gluconate 13C5 0 ±  0.0 x 10
0 5.04 ±  4.7 x 104 8.82 ± 1.4 x 104 0 ±  0.0 x 100 
6-phospho-D-gluconate 13C6 0 ±  0.0 x 10
0 1.26 ±  1.1 x 106 2.16 ± 0.3 x 106 5.33 ± 9.2 x 105 
D-xylulose 5-phosphate 
12C 5.54 ±  9.6 x 101 0 ±  0.0 x 100 1.57 ± 1.4 x 102 5.38 ± 4.6 x 102 
D-xylulose 5-phosphate 
13C1 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-xylulose 5-phosphate 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-xylulose 5-phosphate 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-xylulose 5-phosphate 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-xylulose 5-phosphate 13C5 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-sedoheptulose-1/7-phosphate 
12C 8.18 ±  3.6 x 104 1.62 ±  2.9 x 102 1.86 ± 2.2 x 103 7.63 ± 13.2 x 102 
D-sedoheptulose-1/7-phosphate 
13C1 2.17 ±   0.9 x 103 0 ±  0.0 x 100 0.69 ± 1.2 x 102 0 ±  0.0 x 100 
D-sedoheptulose-1/7-phosphate 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-sedoheptulose-1/7-phosphate 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-sedoheptulose-1/7-phosphate 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0.59 ± 1.0 x 103 0 ±  0.0 x 100 
D-sedoheptulose-1/7-phosphate 13C5 0 ±  0.0 x 10
0 6.70 ±  1.2 x 102 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-sedoheptulose-1/7-phosphate 13C6 0 ±  0.0 x 100 3.65 ±  4.1 x 103 3.20 ± 3.0 x 103 4.34 ± 5.0 x 103 
D-sedoheptulose-1/7-phosphate 
13C7 0 ±  0.0 x 100 8.00 ±  7.9 x 104 6.40 ± 9.0 x 104 9.85 ± 7.7 x 104 
glutamate 
12C 1.98 ±  1.3 x 107 1.19 ±  0.3 x 107 5.12 ± 1.2 x 106 4.63 ± 3.5 x 105 
glutamate 
13C1 1.08 ±  0.7 x 106 1.21 ±  0.002 x 106 7.66 ±  0.7 x 105 6.79 ± 5.4 x 104 
glutamate 13C2 4.38 ±  2.8 x 10
3 5.43 ±  0.2 x 106 4.56 ±  0.7 x 106 8.22 ± 5.2 x 105 
glutamate 13C3 2.70 ±  3.1 x 10
3 5.80 ±  1.2 x 106 6.08 ±  0.4 x 106 2.40 ± 1.7 x 106 
glutamate 13C4 2.07 ±  0.2 x 10
3 3.65 ±  0.9 x 106 5.86 ±  0.3 x 106 3.94 ± 2.6 x 106 
glutamate 13C5 1.23 ±  0.4 x 10
4 8.38 ±  3.0 x 106 1.87 ±  0.009 x 107 2.31 ± 1.6 x 107 
glutamine 
12C 1.49 ±  1.24 x 106 1.12 ±  0.1 x 106 3.03 ±  1.5 x 105 2.00 ± 0.5 x 104 
glutamine 
13C1 2.67 ±  2.0 x 104 3.73 ±  0.2 x 104 1.68 ±  0.6 x 104 3.14 ± 0.5 x 103 
glutamine 13C2 2.71 ±  4.7 x 10
2 3.90 ±  0.7 x 105 2.46 ±  1.2 x 105 2.18 ± 0.4 x 104 
glutamine 13C3 1.95 ±  1.7 x 10
2 4.15 ±  1.6 x 105 4.17 ±  1.7 x 105 8.51 ± 2.0 x 104 
glutamine 13C4 1.13 ±  2.0 x 10
2 2.42 ±  1.3 x 105 3.75 ±  1.3 x 105 2.06 ± 0.2 x 105 
glutamine 13C5 1.72 ±  1.0 x 10
3 7.20 ±  3.6 x 105 1.50 ±  0.3 x 106 1.98 ± 0.3 x 106 
















0 min  2 min 5 min 15 min 
aspartate 13C1 2.17 ±  1.2 x 10
4 2.80 ±  0.6 x 104 1.79 ±  0.5 x 104 6.09 ± 10.6 x 103 
aspartate 13C2 0 ±  0.0 x 10
0 1.81 ±  1.3 x 105 1.67 ±  0.9 x 105 0 ±  0.0 x 100 
aspartate 13C3 0 ±  0.0 x 10
0 5.29 ±  0.7 x 105 3.93 ±  1.2 x 105 0 ±  0.0 x 100 
aspartate 13C4 0 ±  0.0 x 10
0 1.38 ±  0.4 x 106 1.43 ±  0.5 x 106 8.70 ± 15.1 x 105 
leucine/isoleucine 12C 4.34 ± 1.8 x 105 1.94 ±  0.7 x 104 1.68 ±  0.5 x 104 2.61 ± 2.2 x 104 
leucine/isoleucine 13C1 8.26 ± 3.0 x 10
3 0 ±  0.0 x 100 0 ±  0.0 x 100 8.74 ± 15.1 x 102 
leucine/isoleucine 13C2 0 ±  0.0 x 10
0 2.79 ±  0.9 x 104 1.55 ±  0.6 x 104 5.98 ± 5.3 x 103 
leucine/isoleucine 13C3 0 ±  0.0 x 10
0 2.06 ±  3.6 x 103 2.17 ±  3.8 x 103 5.77 ±10.0 x 102 
leucine/isoleucine 13C4 0 ±  0.0 x 10
0 1.83 ±  0.9 x 104 1.85 ±  0.8 x 104 6.91 ± 6.2 x 103 
leucine/isoleucine 13C5 0 ±  0.0 x 10
0 2.38 ±  2.12 x 104 3.23 ±  1.4 x 104 1.80 ± 1.7 x 104 
leucine/isoleucine 13C6 0 ±  0.0 x 10
0 1.57 ±  1.2 x 105 2.68 ±  0.7 x 105 2.54 ± 2.3 x 105 
alanine 12C 5.92 ±   2.2 x 105 2.51 ±  2.7 x 104 7.46 ±  6.5 x 103 2.81 ± 2.7 x 103 
alanine 13C1 6.75 ±   12.0 x 10
2 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
alanine 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
alanine 13C3 0 ±  0.0 x 10
0 3.53 ±  0.6 x 105 4.39 ±  0.6 x 105 1.76 ± 3.0 x 105 
L-Valine 12C 5.38 ± 1.7 x 106 1.70 ±  0.1 x 106 5.62 ±  1.1 x 105 1.79 ± 1.3 x 105 
L-Valine 13C1 2.82 ± 1.1 x 10
5 7.84 ±  1.1 x 104 1.67 ±  0.5 x 104 3.84 ± 3.6 x 103 
L-Valine 13C2 1.68 ± 1.6 x 10
3 2.31 ±  0.4 x 105 1.44 ±  0.03 x 105 5.50 ± 7.3 x 104 
L-Valine 13C3 0 ±  0.0 x 10
0 2.60 ±  0.4 x 105 1.69 ±  0.07 x 105 6.13 ± 7.8 x 104 
L-Valine 13C4 0 ±  0.0 x 10
0 1.48 ±  0.7 x 105 1.72 ±  0.2 x 105 1.42 ± 1.5 x 105 
L-Valine 13C5 0 ±  0.0 x 10


















Table A-4. The average ion counts plus or minus the standard deviation for the metabolites discussed and 




30 min 60 min 120 min 
glucose/fructose-6-phosphate 12C 9.90 ± 2.0 x 104 7.62 ± 0.7 x 104 5.90 ± 2.3 x 104 
glucose/fructose-6-phosphate 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
glucose/fructose-6-phosphate 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
glucose/fructose-6-phosphate 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
glucose/fructose-6-phosphate 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
glucose/fructose-6-phosphate 13C5 1.94 ± 3.4 x 10
4 0 ±  0.0 x 100 0 ±  0.0 x 100 
glucose/fructose-6-phosphate 13C6 
1.31 ± 0.002 x 
106 
5.24 ± 9.1 x 105 0 ±  0.0 x 100 
fructose-1-6-bisphosphate 12C 1.13 ± 1.6 x 105 2.32 ± 1.6 x 104 8.17 ± 9.6 x 104 
fructose-1-6-bisphosphate 13C1 4.99 ± 7.1 x 10
3 1.81 ± 0.8 x 103 3.42 ± 5.2 x 103 
fructose-1-6-bisphosphate 13C2 7.59 ± 13.1 x 10
2 8.58 ± 7.5 x 102 1.84 ± 1.6 x 103 
fructose-1-6-bisphosphate 13C3 1.13 ± 0.6 x 10
4 6.05 ± 1.2 x 103 3.31 ± 2.6 x 103 
fructose-1-6-bisphosphate 13C4 3.36 ± 0.3 x 10
3 1.96 ±0.4 x 103 1.78 ± 1.4 x 103 
fructose-1-6-bisphosphate 13C5 1.11 ± 0.1 x 10
5 7.12 ± 2.7 x 104 3.92 ± 3.1 x 104 
fructose-1-6-bisphosphate 13C6 2.74 ± 0.5 x 10
6 1.59 ± 0.6 x 106 8.61 ± 7.6 x 105 
1,3-Diphosphoglyceric acid 12C 2.54 ± 1.4 x 103 2.90 ± 2.7 x 103 1.17 ± 0.7 x 103 
1,3-Diphosphoglyceric acid 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
1,3-Diphosphoglyceric acid 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
1,3-Diphosphoglyceric acid 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
Pyruvate 12C 4.53 ± 1.3 x 105 1.32 ± 1.2 x 105 1.47 ± 1.0 x 105 
Pyruvate 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
Pyruvate 13C2 1.38 ± 0.9 x 10
5 1.20 ± 1.05 x 104 0 ±  0.0 x 100 
Pyruvate 13C3 7.45 ± 2.6 x 10
6 1.64 ± 1.42 x 106 1.55 ± 1.4 x 106 
alpha-ketoglutarate 12C 6.86 ± 0.8 x 105 3.55 ± 0.5 x 105 1.42 ± 0.5 x 105 
alpha-ketoglutarate 13C1 2.08 ± 0.4 x 10
4  8.92 ± 1.1 x 103 4.40 ± 2.2 x 103 
alpha-ketoglutarate 13C2 1.59 ± 0.5 x 10
5 5.21 ± 1.3 x 104 1.43 ± 0.3 x 104 
alpha-ketoglutarate 13C3 4.85 ± 0.6 x 10
5 2.34 ± 0.5 x 105 8.86 ± 4.4 x 104 
alpha-ketoglutarate 13C4 7.80 ± 1.0 x 10
5 5.26 ± 0.7 x 105 3.98 ± 1.5 x 105 
alpha-ketoglutarate 13C5 5.27 ± 0.5 x 10
6 3.98 ± 0.6 x 106 3.35 ±1.2 x 106 
succinyl-CoA 12C 2.50 ± 1.4 x 103 6.62 ± 11.5 x 102 7.17 ± 4.9 x 103 
succinyl-CoA 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C5 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C6 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C7 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C8 0 ±  0.0 x 10











30 min 60 min 120 min 
succinyl-CoA 13C9 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C10 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C11 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C12 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C13 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C14 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C15 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C16 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C17 0 ±  0.0 x 10
0 6.17 ±10.7 x 102 0 ±  0.0 x 100 
succinyl-CoA 13C18 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C19 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C20 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C21 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C22 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C23 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C24 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C25 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
Succinate 12C 
1.08 ± 0.008 x 
106 
1.22 ± 0.7 x 106 6.63 ±2.5 x 105 
Succinate 13C1 1.28 ± 0.6 x 10
5 2.06 ± 2.4 x 105 2.05 ± 2.9 x 105 
Succinate 13C2 1.48 ± 0.09 x 10
6 1.46 ± 0.2 x 106 9.85 ± 1.5 x 105 
Succinate 13C3 2.10 ± 0.5 x 10
6 4.57 ± 4.5 x 106 3.80 ± 3.6 x 106 
Succinate 13C4 2.67 ± 0.3 x 10
7 6.66 ± 6.3 x 107 5.60 ± 4.7 x 107 
fumarate 12C 1.98 ± 0.2 x 104 2.46 ± 1.8 x 104 
1.14 ± 0.007 x 
104 
fumarate 13C1 6.75 ± 0.6 x 10
3 5.24 ± 5.4 x 103 0 ±  0.0 x 100 
fumarate 13C2 5.72 ± 1.0 x 10
4 4.20 ± 0.3 x 104 1.12 ± 1.0 x 104 
fumarate 13C3 3.09 ± 0.3 x 10
5 3.38 ± 0.9 x 105 2.09 ± 0.4 x 105 
fumarate 13C4 2.61 ± 0.2 x 10
6 3.12 ± 1.2 x 106 2.22 ± 0.3 x 106 
malate 12C 6.20 ± 0.2 x 105 6.85 ± 3.6 x 105 2.88 ± 2.8 x 105 
malate 13C1 1.65 ± 0.2 x 10
5 1.10 ± 0.2 x 105 8.55 ± 2.1 x 104 
malate 13C2 4.39 ± 0.5 x 10
6 
3.95 ± 0.005 x 
106 
3.08 ± 1.9 x 106 
malate 13C3 3.38 ± 0.3 x 10
7 3.24 ± 0.4 x 107 
2.79 ± 0.009 x 
107 
6-phospho-D-gluconate 12C 2.63 ± 0.1 x 104 2.65 ± 0.5 x 104 4.12 ± 2.0 x 104 
6-phospho-D-gluconate 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
6-phospho-D-gluconate 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
6-phospho-D-gluconate 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
6-phospho-D-gluconate 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
6-phospho-D-gluconate 13C5 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
6-phospho-D-gluconate 13C6 0 ±  0.0 x 10










30 min 60 min 120 min 
D-xylulose 5-phosphate 12C 9.37 ± 0.3 x 102 7.40 ± 6.6 x 102 9.75 ± 2.03 x 102 
D-xylulose 5-phosphate 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-xylulose 5-phosphate 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-xylulose 5-phosphate 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-xylulose 5-phosphate 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-xylulose 5-phosphate 13C5 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-sedoheptulose-1/7-phosphate 12C 1.75 ± 2.4 x 103 0 ±  0.0 x 100 1.05 ± 1.8 x 102 
D-sedoheptulose-1/7-phosphate 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-sedoheptulose-1/7-phosphate 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-sedoheptulose-1/7-phosphate 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-sedoheptulose-1/7-phosphate 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-sedoheptulose-1/7-phosphate 13C5 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-sedoheptulose-1/7-phosphate 13C6 3.87 ± 6.7 x 10
3 8.62 ± 14.9 x 102 6.82 ±11.8 x 102 
D-sedoheptulose-1/7-phosphate 13C7 3.15 ± 5.5 x 10
4 5.26 ± 1.8 x 103 2.92 ± 3.0 x 103 
glutamate 12C 5.54 ± 2.4 x 105 4.69 ± 1.4 x 105 2.63 ± 0.6 x 105 
glutamate 13C1 7.46 ± 4.4 x 10
4 4.13 ± 1.5 x 104 2.42 ± 1.2 x 104 
glutamate 13C2 8.09 ±1.0 x 10
5 8.71 ± 3.0 x 105 5.35 ± 2.6 x 105 
glutamate 13C3 2.39 ± 0.2 x 10
6 2.10 ± 0.9 x 106 1.91 ± 1.0 x 106 
glutamate 13C4 4.37 ± 0.4 x 10
6 4.43 ± 1.7 x 106 4.39 ± 2.2 x 106 
glutamate 13C5 2.88 ± 0.3 x 10
7 3.27 ± 0.8 x 107 3.53 ± 1.2 x 107 
glutamine 12C 1.79 ± 0.6 x 104 2.11 ± 0.7 x 104 1.21 ± 0.6 x 104 
glutamine 13C1 2.49 ± 2.4 x 10
3 1.83 ± 1.3 x 103 7.64 ± 8.4 x 102 
glutamine 13C2 1.28 ± 0.4 x 10
4 9.80 ± 2.9 x 103 6.93 ± 3.6 x 103 
glutamine 13C3 4.66 ± 0.6 x 10
4 3.03 ± 1.3 x 104 2.83 ± 1.6 x 104 
glutamine 13C4 1.51 ± 0.2 x 10
5 1.18 ± 0.5 x 105 1.21 ± 0.8 x 105 
glutamine 13C5 1.74 ± 0.1 x 10
6 1.53 ± 0.3 x 106 1.54 ± 0.7 x 106 
aspartate 12C 1.32 ± 0.7 x 105 9.10 ± 4.1 x 104 8.14 ± 4.3 x 104 
aspartate 13C1 1.43 ± 1.4 x 10
4 3.13 ± 5.4 x 103 0 ±  0.0 x 100 
aspartate 13C2 3.63 ± 6.3 x 10
4 0 ±  0.0 x 100 0 ±  0.0 x 100 
aspartate 13C3 1.42 ± 2.45 x 10
5 0 ±  0.0 x 100 0 ±  0.0 x 100 
aspartate 13C4 9.28 ± 16.1 x 10
5 0 ±  0.0 x 100 0 ±  0.0 x 100 
leucine/isoleucine 12C 9.23 ± 6.6 x 104 2.20 ± 1.4 x 105 4.49 ± 3.8 x 105 
leucine/isoleucine 13C1 3.04 ± 1.4 x 10
3 6.03 ± 2.1 x 103 1.24 ± 1.1 x 104 
leucine/isoleucine 13C2 7.71 ± 0.9 x 10
3 1.56 ± 0.7 x 104 3.13 ± 2.3 x 104 
leucine/isoleucine 13C3 1.21 ± 1.0 x 10
3 0 ±  0.0 x 100 0 ±  0.0 x 100 
leucine/isoleucine 13C4 9.97 ± 1.8 x 10
3 2.16 ± 1.3 x 104 1.09 ± 0.9 x 105 
leucine/isoleucine 13C5 2.15 ± 0.1 x 10
4 3.40 ± 1.7 x 104 1.58 ± 1.2 x 105 
leucine/isoleucine 13C6 3.30 ± 0.2 x 10













30 min 60 min 120 min 
alanine 12C 9.57 ± 16.6 x 102 9.11 ± 15.8 x 102 2.37 ± 2.5 x 103 
alanine 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
alanine 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
alanine 13C3 0 ±  0.0 x 10
0 4.13 ± 7.2 x 104 7.96 ± 12.1 x 104 
L-Valine 12C 1.85 ± 2.1 x 105 3.40 ± 2.6 x 104 1.27 ± 0.6 x 104 
L-Valine 13C1 4.69 ± 6.2 x 10
3 0 ±  0.0 x 100 0 ±  0.0 x 100 
L-Valine 13C2 8.40 ± 1.2 x 10
3 9.85 ± 6.1 x 103 0 ±  0.0 x 100 
L-Valine 13C3 1.08 ± 0.2 x 10
4 7.65 ± 2.4 x 103 0 ±  0.0 x 100 
L-Valine 13C4 3.12 ± 0.6 x 10
4 2.25 ± 0.7 x 104 4.09 ± 7.1 x 103 
L-Valine 13C5 9.67 ± 1.1 x 10


































Table A-5. The average ion counts plus or minus the standard deviation for the metabolites discussed and 




0 min 2 min 5 min 15 min 
glucose/fructose-6-phosphate 12C 1.75 ± 0.006 x 106 1.58 ±  0.3 x 104 1.17 ±  0.2 x 105 9.14 ± 1.1 x 104 
glucose/fructose-6-phosphate 13C1 1.02 ± 0.1 x 10
5 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
glucose/fructose-6-phosphate 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
glucose/fructose-6-phosphate 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
glucose/fructose-6-phosphate 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
glucose/fructose-6-phosphate 13C5 0 ±  0.0 x 10
0 6.79 ±  1.2 x 104 5.53 ± 4.8 x 104 5.99 ± 5.3 x 104 
glucose/fructose-6-phosphate 13C6 0 ±  0.0 x 10
0 1.23 ±  0.05 x 106 1.57 ±  0.2 x 106 1.58 ± 1.4 x 106 
fructose-1-6-bisphosphate 12C 1.71 ± 0.6 x 106 5.80 ±  2.4 x 104 6.48 ±  3.6 x 104 5.40 ± 0.7 x 104 
fructose-1-6-bisphosphate 13C1 8.86 ± 2.8 x 10
4 3.54 ±  3.3 x 103 3.69 ±  3.0 x 103 3.32 ± 0.1 x 103 
fructose-1-6-bisphosphate 13C2 2.87 ± 0.9 x 10
4 5.17 ±  3.3 x 103 2.15 ±  1.4 x 103 2.45 ± 0.7 x 103 
fructose-1-6-bisphosphate 13C3 1.05 ± 0.3 x 10
4 9.63 ±  4.3 x 104 7.00 ±  1.4 x 104 6.60 ± 1.2 x 104 
fructose-1-6-bisphosphate 13C4 1.14 ± 0.9 x 10
3 1.64 ±  0.6 x 104 1.26 ± 0.5 x 104 1.60 ± 0.3 x 104 
fructose-1-6-bisphosphate 13C5 1.51 ± 0.4 x 10
4 7.18 ±  3.1 x 104 7.24 ±  1.3 x 104 1.31 ± 0.2 x 105 
fructose-1-6-bisphosphate 13C6 2.66 ± 0.08 x 10
5 1.28 ±  0.6 x 106 1.40 ±  0.3 x 106 2.66 ± 0.4 x 106 
1,3-Diphosphoglyceric acid 12C 3.50 ± 1.3 x 104 1.32 ±  0.008 x 103 2.05 ±  1.4 x 103 9.93 ± 2.9 x 102 
1,3-Diphosphoglyceric acid 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
1,3-Diphosphoglyceric acid 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
1,3-Diphosphoglyceric acid 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
Pyruvate 12C 1.62 ± 2.8 x 104 2.02 ±  3.5 x 103 2.45 ±  2.1 x 103 1.55 ± 0.6 x 103 
Pyruvate 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
Pyruvate 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
Pyruvate 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
alpha-ketoglutarate 12C 8.54 ± 6.1 x 102 6.23 ±  2.3 x 102 3.88 ±  1.2 x 102 4.02 ± 0.5 x 102 
alpha-ketoglutarate 13C1 0 ±  0.0 x 10
0 4.26 ±  5.5 x 102 0 ±  0.0 x 100 0 ±  0.0 x 100 
alpha-ketoglutarate 13C2 0 ±  0.0 x 10
0 6.37 ±  11.0 x 101 0 ±  0.0 x 100 0 ±  0.0 x 100 
alpha-ketoglutarate 13C3 0 ±  0.0 x 10
0 7.80 ±  13.5 x 101 0 ±  0.0 x 100 0 ±  0.0 x 100 
alpha-ketoglutarate 13C4 1.98 ± 1.7 x 10
2 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
alpha-ketoglutarate 13C5 1.06 ± 1.8 x 10
2 1.54 ±  1.3 x 102 8.39 ±  14.5 x 101 6.33 ± 11.0 x 101 
succinyl-CoA 12C 7.36 ± 0.9 x 104 6.19 ±  2.7 x 104 2.42 ±  0.8 x 104 1.59 ± 1.1 x 104 
succinyl-CoA 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C2 0 ±  0.0 x 10
0 1.52 ±  2.6 x 104 4.35 ±  7.6 x 103 0 ±  0.0 x 100 
succinyl-CoA 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C5 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C6 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C7 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C8 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C9 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C10 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C11 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C12 0 ±  0.0 x 10








0 min 2 min 5 min 15 min 
succinyl-CoA 13C13 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C14 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C15 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C16 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C17 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C18 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C19 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C20 0 ±  0.0 x 100 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C21 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C22 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C23 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C24 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C25 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
Succinate 12C 1.82 ± 2.1 x 103 1.97 ±  0.4 x 105 2.75 ±  0.2 x 105 2.39 ± 0.6 x 105 
Succinate 13C1 0 ±  0.0 x 10
0 4.33 ±  0.6 x 105 4.32 ±  0.3 x 105 6.02 ± 0.7 x 105 
Succinate 13C2 0 ±  0.0 x 10
0 4.18 ±  0.7 x 105 6.30 ±  0.8 x 105 1.81 ± 0.1 x 106 
Succinate 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
Succinate 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
fumarate 12C 0 ±  0.0 x 100 1.86 ±  1.6 x 102 1.52 ±  2.6 x 102 6.37 ± 11.0 x 101 
fumarate 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
fumarate 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
fumarate 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
fumarate 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
malate 12C 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
malate 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 1.09 ± 1.9 x 102 
malate 13C2 1.67 ± 0.3 x 10
4 2.43 ±  0.4 x 104 1.89 ±  0.3 x 104 6.54 ± 1.7 x 104 
malate 13C3 5.29 ± 1.3 x 10
2 7.75 ±  8.5 x 102 4.41 ±  2.1 x 102 3.84 ± 2.2 x 103 
6-phospho-D-gluconate 12C 1.64 ± 0.3 x 106 1.14 ±  0.2 x 105 9.71 ±  5.1 x 104 1.10 ± 0.4 x 105 
6-phospho-D-gluconate 13C1 8.49 ± 1.6 x 10
4 4.69 ±  4.1 x 103 2.62 ±  4.5 x 103 2.51 ± 4.3 x 103 
6-phospho-D-gluconate 13C2 2.17 ± 0.3 x 10
4 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
6-phospho-D-gluconate 13C3 0 ±  0.0 x 10
0 8.74 ±  1.3 x 103 2.30 ±  4.0 x 103 0 ±  0.0 x 100 
6-phospho-D-gluconate 13C4 0 ±  0.0 x 10
0 2.66 ±  4.61 x 103 2.52 ±  4.4 x 103 6.16 ± 5.3 x 103 
6-phospho-D-gluconate 13C5 0 ±  0.0 x 10
0 5.44 ± 1.0 x 104 7.24 ±  2.2 x 104 1.74 ± 0.3 x 105 
6-phospho-D-gluconate 13C6 0 ±  0.0 x 10
0 1.18 ±  0.2 x 106 1.58 ±  0.5 x 106 3.68 ± 0.5 x 106 
D-Xylulose 5-phosphate 12C 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-Xylulose 5-phosphate 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-Xylulose 5-phosphate 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-Xylulose 5-phosphate 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-Xylulose 5-phosphate 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-Xylulose 5-phosphate 13C5 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-sedoheptulose-1/7-
phosphate 








0 min 2 min 5 min 15 min 
D-sedoheptulose-1/7-
phosphate 
13C1 4.25 ±  0.3 x 10
3 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-sedoheptulose-1/7-
phosphate 
13C2 0 ±  0.0 x 10
0 5.46 ± 9.5 x 102 0 ±  0.0 x 100 7.25 ± 12.6 x 102 
D-sedoheptulose-1/7-
phosphate 
13C3 0 ±  0.0 x 10
0 1.26 ± 1.1 x 103 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-sedoheptulose-1/7-
phosphate 
13C4 0 ±  0.0 x 10
0 3.96 ± 2.0 x 103 1.43 ± 2.5 x 103 6.29 ± 10.9 x 102 
D-sedoheptulose-1/7-
phosphate 
13C5 0 ±  0.0 x 10
0 9.41 ± 5.5 x 103 4.41 ± 0.9 x 103 3.70 ± 0.9 x 102 
D-sedoheptulose-1/7-
phosphate 
13C6 0 ±  0.0 x 10
0 4.20 ±  1.2 x 103 1.05 ± 0.2 x 104 1.26 ± 0.4 x 103 
D-sedoheptulose-1/7-
phosphate 
13C7 0 ±  0.0 x 10
0 6.78 ±  0.3 x 104 1.27 ± 0.2 x 105 1.89 ± 0.3 x 105 
glutamate 12C 3.03 ±  1.8 x 103 9.87 ±  9.4 x 102 7.30 ± 6.4 x 102 2.36 ± 0.4 x 102 
glutamate 13C1 1.22 ±  0.6 x 10
4 1.09 ±  0.9 x 104 5.18 ± 2.8 x 103 2.26 ± 1.7 x 103 
glutamate 13C2 1.16 ±  1.3 x 10
3 4.38 ±  3.1 x 102 3.42 ± 5.9 x 102 1.51 ± 1.4 x 102 
glutamate 13C3 6.80 ±  2.3 x 10
3 6.04 ±  5.4 x 103 6.97 ± 11.8 x 104 1.52 ± 2.6 x 105 
glutamate 13C4 1.89 ±  2.9 x 10
3 9.55 ±  16.5 x 101 9.63 ± 12.5 x 102 4.11 ± 5.5 x 103 
glutamate 13C5 4.27 ±  1.6 x 10
2 6.94 ±  12.0 x 101 0 ±  0.0 x 100 1.32 ± 1.3 x 103 
glutamine 12C 4.79 ±  26.1 x 105 3.75 ±  15.8 x 105 7.03 ± 157.0 x 104 4.69 ± 8.3 x 105 
glutamine 13C1 
7.99 ±  436.0 x 
102 
3.30 ±  40.7 x 103 6.91 ± 51.5 x 103 6.18 ± 52.3 x 103 
glutamine 13C2 1.18 ±  44.9 x 10
3 2.23 ±  12.7 x 104 4.82 ± 35.8 x 104 2.55 ± 35.0 x 104 
glutamine 13C3 2.14 ±  4.8 x 10
3 1.03 ±  13.5 x 103 5.70 ± 40.7 x 103 1.44 ± 65.6 x 103 
glutamine 13C4 2.21 ±  6.5 x 10
2 5.65 ±  36.5 x 102 4.59 ± 1.3 x 103 1.19 ± 0.009 x 103 
glutamine 13C5 1.25 ±  2.0 x 10
3 6.98 ±  9.5 x 102 2.24 ± 15.2 x 102 5.51 ± 32.8 x 102 
aspartate 12C 2.23 ±  0.2 x 102 4.77 ±  1.6 x 102 5.14 ± 0.3 x 102 3.82 ± 0.3 x 102 
aspartate 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
aspartate 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
aspartate 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
aspartate 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
leucine/isoleucine 12C 1.39 ±  1.3 x 102 2.16 ±  58.5 x 102 1.39 ± 1.2 x 102 1.84 ± 0.2 x 102 
leucine/isoleucine 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
leucine/isoleucine 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
leucine/isoleucine 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
leucine/isoleucine 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
leucine/isoleucine 13C5 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
leucine/isoleucine 13C6 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
alanine 12C 0 ±  0.0 x 100 1.07 ±  0.2 x 103 1.43 ± 1.4 x 103 1.74 ± 0.8 x 103 
alanine 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
alanine 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
alanine 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
L-Valine 12C 4.26 ±  3.7 x 102 4.34 ±  1.2 x 103 9.34 ± 1.2 x 103 3.62 ± 0.5 x 103 
L-Valine 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
L-Valine 13C2 0 ±  0.0 x 10








0 min 2 min 5 min 15 min 
L-Valine 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 2.82 ± 4.9 x 103 0 ±  0.0 x 100 
L-Valine 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
L-Valine 13C5 0 ±  0.0 x 10



























Table A-6. The average ion counts plus or minus the standard deviation for the metabolites discussed and 
their isotopomers for the 25 °C experiment at 30, 60, and 120 minutes are shown. 
metabolite labeling pattern 30 min 60 min 120 min 
glucose/fructose-6-phosphate 12C 7.68 ±  2.0 x 104 7.10 ± 4.3 x 104 5.92 ± 0.8 x 104 
glucose/fructose-6-phosphate 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
glucose/fructose-6-phosphate 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
glucose/fructose-6-phosphate 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
glucose/fructose-6-phosphate 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
glucose/fructose-6-phosphate 13C5 2.19 ±  3.8 x 10
4 0 ±  0.0 x 100 0 ±  0.0 x 100 
glucose/fructose-6-phosphate 13C6 1.10 ±  1.0 x 10
6 0 ±  0.0 x 100 0 ±  0.0 x 100 
fructose-1-6-bisphosphate 12C 1.61 ±  1.7 x 105 7.26 ± 4.7 x 104 1.61 ± 1.2 x 105 
fructose-1-6-bisphosphate 13C1 9.45 ± 8.1 x 10
3 2.55 ± 0.2 x 103 8.71 ± 8.2 x 103 
fructose-1-6-bisphosphate 13C2 2.68 ±  2.5 x 10
3 1.42 ± 0.7 x 103 2.18 ± 1.6 x 103 
fructose-1-6-bisphosphate 13C3 5.21 ±  1.4 x 10
4 3.83 ± 1.3 x 104 1.89 ± 0.2 x 104 
fructose-1-6-bisphosphate 13C4 1.57 ±  0.4 x 10
4 1.23 ± 0.5 x 104 5.18 ± 2.3 x 103 
fructose-1-6-bisphosphate 13C5 1.67 ±  0.3 x 10
5 1.64 ± 0.1 x 105 1.02 ± 0.1 x 105 
fructose-1-6-bisphosphate 13C6 3.43 ±  0.7 x 10
6 3.37 ± 0.4 x 106 2.25 ± 0.2 x 106 
1,3-Diphosphoglyceric acid 12C 1.26 ±  0.9 x 103 5.12 ± 0.5 x 102 2.22 ± 1.1 x 103 
1,3-Diphosphoglyceric acid 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
1,3-Diphosphoglyceric acid 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
1,3-Diphosphoglyceric acid 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
Pyruvate 12C 0 ±  0.0 x 100 1.04 ± 1.8 x 102 0 ±  0.0 x 100 
Pyruvate 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
Pyruvate 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
Pyruvate 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
alpha-ketoglutarate 12C 7.49 ±  0.4 x 102 7.00 ± 3.1 x 102 3.61 ±0.6 x 102 
alpha-ketoglutarate 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
alpha-ketoglutarate 13C2 0 ±  0.0 x 10
0 7.50 ± 13.0 x 101 9.54 ± 16.5 x 101 
alpha-ketoglutarate 13C3 0 ±  0.0 x 10
0 8.49 ± 14.7 x 101 8.98 ± 15.5 x 101 
alpha-ketoglutarate 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
alpha-ketoglutarate 13C5 0 ±  0.0 x 10
0 9.81 ± 17.0 x 101 1.02 ± 1.8 x 102 
succinyl-CoA 12C 1.39 ±  1.6 x 104 2.97 ± 5.1 x 103 1.03 ± 0.9 x 104 
succinyl-CoA 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C5 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C6 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C7 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C8 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C9 0 ±  0.0 x 10






Table A-6 continued. 
metabolite labeling pattern 30 min 60 min 120 min 
succinyl-CoA 13C10 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C11 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C12 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C13 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C14 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C15 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C16 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C17 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C18 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C19 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C20 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C21 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C22 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C23 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C24 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C25 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
Succinate 12C 8.98 ±  2.0 x 104 2.55 ± 0.5 x 104 2.40 ± 0.2 x 104 
Succinate 13C1 5.65 ±  1.8 x 10
5 2.53 ± 0.4 x 105 1.93 ± 0.4 x 105 
Succinate 13C2 2.34 ±  0.1 x 10
6 1.72 ± 0.2 x 106 2.24 ± 0.2 x 106 
Succinate 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
Succinate 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
fumarate 12C 1.37 ±  2.4 x 102 0 ±  0.0 x 100 0 ±  0.0 x 100 
fumarate 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
fumarate 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
fumarate 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
fumarate 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
malate 12C 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
malate 13C1 0 ±  0.0 x 10
0 6.86 ± 11.9 x 101 1.74 ± 3.0 x 102 
malate 13C2 4.22 ±  0.7 x 10
4 2.09 ± 0.2 x 104 4.65 ±0.9 x 104 
malate 13C3 2.82 ±  2.1 x 10
3 1.53 ± 1.1 x 103 6.07 ± 0.6 x 103 
6-phospho-D-gluconate 12C 1.62 ±  1.5 x 105 4.78 ± 1.3 x 104 8.41 ± 5.8 x 104 
6-phospho-D-gluconate 13C1 5.83 ±  10.1 x 10
3 0 ±  0.0 x 100 0 ±  0.0 x 100 
6-phospho-D-gluconate 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
6-phospho-D-gluconate 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
6-phospho-D-gluconate 13C4 2.87 ±  5.0 x 10
3 0 ±  0.0 x 100 0 ±  0.0 x 100 
6-phospho-D-gluconate 13C5 1.99 ± 0.6 x 10
5 1.06 ± 0.2 x 105 1.86 ± 3.2 x 104 
6-phospho-D-gluconate 13C6 4.13 ±  1.1 x 10
6 2.37 ± 0.3 x 106 3.85 ± 6.7 x 105 
D-Xylulose 5-phosphate 12C 5.42  9.4 x 101 5.86 ± 10.2 x 101 0 ±  0.0 x 100 
D-Xylulose 5-phosphate 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-Xylulose 5-phosphate 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-Xylulose 5-phosphate 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-Xylulose 5-phosphate 13C4 0 ±  0.0 x 10




Table A-6 continued. 
metabolite labeling pattern 30 min 60 min 120 min 
D-Xylulose 5-phosphate 13C5 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-sedoheptulose-1/7-phosphate 12C 0 ±  0.0 x 100 1.21 ± 2.1 x 103 0 ±  0.0 x 100 
D-sedoheptulose-1/7-phosphate 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-sedoheptulose-1/7-phosphate 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-sedoheptulose-1/7-phosphate 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-sedoheptulose-1/7-phosphate 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 6.97 ± 12.1 x 102 
D-sedoheptulose-1/7-phosphate 13C5 2.72 ± 2.6 x 10
3 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-sedoheptulose-1/7-phosphate 13C6 7.51 ± 4.3 x 10
3 8.01 ± 13.9 x 102 7.75 ± 3.6 x 103 
D-sedoheptulose-1/7-phosphate 13C7 1.89 ± 0.2 x 10
5 7.10 ± 10.1 x 103 1.68 ± 0.3 x 105 
glutamate 12C 1.71 ± 1.6 x 102 3.34 ± 2.3 x 102 2.32 ± 0.3 x 102 
glutamate 13C1 1.86 ± 0.9 x 10
3 1.52 ± 0.5 x 103 1.66 ± 0.6 x 103 
glutamate 13C2 0 ±  0.0 x 10
0 7.65 ± 13.2 x 101 1.50 ± 1.3 x 102 
glutamate 13C3 7.50 ± 11.4 x 10
3 1.91 ± 3.2 x 105 1.23 ± 1.9 x 105 
glutamate 13C4 7.10 ± 4.2 x 10
2 3.47 ± 5.3 x 103 6.57 ± 8.4 x 102 
glutamate 13C5 8.07 ± 9.5 x 10
2 9.51 ± 7.1 x 102 3.33 ± 1.4 x 102 
glutamine 12C 7.29 ± 6.9 x 105 
3.53 ± 0.007 x 
105 
3.33 ± 1.4 x 102 
glutamine 13C1 1.44 ± 5.7 x 10
4 1.87 ± 0.7 x 104 8.94 ± 0.4 x 102 
glutamine 13C2 1.18 ± 5.1 x 10
5 1.30 ± 0.01 x 105 7.86 ± 13.6 x 101 
glutamine 13C3 6.03 ± 115.0 x 10
3 0 ±  0.0 x 100 6.35 ± 11.0 x 101 
glutamine 13C4 1.63 ± 5.4 x 10
2 5.47 ± 8.2 x 102 4.93 ± 2.3 x 103 
glutamine 13C5 1.99 ± 0.8 x 10
3 7.41 ± 7.5 x 102 3.02 ± 3.0 x 102 
aspartate 12C 3.63 ± 1.0 x 102 5.26 ± 4.3 x 102 3.46 ± 0.9 x 102 
aspartate 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
aspartate 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
aspartate 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
aspartate 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
leucine/isoleucine 12C 1.70 ± 0.08 x 102 2.86 ± 1.2 x 102 2.18 ± 0.6 x 102 
leucine/isoleucine 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
leucine/isoleucine 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
leucine/isoleucine 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
leucine/isoleucine 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
leucine/isoleucine 13C5 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
leucine/isoleucine 13C6 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
alanine 12C 1.20 ± 1.0 x 103 8.26 ± 2.8 x 102 7.11 ± 0.8 x 102 
alanine 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
alanine 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
alanine 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
L-Valine 12C 3.80 ± 1.1 x 102 5.43 ± 1.9 x 102 5.31 ± 4.9 x 102 
L-Valine 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
L-Valine 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
L-Valine 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
L-Valine 13C4 0 ±  0.0 x 10




Table A-6 continued. 
metabolite labeling pattern 30 min 60 min 120 min 
L-Valine 13C5 0 ±  0.0 x 10




Table A-7. The average ion counts plus or minus the standard deviation for the metabolites discussed and 
their isotopomers for the 3 °C experiment at 0, 2, 5, and 15 minutes are shown. 
metabolite labeling pattern 0 min 2 min 5 min 15 min 
glucose/fructose-6-phosphate 12C 1.68 ± 0.4 x 106 6.45 ± 1.0 x 105 4.21 ± 2.0 x 105 2.99 ± 0.7 x 105 
glucose/fructose-6-phosphate 13C1 8.73 ± 1.8 x 10
4 4.83 ± 0.6 x 104 2.85 ± 2.5 x 104 2.36 ± 2.2 x 104 
glucose/fructose-6-phosphate 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 1.49 ± 2.6 x 104 1.65 ± 2.9 x 104 
glucose/fructose-6-phosphate 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 1.04 ± 0.2 x 105 1.09 ± 0.2 x 105 
glucose/fructose-6-phosphate 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 6.53 ± 11.3 x 103 3.40 ± 3.3 x 104 
glucose/fructose-6-phosphate 13C5 0 ±  0.0 x 10
0 0 ±  0.0 x 100 7.16 ± 0.8 x 104 1.22 ± 0.2 x 105 
glucose/fructose-6-phosphate 13C6 0 ±  0.0 x 10
0 5.68 ± 0.3 x 105 8.68 ± 1.8 x 105 1.30 ± 0.4 x 106 
fructose-1-6-bisphosphate 12C 1.97 ± 1.8 x 105 8.38 ± 7.9 x 105 2.31 ± 3.9 x 105 1.54 ± 1.8 x 105 
fructose-1-6-bisphosphate 13C1 1.62 ± 1.4 x 10
4 6.20 ± 5.8 x 104 1.97 ± 3.3 x 104 1.50 ± 1.4 x 104 
fructose-1-6-bisphosphate 13C2 1.18 ± 1.0 x 10
4 4.30 ± 3.3 x 104 1.90 ± 3.0 x 104 1.67 ± 1.4 x 104 
fructose-1-6-bisphosphate 13C3 1.87 ± 1.4 x 10
5 7.56 ± 6.5 x 105 8.59 ± 14.9 x 103 2.46 ± 2.4 x 105 
fructose-1-6-bisphosphate 13C4 1.75 ± 1.1 x 10
4 5.62 ± 4.37 x 104 2.73 ± 4.4 x 104 2.46 ± 2.0 x 104 
fructose-1-6-bisphosphate 13C5 2.75 ± 1.7 x 10
4 8.28 ± 6.7 x 104 4.44 ± 7.42 x 104 4.08 ± 3.7 x 104 
fructose-1-6-bisphosphate 13C6 2.98 ± 2.1 x 10
5 9.70 ± 7.7 x 105 4.44 ± 7.3 x 105 4.21 ± 4.4 x 105 
1,3-Diphosphoglyceric acid 12C 1.64 ± 1.3 x 103 4.75 ± 2.9 x 103 1.17 ± 1.6 x 103 1.26 ± 1.6 x 103 
1,3-Diphosphoglyceric acid 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
1,3-Diphosphoglyceric acid 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
1,3-Diphosphoglyceric acid 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
Pyruvate 12C 9.77 ± 7.8 x 106 8.35 ± 1.5 x 105 6.00 ± 2.8 x 105 2.80 ± 1.3 x 105 
Pyruvate 13C1 2.41 ± 3.1 x 10
5 0 ±  0.0 x 100 2.85 ± 4.9 x 103 0 ±  0.0 x 100 
Pyruvate 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 3.30 ± 5.7 x 103 
Pyruvate 13C3 0 ±  0.0 x 10
0 2.4 ± 1.2 x 105 3.51 ± 2.1 x 105 5.00 ± 2.0 x 105 
alpha-ketoglutarate 12C 3.84 ± 1.1 x 106 2.10 ± 0.3 x 106 1.34 ± 0.1 x 106 7.91 ± 2.0 x 105 
alpha-ketoglutarate 13C1 1.73 ± 0.8 x 10
5 5.22 ± 2.2 x 104 2.68 ±0.2 x 104 1.52 ± 0.4 x 104 
alpha-ketoglutarate 13C2 1.06 ± 0.3 x 10
4 1.34 ± 0.2 x 104 3.64 ± 0.5 x 104 7.90 ± 3.7 x 104 
alpha-ketoglutarate 13C3 1.60 ± 2.8 x 10
2 1.09 ± 0.2 x 103 4.69 ± 1.4 x 103 8.63 ± 4.2 x 103 
alpha-ketoglutarate 13C4 5.44 ± 3.6 x 10
2 4.4 ± 0.4 x 102 8.01 ± 5.7 x 102 3.96 ± 0.4 x 102 
alpha-ketoglutarate 13C5 0 ±  0.0 x 10
0 7.69 ± 13.3 x 101 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 12C 6.74 ± 8.7 x 103 4.32 ± 5.6 x 104 2.69 ± 4.7 x 104 2.10 ± 3.6 x 103 
succinyl-CoA 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C5 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C6 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C7 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C8 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C9 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C10 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C11 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C12 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C13 0 ±  0.0 x 10




Table A-7 continued. 
metabolite labeling pattern 0 min 2 min 5 min 15 min 
succinyl-CoA 13C14 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C15 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C16 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C17 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C18 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C19 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C20 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C21 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C22 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C23 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C24 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C25 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
Succinate 12C 7.20 ± 2.2 x 106 7.55 ± 2.5 x 106 5.03 ± 2.4 x 106 3.64 ± 1.3 x 106 
Succinate 13C1 3.25 ± 1.1 x 10
5 3.45 ± 1.1 x 105 2.28 ± 1.3 x 105 1.81 ± 0.8 x 105 
Succinate 13C2 0 ±  0.0 x 10
0 4.36 ± 1.3 x 104 2.54 ± 1.1 x 105 5.21 ± 2.1 x 105 
Succinate 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 4.70 ± 0.7 x 103 1.84 ± 0.7 x 104 
Succinate 13C4 0 ±  0.0 x 10
0 2.16 ± 0.8 x 104 7.23 ± 3.1 x 104 2.93 ± 1.2 x 105 
fumarate 12C 3.34 ± 0.7 x 105 2.61 ± 0.7 x 105 1.41 ± 0.3 x 105 9.11 ± 1.9 x 104 
fumarate 13C1 3.57 ± 3.1 x 10
3 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
fumarate 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 5.30 ± 9.2 x 102 4.62 ± 4.2 x 103 
fumarate 13C3 0 ±  0.0 x 10
0 9.26 ± 10.1 x 103 2.29 ± 0.2 x 104 5.04 ± 2.0 x 104 
fumarate 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
malate 12C 1.61 ± 1.0 x 106 2.12 ± 1.8 x 106 8.36 ± 9.7 x 105 3.17 ± 5.5 x 105 
malate 13C1 2.09 ± 1.0 x 10
4 3.82 ± 1.7 x 104 1.91 ± 1.7 x 104 1.55 ± 0.7 x 104 
malate 13C2 2.34 ± 1.4 x 10
5 3.61 ± 1.3 x 105 2.55 ± 3.6 x 105 5.29 ± 2.1 x 105 
malate 13C3 2.64 ± 2.1 x 10
4 1.05 ± 0.3 x 104 1.27 ± 1.4 x 104 3.44 ± 1.4 x 104 
6-phospho-D-gluconate 12C 1.91 ± 1.1 x 103 3.83 ± 2.9 x 104 2.48 ± 0.6 x 104 2.02 ± 0.1 x 104 
6-phospho-D-gluconate 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
6-phospho-D-gluconate 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
6-phospho-D-gluconate 13C3 0 ±  0.0 x 10
0 3.36 ± 5.8 x 103 0 ±  0.0 x 100 0 ±  0.0 x 100 
6-phospho-D-gluconate 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
6-phospho-D-gluconate 13C5 0 ±  0.0 x 10
0 4.01 ± 7.0 x 103 0 ±  0.0 x 100 0 ±  0.0 x 100 
6-phospho-D-gluconate 13C6 0 ±  0.0 x 10
0 4.23 ± 7.3 x 104 1.80 ± 3.1 x 104 0 ±  0.0 x 100 
D-Xylulose 5-phosphate 12C 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-Xylulose 5-phosphate 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-Xylulose 5-phosphate 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-Xylulose 5-phosphate 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-Xylulose 5-phosphate 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-Xylulose 5-phosphate 13C5 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-sedoheptulose-1/7-phosphate 12C 1.8 ± 0.7 x 105 4.55 ± 0.4 x 104 1.47 ± 1.2 x 104 6.41 ± 1.1 x 103 
D-sedoheptulose-1/7-phosphate 13C1 9.54 ± 2.5 x 10
3 4.23 ± 0.6 x 103 4.53 ± 2.3 x 103 1.73 ± 1.6 x 103 
D-sedoheptulose-1/7-phosphate 13C2 0 ±  0.0 x 10





Table A-7 continued. 
metabolite labeling pattern 0 min 2 min 5 min 15 min 
D-sedoheptulose-1/7-phosphate 13C3 0 ±  0.0 x 10
0 4.23 ± 2.9 x 103 1.19 ± 0.005 x 104 1.42 ± 0.4 x 104 
D-sedoheptulose-1/7-phosphate 13C4 0 ±  0.0 x 10
0 3.42 ± 0.9 x 103 1.71 ± 1.1 x 104 2.84 ± 0.7 x 104 
D-sedoheptulose-1/7-phosphate 13C5 0 ±  0.0 x 10
0 3.66 ± 1.1 x 103 2.32 ± 0.7 x 104 3.02 ± 0.5 x 104 
D-sedoheptulose-1/7-phosphate 13C6 0 ±  0.0 x 10
0 2.04 ± 2.3 x 103 8.64 ± 4.6 x 103 1.54 ± 0.8 x 104 
D-sedoheptulose-1/7-phosphate 13C7 0 ±  0.0 x 10
0 3.54 ± 1.1 x 103 2.67 ± 0.2 x 104 4.12 ± 2.3 x 104 
glutamate 12C 3.91 ± 0.1 x 107 2.34 ± 0.8 x 107 3.01 ± 2.0 x 107 1.64 ± 0.3 x 107 
glutamate 13C1 
2.16 ± 0.01 x 
106 
1.26 ± 0.4 x 106 1.72 ± 1.1 x 106 9.98 ± 1.5 x 105 
glutamate 13C2 
2.42 ± 0.03 x 
103 
1.48 ± 0.5 x 105 1.60 ± 0.8 x 106 2.91 ± 0.2 x 106 
glutamate 13C3 6.17 ± 0.5 x 10
3 5.82 ± 4.7 x 103 1.56 ± 0.2 x 103 1.93 ± 1.2 x 103 
glutamate 13C4 1.46 ± 0.6 x 10
3 1.36 ± 0.4 x 103 1.50 ± 0.5 x 103 1.39 ± 0.2 x 103 
glutamate 13C5 2.07 ± 0.3 x 10
4 1.45 ± 0.1 x 104 8.01 ± 3.8 x 103 8.90 ± 7.2 x 103 
glutamine 12C 2.07 ± 0.3 x 10
4 1.45 ± 0.1 x 104 8.01 ± 3.8 x 103 8.90 ± 7.2 x 103 
glutamine 13C1 4.15 ± 0.2 x 10
6 2.34 ± 0.5 x 106 2.61 ± 0.4 x 106 
1.58 ± 0.07 x 
106 
glutamine 13C2 7.60 ± 1.7 x 10
4 4.20 ± 0.08 x 104 4.36 ± 0.3 x 104 4.07 ± 0.7 x 104 
glutamine 13C3 1.19 ± 0.1 x 10
5 2.72 ± 0.1 x 104 2.29 ± 2.2 x 104 1.27 ± 0.5 x 105 
glutamine 13C4 4.54 ± 1.3 x 10
3 2.53 ± 2.1 x 103 4.83 ± 1.0 x 103 1.35 ± 0.6 x 104 
glutamine 13C5 
7.31 ± 10.7 x 
102 
1.37 ± 0.2 x 103 6.49 ± 5.7 x 102 3.65 ± 4.6 x 103 
aspartate 12C 
3.51 ± 0.03 x 
106 
1.68 ± 0.6 x 106 1.57 ± 0.3 x 106 8.93 ± 1.5 x 105 
aspartate 13C1 4.57 ± 0.5 x 10
4 2.52 ± 0.8 x 104 3.98 ± 1.3 x 104 2.96 ± 0.5 x 104 
aspartate 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 2.64 ± 0.8 x 104 4.90 ± 0.7 x 104 
aspartate 13C3 0 ±  0.0 x 10
0 6.95 ± 1.8 x 104 6.02 ± 1.7 x 105 8.31 ± 0.5 x 105 
aspartate 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 1.03 ± 0.3 x 104 2.92 ± 0.4 x 104 
leucine/isoleucine 12C 8.36 ± 1.9 x 105 9.31 ± 0.5 x 105 8.36 ± 2.0 x 105 8.50 ± 0.7 x 105 
leucine/isoleucine 13C1 1.62 ± 0.4 x 10
4 1.82 ± 0.2 x 104 1.67 ± 0.1 x 104 1.80 ± 0.3 x 104 
leucine/isoleucine 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 7.38 ± 5.4 x 103 8.66 ± 1.9 x 103 
leucine/isoleucine 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
leucine/isoleucine 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
leucine/isoleucine 13C5 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
leucine/isoleucine 13C6 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
alanine 12C 3.31 ± 0.4 x 105 4.49 ± 1.7 x 104 1.19 ± 1.0 x 105 4.21 ± 1.5 x 104 
alanine 13C1 0 ±  0.0 x 10
0 2.25 ± 3.9 x 105 0 ±  0.0 x 100 3.12 ± 5.4 x 105 
alanine 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
alanine 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 7.96 ± 6.9 x 103 2.67 ± 0.4 x 104 
L-Valine 12C 9.67 ± 1.5 x 106 5.98 ± 0.5 x 106 5.99 ± 0.9 x 106 
4.07 ± 0.06 x 
106 
L-Valine 13C1 
5.52 ± 0.08 x 
105 
3.13 ± 0.3 x 105 3.41 ± 0.7 x 105 2.45 ± 0.1 x 105 
L-Valine 13C2 4.05 ± 0.5 x 10
3 1.27 ± 0.3 x 104 2.21 ± 0.5 x 105 4.05 ± 0.5 x 105 
L-Valine 13C3 0 ±  0.0 x 10
0 8.24 ± 1.2 x 103 2.21 ± 0.4 x 105 4.30 ± 0.4 x 105 
L-Valine 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 8.36 ± 4.0 x 103 2.90 ±0.5 x 104 
L-Valine 13C5 0 ±  0.0 x 10
0 8.88 ± 15.4 x 102 1.40 ± 0.5 x 105 5.26 ± 0.6 x 105 





Table A-8. The average ion counts plus or minus the standard deviation for the metabolites discussed and 
their isotopomers for the 3 °C experiment at 30, 60 and 120 minutes are shown. 
metabolite labeling pattern 30 min 60 min 120 min 
glucose/fructose-6-phosphate 12C 1.86 ± 0.5 x 105 1.32 ± 0.5 x 105 9.54 ± 0.9 x 104 
glucose/fructose-6-phosphate 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
glucose/fructose-6-phosphate 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
glucose/fructose-6-phosphate 13C3 6.91 ± 1.8 x 10
4 3.61 ± 3.2 x 104 0 ±  0.0 x 100 
glucose/fructose-6-phosphate 13C4 1.71 ± 3.0 x 10
4 2.16 ± 3.7 x 104 0 ±  0.0 x 100 
glucose/fructose-6-phosphate 13C5 9.26 ± 1.8 x 10
4 7.10 ± 6.3 x 104 8.49 ± 1.7 x 104 
glucose/fructose-6-phosphate 13C6 1.27 ± 0.3 x 10
6 1.32 ± 0.4 x 106 1.23 ± 0.2 x 106 
fructose-1-6-bisphosphate 12C 4.60 ± 3.5 x 105 4.05 ± 4.6 x 105 2.96 ± 1.7 x 105 
fructose-1-6-bisphosphate 13C1 3.43 ± 2.3 x 10
4 3.23 ± 3.6 x 104 2.36 ± 1.0 x 104 
fructose-1-6-bisphosphate 13C2 3.11 ± 2.0 x 10
4 2.09 ± 2.2 x 104 2.39 ± 1.0 x 104 
fructose-1-6-bisphosphate 13C3 5.26 ±3.6 x 10
5 3.87 ± 4.1 x 105 3.83 ± 1.5 x 105 
fructose-1-6-bisphosphate 13C4 5.19 ± 3.6 x 10
4 3.11 ± 3.2 x 104 2.80 ± 3.1 x 104 
fructose-1-6-bisphosphate 13C5 9.34 ± 7.0 x 10
4 5.48 ± 5.3 x 104 5.59 ± 4.3 x 104 
fructose-1-6-bisphosphate 13C6 9.56 ± 7.2 x 10
5 6.24 ± 6.4 x 105 6.56 ± 4.7 x 105 
1,3-Diphosphoglyceric acid 12C 1.10 ± 0.1 x 103 4.33 ± 3.8 x 102 5.03 ± 0.4 x 102 
1,3-Diphosphoglyceric acid 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
1,3-Diphosphoglyceric acid 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
1,3-Diphosphoglyceric acid 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
Pyruvate 12C 1.40 ± 0.1 x 105 1.48 ± 0.7 x 105 5.13 ± 0.8 x 104 
Pyruvate 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
Pyruvate 13C2 0 ±  0.0 x 10
0 5.03 ± 8.7 x 103 0 ±  0.0 x 100 
Pyruvate 13C3 2.40 ± 2.0 x 10
5 3.95 ± 3.7 x 105 0 ±  0.0 x 100 
alpha-ketoglutarate 12C 6.27 ± 1.3 x 105 5.83 ± 2.5 x 105 3.88 ± 1.2 x 105 
alpha-ketoglutarate 13C1 1.25 ± 0.2 x 10
4 1.52 ± 0.5 x 104 8.60 ± 4.0 x 103 
alpha-ketoglutarate 13C2 1.10 ± 0.4 x 10
5 2.51 ± 1.0 x 105 2.20 ± 0.4 x 105 
alpha-ketoglutarate 13C3 1.36 ± 0.3 x 10
4 4.53 ± 1.8 x 104 6.38 ± 0.1 x 104 
alpha-ketoglutarate 13C4 4.89 ± 1.1 x 10
2 4.29 ± 0.4 x 102 4.57 ± 2.2 x 102 
alpha-ketoglutarate 13C5 1.21 ± 2.1 x 10
2 1.10 ± 1.9 x 102 2.70 ± 2.8 x 102 
succinyl-CoA 12C 3.10 ± 2.8 x 104 1.47 ± 2.2 x 104 1.63 ± 2.8 x 104 
succinyl-CoA 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C5 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C6 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C7 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C8 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C9 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C10 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C11 0 ±  0.0 x 10




Table A-8 continued. 
metabolite labeling pattern 30 min 60 min 120 min 
succinyl-CoA 13C12 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C13 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C14 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C15 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C16 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C17 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C18 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C19 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C20 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C21 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C22 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C23 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C24 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C25 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
Succinate 12C 3.02 ± 0.4 x 106 2.01 ± 0.3 x 106 1.83 ± 0.1 x 106 
Succinate 13C1 1.60 ± 0.2 x 10
5 1.20 ± 0.2 x 105 1.24 ± 0.03 x 105 
Succinate 13C2 7.83 ± 0.7 x 10
5 8.06 ± 1.3 x 105 1.03 ± 0.1 x 106 
Succinate 13C3 1.13 ± 0.2 x 10
5 2.18 ± 0.3 x 105 4.49 ± 0.6 x 105 
Succinate 13C4 8.06 ± 1.1 x 10
5 1.62 ± 0.4 x 106 3.22 ± 0.7 x 106 
fumarate 12C 6.73 ± 0.6 x 104 3.99 ± 0.8 x 104 2.45 ± 0.8 x 104 
fumarate 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
fumarate 13C2 7.53 ± 1.4 x 10
3 5.83 ± 5.1 x 103 6.60 ± 5.8 x 103 
fumarate 13C3 8.52 ± 1.0 x 10
4 9.88 ± 2.0 x 104 1.17 ± 0.2 x 105 
fumarate 13C4 1.01 ± 0.2 x 10
4 1.75 ± 0.2 x 104 4.21 ± 1.2 x 104 
malate 12C 6.47 ± 5.7 x 105 4.48 ± 4.4 x 105 0 ±  0.0 x 100 
malate 13C1 2.29 ± 0.8 x 10
4 1.65 ± 0.5 x 104 1.34 ±0.5 x 104 
malate 13C2 8.24 ± 0.3 x 10
5 8.21 ± 4.4 x 105 1.03 ± 0.5 x 106 
malate 13C3 9.52 ± 7.3 x 10
4 1.74 ± 1.3 x 105 3.63 ± 2.0 x 105 
6-phospho-D-gluconate 12C 2.92 ± 1.8 x 104 2.27 ± 0.3 x 104 2.05 ± 0.1 x 104 
6-phospho-D-gluconate 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
6-phospho-D-gluconate 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
6-phospho-D-gluconate 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
6-phospho-D-gluconate 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
6-phospho-D-gluconate 13C5 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
6-phospho-D-gluconate 13C6 3.20 ± 3.7 x 10
4 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-Xylulose 5-phosphate 12C 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-Xylulose 5-phosphate 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-Xylulose 5-phosphate 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-Xylulose 5-phosphate 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-Xylulose 5-phosphate 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-Xylulose 5-phosphate 13C5 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 





Table A-8 continued. 
metabolite labeling pattern 30 min 60 min 120 min 
D-sedoheptulose-1/7-phosphate 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-sedoheptulose-1/7-phosphate 13C2 1.45 ± 1.3 x 10
3 1.07 ± 10.7 x 102 7.17 ± 12.4 x 102 
D-sedoheptulose-1/7-phosphate 13C3 3.47 ± 3.0 x 10
3 1.81 ± 1.6 x 103 0 ±  0.0 x 100 
D-sedoheptulose-1/7-phosphate 13C4 1.08 ± 1.3 x 10
4 6.20 ± 5.2 x 103 1.94 ± 1.8 x 103 
D-sedoheptulose-1/7-phosphate 13C5 1.33 ± 1.6 x 10
4 4.87 ± 3.4 x 103 5.21 ± 4.6 x 103 
D-sedoheptulose-1/7-phosphate 13C6 1.48 ± 1.4 x 10
4 3.94 ± 0.5 x 103 1.02 ± 1.0 x 104 
D-sedoheptulose-1/7-phosphate 13C7 5.96 ± 6.0 x 10
4 9.36 ± 1.1 x 104 6.34 ± 5.8 x 104 
glutamate 12C 1.58 ± 0.5 x 107 1.07 ± 0.5 x 107 7.03 ± 2.1 x 106 
glutamate 13C1 1.11 ± 0.3 x 10
6 9.03 ± 3.9 x 105 7.30 ± 2.0 x 105 
glutamate 13C2 5.01 ± 1.2 x 10
6 6.20 ± 1.8 x 106 6.37 ± 0.9 x 106 
glutamate 13C3 9.84 ± 17.1 x 10
1 1.38 ± 2.0 x 103 1.43 ± 0.6 x 103 
glutamate 13C4 1.09 ± 1.9 x 10
2 1.74 ± 3.0 x 103 1.36 ± 0.3 x 104 
glutamate 13C5 4.89 ± 7.3 x 10
3 3.40 ± 2.8 x 103 7.76 ± 2.8 x 103 
glutamine 12C 4.89 ± 7.3 x 103 3.40 ± 2.8 x 103 7.76 ± 2.8 x 103 
glutamine 13C1 1.57 ± 0.5 x 10
6 8.30 ± 7.3 x 105 6.87 ± 3.5 x 105 
glutamine 13C2 5.15 ± 0.6 x 10
4 5.23 ± 1.4 x 104 5.73 ± 1.9 x 104 
glutamine 13C3 3.58 ±0.3 x 10
5 3.50 ± 1.2 x 105 5.11 ± 1.3 x 105 
glutamine 13C4 4.07 ±0.1 x 10
4 6.56 ± 0.6 x 104 1.15 ± 0.2 x 105 
glutamine 13C5 1.29 ± 1.2 x 10
3 9.44 ± 16.3 x 101 5.36 ± 5.5 x 102 
aspartate 12C 8.20 ± 1.3 x 105 4.64 ± 1.7 x 105 2.97 ± 1.0 x 105 
aspartate 13C1 3.74 ± 0.2 x 10
4 2.32 ± 0.6 x 104 2.53 ± 0.1 x 104 
aspartate 13C2 1.63 ± 0.5 x 10
5 1.70 ± 1.0 x 105 2.61 ± 0.6 x 105 
aspartate 13C3 1.43 ± 0.3 x 10
6 1.65 ± 0.4 x 106 2.30 ± 0.1 x 106 
aspartate 13C4 1.31 ± 0.6 x 10
5 3.23 ± 0.7 x 105 7.20 ± 0.4 x 105 
leucine/isoleucine 12C 9.01 ± 1.6 x 105 7.52 ± 0.5 x 105 8.84 ± 1.0 x 105 
leucine/isoleucine 13C1 1.75 ± 0.08 x 10
4 1.47 ± 0.2 x 104 2.04 ± 0.4 x 104 
leucine/isoleucine 13C2 1.16 ± 1.0 x 10
4 1.51 ± 1.3 x 104 4.65 ± 8.1 x 104 
leucine/isoleucine 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
leucine/isoleucine 13C4 6.75 ± 0.5 x 10
3 1.36 ± 0.3 x 104 3.62 ± 0.8 x 104 
leucine/isoleucine 13C5 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
leucine/isoleucine 13C6 2.99 ± 2.8 x 10
3 1.92 ± 0.6 x 104 1.26 ± 0.4 x 105 
alanine 12C 7.51 ± 5.0 x 104 3.20 ± 0.4 x 104 1.77 ± 0.1 x 104 
alanine 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 3.40 ± 5.9 x 105 
alanine 13C2 1.49 ± 2.6 x 10
3 0 ±  0.0 x 100 0 ±  0.0 x 100 
alanine 13C3 8.32 ± 4.8 x 10
4 1.93 ±0.4 x 105 1.35 ± 1.2 x 105 
L-Valine 12C 4.53 ± 1.0 x 106 3.11 ±0.9 x 106 2.80 ± 0.5 x 106 
L-Valine 13C1 2.84 ± 0.7 x 10
5 1.95 ± 0.6 x 105 1.87 ± 0.3 x 105 
L-Valine 13C2 7.49 ± 0.7 x 10
5 8.46 ±1.0 x 105 9.38 ± 0.9 x 105 
L-Valine 13C3 8.23 ± 0.6 x 10
5 9.74 ± 1.0 x 105 1.10  ± 0.1 x 106 
L-Valine 13C4 1.87 ± 0.3 x 10
5 3.78 ± 0.8 x 105 7.34 ± 0.4 x 105 
L-Valine 13C5 1.88 ± 0.3 x 10
6 3.77 ± 0.5 x 106 6.78 ± 0.7 x 106 




Table A-9. The average ion counts plus or minus the standard deviation for the metabolites discussed and 
their isotopomers for the wild type Salmonella enterica study at 0, 2, 5, and 15 minutes are shown. 
metabolite labeling  pattern 0 min 2 min 5 min 15 min 
glucose/fructose-6-phosphate 12C 5.37 ± 1.3 x 105 1.84 ± 0.4 x 105 1.70 ± 0.6 x 105 1.36 ± 0.5 x 105 
glucose/fructose-6-phosphate 13C1 1.46 ± 1.7 x 10
4 6.04 ± 10.5 x 103 0 ±  0.0 x 100 8.03 ± 0.9 x 10 
glucose/fructose-6-phosphate 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
glucose/fructose-6-phosphate 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
glucose/fructose-6-phosphate 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
glucose/fructose-6-phosphate 13C5 0 ±  0.0 x 10
0 2.75 ± 2.9 x 104 4.47 ± 2.3 x 104 2.7 ± 2.5 x 104 
glucose/fructose-6-phosphate 13C6 5.76 ± 10.0 x 10
3 4.64 ± 6.8 x 105 6.69 ± 4.3 x 105 1.65 ± 1.6 x 105 
fructose-1-6-bisphosphate 12C 2.29 ± 1.8 x 105 5.29 ± 2.1 x 104 1.01 ± 1.3 x 105 1.63 ± 0.5 x 105 
fructose-1-6-bisphosphate 13C1 9.57 ± 9.4 x 10
3 2.89 ± 4.1 x 103 2.31 ± 0.6 x 103 1.20 ± 2.4 x 104 
fructose-1-6-bisphosphate 13C2 5.11 ± 5.7 x 10
3 1.45 ± 2.5 x 103 2.02 ± 3.5 x 103 6.28 ± 4.7 x 103 
fructose-1-6-bisphosphate 13C3 3.54 ± 3.1 x 10
3 6.21 ± 7.7 x 103 9.35 ± 11.3 x 103 7.20 ± 1.3 x 103 
fructose-1-6-bisphosphate 13C4 4.19 ± 7.3 x 10
2 3.38 ± 3.1 x 103 3.31 ± 2.7 x 103 2.32 ± 3.2 x 103 
fructose-1-6-bisphosphate 13C5 1.22 ± 1.1 x 10
4 1.14 ± 1.0 x 104 7.90 ± 4.6 x 103 1.35 ± 0.5 x 104 
fructose-1-6-bisphosphate 13C6 1.82 ± 1.6 x 10
5 3.37 ± 2.9 x 105 3.99 ± 3.2 x 105 2.52 ± 0.6 x 105 
D-glyceraldehdye-3-phosphate 12C 4.06 ± 0.6 x 106 2.46 ± 0.7 x 106 2.04 ± 0.5 x 106 1.31 ± 0.5 x 106 
D-glyceraldehdye-3-phosphate 13C1 3.62 ± 0.9 x 10
4 3.00 ± 2.8 x 104 2.25 ± 0.4 x 104 2.65 ± 0.8 x 104 
D-glyceraldehdye-3-phosphate 13C2 4.46 ± 2.5 x 10
3 5.30 ± 3.5 x 103 3.54 ± 1.2 x 103 7.10 ± 3.3 x 103 
D-glyceraldehdye-3-phosphate 13C3 0 ±  0.0 x 10
0 8.51 ± 14.7 x 103 1.23 ± 1.1 x 105 4.81 ± 1.5 x 105 
1,3-diphopshateglycerate 12C 7.01 ± 5.7 x 103 4.02 ± 5.0 x 103 4.33 ± 1.3 x 103 7.67 ± 1.1 x 103 
1,3-diphopshateglycerate 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
1,3-diphopshateglycerate 13C2 1.40 ± 2.4 x 10
3 2.90 ± 5.0 x 103 1.91 ± 2.1 x 103 3.53 ± 6.1 x 102 
1,3-diphopshateglycerate 13C3 5.23 ± 9.1 x 10
2 4.19 ± 7.3 x 103 1.38 ± 1.4 x 104 9.67 ± 8.5 x 103 
3/2-phosphoglycerate 12C 4.81 ± 3.4 x 104 2.31 ± 1.1 x 104 2.77 ± 2.1 x 104 1.47 ± 1.0 x 104 
3/2-phosphoglycerate 13C1 2.76 ± 2.8 x 10
2 0 ±  0.0 x 100 3.86 ± 6.7 x 102 3.24 ± 5.6 x 102 
3/2-phosphoglycerate 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
3/2-phosphoglycerate 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
pyruvate 12C 2.43 ± 1.2 x 108 3.41 ± 3.0 x 107 1.18 ± 0.6 x 107 6.78 ± 2.8 x 106 
pyruvate 13C1 8.83 ± 4.5 x 10
6 1.89 ± 2.0 x 106 2.05 ± 3.3 x 105 4.77 ± 2.8 x 104 
pyruvate 13C2 2.60 ± 0.5 x 10
4 3.38 ± 3.0 x 106 2.28 ± 3.5 x 106 8.85 ± 7.6 x 104 
pyruvate 13C3 0 ±  0.0 x 10
0 9.37 ± 8.0 x 107 6.67 ± 8.3 x 107 1.03 ±0.6 x 107 
alpha-ketoglutarate 12C 9.04 ± 0.6 x 107 3.99 ± 1.6 x 107 1.09 ± 0.5 x 107 2.18 ± 0.9 x 106 
alpha-ketoglutarate 13C1 4.54 ± 0.3 x 10
6 2.93 ± 1.3 x 106 7.33 ± 4.1 x 105 9.99 ± 1.5 x 104 
alpha-ketoglutarate 13C2 3.24 ± 0.3 x 10
5 1.48 ± 0.4 x 107 6.94 ± 2.2 x 106 7.92 ± 4.1 x 105 
alpha-ketoglutarate 13C3 6.09 ± 0.7 x 10




Table A-9 continued. 
metabolite labeling  pattern 0 min 2 min 5 min 15 min 
alpha-ketoglutarate 13C4 0 ±  0.0 x 10
0 1.03 ± 0.2 x 107 1.34 ± 0.4 x 107 6.52 ± 1.7 x 106 
alpha-ketoglutarate 13C5 0 ±  0.0 x 10
0 1.53 ± 0.1 x 107 3.33 ± 1.2 x 107 2.88 ± 0.5 x 107 
succinyl-CoA 12C 9.64 ± 14.7 x 103 1.10 ± 1.9 x 103 3.47 ± 6.0 x 103 2.65 ± 1.2 x 104 
succinyl-CoA 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 2.22 ± 2.2 x 103 
succinyl-CoA 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C4 0 ±  0.0 x 10
0 3.13 ± 5.4 x 103 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C5 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C6 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C7 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C8 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C9 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C10 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C11 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C12 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C13 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C14 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C15 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C16 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C17 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C18 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C19 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C20 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C21 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C22 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C23 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C24 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C25 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinate 12C 1.01 ± 0.07 x 108 3.63 ± 0.7 x 107 9.15 ± 1.9 x 106 3.33 ± 1.0 x 106 
succinate 13C1 4.66 ± 0.3 x 10
6 5.43 ± 0.5 x 106 2.66 ± 0.4 x 106 7.94 ± 1.2 x 105 
succinate 13C2 6.72 ± 6.0 x 10
3 2.57 ± 0.2 x 107 1.81 ± 0.2 x 107 7.23 ± 0.5 x 106 
succinate 13C3 4.65 ± 4.2 x 10
3 7.36 ± 0.9 x 106 1.48 ± 0.2 x 107 8.48 ± 0.1 x 106 
succinate 13C4 0 ±  0.0 x 10
0 3.12 ± 0.3 x 107 6.79 ± 1.3 x 107 6.95 ± 0.2 x 107 
fumarate 12C 6.27 ± 0.5 x 106 1.78 ± 0.5 x 106 2.26 ± 0.7 x 105 3.17 ± 2.0 x 104 
fumarate 13C1 1.32 ± 0.1 x 10
5 1.14 ± 0.3 x 105 5.39 ± 1.7 x 104 1.07 ± 0.2 x 104 
fumarate 13C2 6.55 ± 11.3 x 10




Table A-9 continued. 
metabolite labeling  pattern 0 min 2 min 5 min 15 min 
fumarate 13C3 6.55 ± 2.6 x 10
2 1.67 ± 0.3 x 106 1.20 ± 0.5 x 106 5.41 ± 0.8 x 105 
fumarate 13C4 1.14 ± 1.6 x 10
3 3.31 ± 0.5 x 106 3.66 ± 2.3 x 106 2.39 ± 0.3 x 106 
malate 12C 9.38 ± 7.3 x 106 3.27 ± 3.3 x 106 9.89 ± 4.4 x 105 5.59 ± 1.3 x 105 
malate 13C1 4.67 ± 7.8 x 10
5 3.04 ± 3.7 x 105 2.04 ± 1.8 x 105 4.59 ± 2.3 x 104 
malate 13C2 1.36 ± 2.2 x 10
4 1.73 ± 2.6 x 106 7.56 ± 13.1 x 105 5.72 ± 2.7 x 105 
malate 13C3 3.00 ± 5.2 x 10
3 3.43 ± 3.6 x 106 1.38 ± 2.4 x 106 1.90 ± 0.4 x 106 
malate 13C4 2.05 ± 3.56 x 10
3 5.51 ± 5.1 x 106 5.49 ± 9.5 x 106 9.29 ± 1.7 x 106 
6-phospho-D-gluconate 12C 6.06 ± 9.5 x 105 5.21 ± 5.2 x 104 1.29 ± 1.4 x 105 8.34 ± 8.9 x 104 
6-phospho-D-gluconate 13C1 1.75 ± 1.9 x 10
4 1.37 ± 1.3 x 103 1.04 ± 1.8 x 103 2.34 ± 4.1 x 103 
6-phospho-D-gluconate 13C2 5.05 ± 6.1 x 10
3 0 ±  0.0 x 100 2.26 ± 3.9 x 103 2.09 ± 3.6 x 103 
6-phospho-D-gluconate 13C3 8.52 ± 8.2 x 10
2 0 ±  0.0 x 100 1.93 ± 3.3 x 103 0 ±  0.0 x 100 
6-phospho-D-gluconate 13C4 0 ±  0.0 x 10
0 3.86 ± 6.7 x 103 4.43 ± 7.7 x 103 0 ±  0.0 x 100 
6-phospho-D-gluconate 13C5 4.38 ± 6.7 x 10
3 5.21 ± 8.7 x 104 9.72 ± 11.3 x 105 3.58 ± 0.6 x 104 
6-phospho-D-gluconate 13C6 5.26 ± 4.6 x 10
4 1.00 ± 1.7 x 106 2.32 ± 3.6 x 106 5.63 ± 2.5 x 105 
ribose/ ribulose/ xyulose-phosphate 12C 1.62 ± 0.9 x 104 1.51 ± 0.7 x 104 2.40 ± 0.7 x 104 1.99 ± 1.7 x 104 
ribose/ ribulose/ xyulose-phosphate 13C1 4.45 ± 7.7 x 10
2 5.06 ± 7.0 x 102 0 ±  0.0 x 100 3.11 ± 1.7 x 104 
ribose/ ribulose/ xyulose-phosphate 13C2 3.68 ± 3.4 x 10
3 0 ±  0.0 x 100 5.86 ± 10.2 x 103 0 ±  0.0 x 100 
ribose/ ribulose/ xyulose-phosphate 13C3 5.96 ± 5.6 x 10
2 2.47 ± 4.3 x 102 3.78 ± 3.3 x 102 0 ±  0.0 x 100 
ribose/ ribulose/ xyulose-phosphate 13C4 1.51 ± 2.6 x 10
2 1.59 ± 2.8 x 102 1.88 ± 3.3 x 102 0 ±  0.0 x 100 
ribose/ ribulose/ xyulose-phosphate 13C5 1.81 ± 3.1 x 10
2 1.32 ± 1.8 x 103 6.02 ± 10.4 x 102 
8.79 ± 15.2 x 
102 
D-sedoheptulose-1/7-phosphate 12C 2.81 ± 4.2 x 105 2.29 ± 2.5 x 104 6.28 ±9.9 x 104 1.39 ± 0.9 x 105 
D-sedoheptulose-1/7-phosphate 13C1 6.03 ± 10.4 x 10
2 0 ±  0.0 x 100 4.95 ± 8.6 x 102 
9.79 ± 17.0 x 
102 
D-sedoheptulose-1/7-phosphate 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-sedoheptulose-1/7-phosphate 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-sedoheptulose-1/7-phosphate 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-sedoheptulose-1/7-phosphate 13C5 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-sedoheptulose-1/7-phosphate 13C6 0 ±  0.0 x 10
0 4.33 ± 4.5 x 103 1.00 ± 1.2 x 104 6.47 ± 5.0 x 103 
D-sedoheptulose-1/7-phosphate 13C7 5.90 ± 6.5 x 10
4 4.48 ± 6.9 x 105 6.42 ± 8.9 x 105 2.68 ± 1.1 x 105 
D-erythrose-4-phosphate 12C 5.10 ± 4.3 x 104 5.74 ± 4.1 x 104 2.23 ± 2.2 x 104 3.97 ± 2.7 x 104 
D-erythrose-4-phosphate 13C1 9.04 ± 8.5 x 10
2 1.04 ± 1.2 x 103 0 ±  0.0 x 100 3.12 ± 5.4 x 102 
D-erythrose-4-phosphate 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-erythrose-4-phosphate 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-erythrose-4-phosphate 13C4 0 ±  0.0 x 10






Table A-10. The average ion counts plus or minus the standard deviation for each metabolite discussed and 
their isotopomers wild type Salmonella enterica experiment at 30, 60, and 120 minutes are shown. 
metabolite labeling  pattern 30 min 60 min 120 min 
glucose/fructose-6-phosphate 12C 2.63 ± 1.2 x 105 8.30 ± 1.8 x 105 1.49 ± 0.3 x 106 
glucose/fructose-6-phosphate 13C1 7.37 ± 12.8 x 10
3 1.35 ± 1.5 x 104 6.69 ± 0.9 x 104 
glucose/fructose-6-phosphate 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 2.20 ± 3.8 x 103 
glucose/fructose-6-phosphate 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
glucose/fructose-6-phosphate 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
glucose/fructose-6-phosphate 13C5 2.94 ± 0.4 x 10
4 1.87 ± 3.2 x 104 1.34 ± 1.2 x 104 
glucose/fructose-6-phosphate 13C6 3.23 ± 1.3 x 10
5 4.07 ± 7.1 x 105 1.45 ± 1.3 x 105 
fructose-1-6-bisphosphate 12C 1.65 ± 1.5 x 105 8.49 ± 7.2 x 104 7.51 ± 4.9 x 104 
fructose-1-6-bisphosphate 13C1 5.03 ± 2.2 x 10
3 4.98 ± 3.8 x 103 5.01 ± 3.5 x 103 
fructose-1-6-bisphosphate 13C2 8.66 ± 10.2 x 10
2 2.21 ± 1.3 x 103 2.76 ± 4.8 x 102 
fructose-1-6-bisphosphate 13C3 1.20 ± 0.4 x 10
4 1.66 ± 1.1 x 104 6.65 ± 8.2 x 103 
fructose-1-6-bisphosphate 13C4 2.99 ± 0.5 x 10
3 4.92 ± 2.6 x 103 4.20 ± 7.3 x 102 
fructose-1-6-bisphosphate 13C5 7.48 ± 3.9 x 10
3 2.04 ± 1.8 x 104 1.15 ± 1.5 x 104 
fructose-1-6-bisphosphate 13C6 2.91 ± 1.5 x 10
5 5.15 ± 1.5 x 105 2.45 ± 1.8 x 105 
D-glyceraldehdye-3-phosphate 12C 4.04 ± 0.6 x 105 3.64 ± 1.3 x 105 4.85 ± 0.9 x 105 
D-glyceraldehdye-3-phosphate 13C1 2.61 ± 2.6 x 10
4 0 ±  0.0 x 100 9.67 ± 16.7 x 103 
D-glyceraldehdye-3-phosphate 13C2 4.49 ± 0.6 x 10
3 7.19 ± 3.6 x 103 2.45 ± 0.4 x 104 
D-glyceraldehdye-3-phosphate 13C3 1.76 ± 0.4 x 10
5 5.62 ± 2.0 x 105 1.42 ± 0.1 x 106 
1,3-diphopshateglycerate 12C 1.36 ± 1.0 x 104 1.81 ± 0.6 x 104 3.08 ± 1.5 x 104 
1,3-diphopshateglycerate 13C1 1.66 ± 2.9 x 10
3 1.94 ± 1.7 x 103 1.52 ± 2.6 x 103 
1,3-diphopshateglycerate 13C2 9.64 ± 16.7 x 10
2 7.25 ± 12.6 x 102 7.65 ± 3.7 x 103 
1,3-diphopshateglycerate 13C3 1.31 ± 1.2 x 10
4 0 ±  0.0 x 100 1.42 ± 2.1 x 104 
3/2-phosphoglycerate 12C 2.39 ± 0.8 x 104 6.38 ± 4.2 x 103 8.24 ± 8.9 x 103 
3/2-phosphoglycerate 13C1 0 ±  0.0 x 10
0 9.64 ± 16.7 x 102 3.27 ± 5.7 x 102 
3/2-phosphoglycerate 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
3/2-phosphoglycerate 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
pyruvate 12C 5.22 ± 0.4 x 106 3.41 ± 2.1 x 106 3.37 ± 1.8 x 106 
pyruvate 13C1 4.75 ±1.2 x 10
4 3.86 ± 2.7 x 104 1.86 ± 1.7 x 104 
pyruvate 13C2 3.15 ± 0.7 x 10
4 1.99 ± 1.3 x 104 2.36 ± 2.3 x 104 
pyruvate 13C3 3.15 ± 1.4 x 10
6 3.34 ± 0.6 x 106 3.34 ± 0.6 x 106 
alpha-ketoglutarate 12C 2.02 ± 0.7 x 106 1.11 ± 0.6 x 106 7.86 ± 1.7 x 105 
alpha-ketoglutarate 13C1 1.70 ± 0.4 x 10
5 1.17 ± 0.7 x 105 7.78 ± 1.0 x 104 
alpha-ketoglutarate 13C2 1.28 ± 0.4 x 10
6 4.16 ± 1.9 x 105 2.56 ± 0.4 x 105 
alpha-ketoglutarate 13C3 3.19 ± 0.7 x 10




Table A.10 continued. 
metabolite labeling  pattern 30 min 60 min 120 min 
alpha-ketoglutarate 13C4 4.68 ± 1.0 x 10
6 3.06 ± 0.3 x 106 3.42 ± 0.2 x 106 
alpha-ketoglutarate 13C5 1.38 ±0.2 x 10
7 1.13 ± 0.1 x 107 1.32 ± 0.3 x 107 
succinyl-CoA 12C 1.94 ± 1.8 x 104 2.05 ± 1.8 x 103 1.62 ± 2.8 x 103 
succinyl-CoA 13C1 0 ±  0.0 x 10
0 1.01 ± 1.8 x 103 0 ±  0.0 x 100 
succinyl-CoA 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C5 1.75 ± 3.0 x 10
3 0 ±  0.0 x 100 6.90 ± 12.0 x 102 
succinyl-CoA 13C6 0 ±  0.0 x 10
0 0 ±  0.0 x 100 9.18 ± 15.9 x 102 
succinyl-CoA 13C7 0 ±  0.0 x 10
0 1.26 ± 2.2 x 103 0 ±  0.0 x 100 
succinyl-CoA 13C8 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C9 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C10 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C11 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C12 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C13 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C14 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C15 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C16 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C17 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C18 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C19 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C20 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C21 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C22 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C23 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C24 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C25 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinate 12C 3.38 ± 0.2 x 106 3.43 ± 1.7 x 106 2.13 ± 0.9 x 106 
succinate 13C1 1.37 ± 0.3 x 10
6 1.04 ± 0.3 x 106 4.94 ± 1.4 x 105 
succinate 13C2 6.47 ± 0.8 x 10
6 4.77 ± 0.6 x 106 3.09 ± 0.8 x 106 
succinate 13C3 6.49 ± 0.2 x 10
6 5.95 ± 0.3 x 106 4.45 ± 1.4 x 106 
succinate 13C4 3.46 ± 0.5 x 10
7 4.66 ± 0.9 x 107 4.50 ± 1.9 x 107 
fumarate 12C 2.42 ± 2.1 x 104 2.64 ± 2.0 x 104 2.23 ± 1.4 x 104 
fumarate 13C1 2.11 ± 0.4 x 10
4 9.62 ± 8.2 x 103 6.22 ± 5.7 x 103 
fumarate 13C2 1.24 ± 0.3 x 10




Table A-10 continued. 
metabolite labeling  pattern 30 min 60 min 120 min 
fumarate 13C3 3.45 ± 0.5 x 10
5 2.01 ± 0.05 x 105 2.40 ± 0.7 x 105 
fumarate 13C4 1.15 ± 0.2 x 10
6 1.08 ± 0.05 x 106 1.02 ± 0.4 x 106 
malate 12C 6.71 ± 2.9 x 105 8.44 ± 2.9 x 105 5.15 ± 0.9 x 105 
malate 13C1 3.42 ± 1.8 x 10
4 7.19 ± 9.0 x 104 3.44 ± 1.8 x 104 
malate 13C2 5.56 ± 2.1 x 10
5 3.24 ± 2.9 x 105 1.79 ± 1.0 x 105 
malate 13C3 4.29 ± 7.4 x 10
5 1.02 ± 1.0 x 106 6.58 ± 6.1 x 105 
malate 13C4 1.70 ± 1.5 x 10
6 1.18 ± 1.2 x 106 1.68 ± 1.9 x 106 
6-phospho-D-gluconate 12C 1.25 ± 0.9 x 105 8.16 ± 5.1 x 104 4.37 ± 2.7 x 104 
6-phospho-D-gluconate 13C1 0 ±  0.0 x 10
0 7.80 ± 13.5 x 102 0 ±  0.0 x 100 
6-phospho-D-gluconate 13C2 2.05 ± 1.8 x 10
3 0 ±  0.0 x 100 0 ±  0.0 x 100 
6-phospho-D-gluconate 13C3 3.42 ± 5.9 x 10
2 1.34 ± 2.3 x 103 0 ±  0.0 x 100 
6-phospho-D-gluconate 13C4 9.19 ± 15.9 x 10
2 4.09 ± 7.1 x 102 0 ±  0.0 x 100 
6-phospho-D-gluconate 13C5 2.26 ± 2.9 x 10
3 1.86 ± 1.8 x 104 8.18 ± 10.3 x 103 
6-phospho-D-gluconate 13C6 1.81 ± 0.9 x 10
5 2.99 ± 0.7 x 105 2.78 ± 2.7 x 105 
ribose/ ribulose/ xyulose-
phosphate 
12C 1.70 ± 0.5 x 104 1.08 ± 0.4 x 104 3.20 ± 1.8 x 104 
ribose/ ribulose/ xyulose-
phosphate 
13C1 5.06 ± 5.1 x 10
2 0 ±  0.0 x 100 3.72 ± 6.5 x 102 
ribose/ ribulose/ xyulose-
phosphate 
13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 2.48 ± 4.3 x 103 
ribose/ ribulose/ xyulose-
phosphate 
13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
ribose/ ribulose/ xyulose-
phosphate 
13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 1.75 ± 3.0 x 102 
ribose/ ribulose/ xyulose-
phosphate 
13C5 0 ±  0.0 x 10
0 4.06 ± 7.0 x 102 2.67 ± 4.6 x 102 
D-sedoheptulose-1/7-phosphate 12C 1.63 ± 1.9 x 105 3.40 ± 2.1 x 104 2.60 ± 2.6 x 104 
D-sedoheptulose-1/7-phosphate 13C1 0 ±  0.0 x 10
0 4.48 ± 7.8 x 102 0 ±  0.0 x 100 
D-sedoheptulose-1/7-phosphate 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-sedoheptulose-1/7-phosphate 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-sedoheptulose-1/7-phosphate 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-sedoheptulose-1/7-phosphate 13C5 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-sedoheptulose-1/7-phosphate 13C6 5.36 ± 2.3 x 10
3 5.41 ± 3.8 x 103 3.49 ± 1.2 x 103 
D-sedoheptulose-1/7-phosphate 13C7 2.06 ± 1.8 x 10
5 5.78 ± 4.7 x 105 3.89 ± 3.1 x 105 
D-erythrose-4-phosphate 12C 1.33 ± 0.8 x 104 1.08 ± 0.9 x 104 3.13 ± 2.4 x 104 
D-erythrose-4-phosphate 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-erythrose-4-phosphate 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-erythrose-4-phosphate 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-erythrose-4-phosphate 13C4 0 ±  0.0 x 10




Table A-11. The average ion counts plus or minus the standard deviation for the metabolites discussed and 




0 min 2 min 5 min 15 min 
glucose/fructose-6-phosphate 12C 7.67 ± 1.7 x 105 1.79 ± 0.2 x 105 1.05 ± 1.4 x 105 1.67 ± 0.5 x 105 
glucose/fructose-6-phosphate 13C1 8.19 ± 1.0 x 10
4 0 ±  0.0 x 100 1.03 ± 0.6 x 104 0 ±  0.0 x 100 
glucose/fructose-6-phosphate 13C2 3.86 ± 6.7 x 10
3 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
glucose/fructose-6-phosphate 13C3 0 ±  0.0 x 10
0 2.86 ± 5.0 x 103 0 ±  0.0 x 100 0 ±  0.0 x 100 
glucose/fructose-6-phosphate 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 2.67 ± 4.6 x 103 
glucose/fructose-6-phosphate 13C5 0 ±  0.0 x 10
0 8.25 ± 4.0 x 104 6.34 ± 7.3 x 104 1.68 ± 2.9 x 104 
glucose/fructose-6-phosphate 13C6 0 ±  0.0 x 10
0 4.82 ± 3.5 x 105 4.03 ± 6.1 x 105 4.97 ± 5.2 x 105 
fructose-1-6-bisphosphate 12C 2.57 ± 1.9 x 106 9.38 ± 8.8 x 104 6.48 ± 8.4 x 104 1.66 ± 1.7 x 105 
fructose-1-6-bisphosphate 13C1 5.85 ± 7.5 x 10
4 5.76 ± 7.5 x 103 1.22 ± 1.1 x 104 1.89 ± 3.3 x 103 
fructose-1-6-bisphosphate 13C2 2.93 ± 2.2 x 10
4 2.08 ± 2.6 x 104 0 ±  0.0 x 100 1.13 ± 1.6 x 104 
fructose-1-6-bisphosphate 13C3 1.25 ± 1.6 x 10
4 1.24 ± 1.6 x 105 2.14 ± 2.2 x 105 8.98 ± 4.0 x 104 
fructose-1-6-bisphosphate 13C4 1.19 ± 0.6 x 10
4 2.23 ± 3.9 x 104 2.15 ± 2.2 x 104 6.73 ± 11.7 x 103 
fructose-1-6-bisphosphate 13C5 5.88 ± 8.8 x 10
3 5.57 ± 6.5 x 104 2.57 ± 1.5 x 105 1.43 ± 1.5 x 105 
fructose-1-6-bisphosphate 13C6 1.32 ± 1.2 x 10
5 1.40 ± 1.0 x 106 1.13 ± 2.1 x 106 1.80 ± 1.8 x 106 
D-glyceraldehdye-3-phosphate 12C 1.41 ± 0.2 x 106 8.91 ± 1.9 x 105 3.25 ± 10.0 x 105 5.65 ± 1.6 x 105 
D-glyceraldehdye-3-phosphate 13C1 1.32 ± 0.2 x 10
4 1.09 ± 0.5 x 104 1.32 ± 1.4 x 104 1.24 ± 0.6 x 104 
D-glyceraldehdye-3-phosphate 13C2 2.17 ± 1.0 x 10
3 0 ±  0.0 x 100 7.12 ± 6.8 x 102 2.31 ± 0.1 x 103 
D-glyceraldehdye-3-phosphate 13C3 0 ±  0.0 x 10
0 5.55 ± 9.6 x 102 6.10 ± 13.2 x 103 1.00 ± 0.3 x 105 
1,3-diphopshateglycerate 12C 9.31 ± 4.4 x 104 5.05 ± 1.6 x 104 1.20 ± 0.8 x 105 1.11 ± 0.5 x 104 
1,3-diphopshateglycerate 13C1 8.60 ± 14.9 x 10
2 7.47 ± 6.5 x 103 1.48 ± 0.9 x 104 0 ±  0.0 x 100 
1,3-diphopshateglycerate 13C2 9.96 ± 6.3 x 10
3 1.96 ± 1.3 x 104 7.92 ± 7.7 x 103 0 ±  0.0 x 100 
1,3-diphopshateglycerate 13C3 9.29 ± 2.5 x 10
4 3.09 ± 1.9 x 105 2.68 ± 2.0 x 105 5.89 ± 1.8 x 104 
3/2-phosphoglycerate 12C 3.85 ± 4.9 x 104 4.04 ± 1.7 x 104 1.40 ± 4.6 x 104 4.08 ± 1.2 x 104 
3/2-phosphoglycerate 13C1 1.82 ± 1.2 x 10
7 1.16 ± 0.5 x 107 1.02 ± 4.8 x 106 5.38 ± 2.0 x 106 
3/2-phosphoglycerate 13C2 4.79 ± 6.7 x 10
5 1.52 ± 1.1 x 105 3.30 ± 4.5 x 104 2.68 ± 1.8 x 104 
3/2-phosphoglycerate 13C3 0 ±  0.0 x 10
0 2.52 ± 2.5 x 105 1.64 ± 1.7 x 104 5.41 ± 7.1 x 105 
pyruvate 12C 0 ±  0.0 x 100 1.31 ± 0.8 x 107 6.92 ± 9.2 x 106 2.44 ± 1.5 x 107 
pyruvate 13C1 5.19 ± 1.0 x 10
7 3.04 ± 0.5 x 107 1.75 ± 14.9 x 106 3.13 ± 0.2 x 106 
pyruvate 13C2 2.39 ± 0.6 x 10
6 1.70 ± 0.5 x 106 3.49 ± 9.2 x 105 1.38 ± 0.3 x 105 
pyruvate 13C3 1.64 ± 0.4 x 10
5 6.80 ± 1.1 x 106 1.87 ± 9.0 x 106 2.50 ± 0.7 x 106 











0 min 2 min 5 min 15 min 
alpha-ketoglutarate 13C1 0 ±  0.0 x 10
0 2.41 ± 0.4 x 106 2.10 ± 8.3 x 106 1.16 ± 0.1 x 107 
alpha-ketoglutarate 13C2 1.62 ± 2.8 x 10
3 2.16 ± 0.7 x 106 3.90 ± 11.1 x 106 3.70 ± 0.3 x 107 
alpha-ketoglutarate 13C3 1.77 ± 0.9 x 10
5 1.66 ± 2.1 x 104 3.35 ± 3.8 x 104 6.61 ± 6.7 x 103 
alpha-ketoglutarate 13C4 3.93 ± 2.1 x 10
4 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
alpha-ketoglutarate 13C5 0 ±  0.0 x 10
0 1.08 ± 1.9 x 104 1.90 ± 1.1 x 104 1.84 ± 3.2 x 103 
succinyl-CoA 12C 0 ±  0.0 x 100 1.97 ± 3.4 x 103 1.25 ± 0.9 x 104 2.58 ± 4.5 x 103 
succinyl-CoA 13C1 0 ±  0.0 x 10
0 1.85 ± 3.2 x 103 0 ±  0.0 x 100 1.41 ± 2.5 x 104 
succinyl-CoA 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C5 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C6 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 2.28 ± 4.0 x 103 
succinyl-CoA 13C7 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C8 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C9 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C10 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C11 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C12 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C13 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C14 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C15 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C16 1.15 ± 2.0 x 10
3 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C17 1.13 ± 2.0 x 10
3 1.38 ± 2.4 x 103 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C18 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C19 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C20 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C21 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C22 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C23 3.99 ± 1.1 x 10
7 2.07 ± 1.0 x 107 3.91 ± 11.8 x 106 1.71 ± 0.6 x 106 
succinyl-CoA 13C24 1.80 ± 0.5 x 10
6 1.44 ± 0.8 x 106 3.73 ± 14.6 x 105 1.62 ± 1.4 x 105 
succinyl-CoA 13C25 1.68 ± 0.7 x 10
4 6.72 ± 2.8 x 106 2.51 ± 9.3 x 106 2.05 ± 1.8 x 106 
succinate 12C 1.29 ± 2.2 x 103 9.24 ± 5.2 x 105 1.74 ± 4.5 x 106 2.89 ± 2.5 x 106 
succinate 13C1 4.40 ± 7.6 x 10
4 3.81 ± 1.7 x 106 5.19 ± 13.3 x 106 1.97 ± 1.7 x 107 
succinate 13C2 2.77 ± 0.7 x 10
6 1.04 ± 0.5 x 106 1.11 ± 2.6 x 105 2.27 ± 0.3 x 104 
succinate 13C3 3.76 ± 1.4 x 10









0 min 2 min 5 min 15 min 
succinate 13C4 8.12 ± 10.5 x 10
2 2.38 ± 1.3 x 105 1.22 ± 2.2 x 105 5.30 ± 0.3 x 104 
fumarate 12C 7.56 ± 8.6 x 102 4.16 ± 2.3 x 105 1.98 ± 3.2 x 105 3.07 ± 0.2 x 105 
fumarate 13C1 2.49 ± 2.8 x 10
3 3.02 ± 2.1 x 105 3.94 ± 6.5 x 105 1.13 ± 0.2 x 106 
fumarate 13C2 2.14 ± 0.7 x 10
7 3.93 ± 3.0 x 106 8.41 ± 22.6 x 105 5.75 ± 0.8 x 105 
fumarate 13C3 4.26 ± 5.8 x 10
5 4.91 ± 6.1 x 105 1.73 ± 1.6 x 105 3.14 ± 3.7 x 104 
fumarate 13C4 3.02 ± 2.8 x 10
4 1.33 ± 0.9 x 106 1.02 ±2.3 x 106 5.60 ± 7.3 x 105 
malate 12C 3.62 ± 3.3 x 103 9.96 ± 11.9 x 105 1.71 ± 3.5 x 106 1.80 ± 2.1 x 106 
malate 13C1 6.69 ± 11.6 x 10
3 1.01 ± 1.5 x 106 3.48 ± 6.0 x 106 6.54 ± 9.2 x 106 
malate 13C2 4.47 ± 2.2 x 10
3 4.77 ± 3.5 x 103 2.00 ± 3.0 x 103 4.89 ± 1.3 x 103 
malate 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
malate 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
6-phospho-D-gluconate 12C 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
6-phospho-D-gluconate 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
6-phospho-D-gluconate 13C2 3.10 ± 3.2 x 10
6 4.46 ± 3.4 x 104 1.53 ± 1.2 x 105 1.19 ± 1.0 x 105 
6-phospho-D-gluconate 13C3 1.75 ± 2.2 x 10
5 2.94 ± 5.1 x 103 1.19 ± 0.9 x 104 5.04 ± 4.9 x 103 
6-phospho-D-gluconate 13C4 2.82 ± 4.1 x 10
4 1.17 ± 2.0 x 103 2.16 ± 2.5 x 103 2.94 ± 5.1 x 102 
6-phospho-D-gluconate 13C5 1.25 ± 2.2 x 10
3 1.77 ± 2.0 x 104 4.39 ± 3.1 x 104 1.82 ± 1.0 x 104 
6-phospho-D-gluconate 13C6 0 ±  0.0 x 10
0 1.99 ± 2.7 x 103 4.55 ± 2.9 x 104 1.29 ± 0.6 x 104 
ribose/ ribulose/ xyulose-phosphate 12C 4.70 ± 4.2 x 104 3.29 ± 3.0 x 104 2.50 ± 1.7 x 105 1.31 ± 0.6 x 105 
ribose/ ribulose/ xyulose-phosphate 13C1 8.96 ± 11.3 x 10
5 5.40 ± 4.3 x 105 4.06 ± 2.8 x 106 2.47 ± 1.3 x 106 
ribose/ ribulose/ xyulose-phosphate 13C2 1.33 ± 1.0 x 10
4 1.32 ± 0.5 x 104 1.94 ± 1.7 x 104 2.10 ± 1.5 x 104 
ribose/ ribulose/ xyulose-phosphate 13C3 3.62 ± 3.2 x 10
2 1.57 ± 2.7 x 102 3.72 ± 2.2 x 102 0 ±  0.0 x 100 
ribose/ ribulose/ xyulose-phosphate 13C4 4.55 ± 7.9 x 10
3 2.74 ± 4.8 x 103 5.92 ± 3.4 x 103 1.14 ± 0.1 x 104 
ribose/ ribulose/ xyulose-phosphate 13C5 0 ±  0.0 x 10
0 1.88 ± 3.3 x 102 6.83 ± 7.8 x 102 3.04 ± 0.6 x 103 
D-sedoheptulose-1/7-phosphate 12C 0 ±  0.0 x 100 0 ±  0.0 x 100 3.13 ± 1.8 x 102 1.74 ± 3.0 x 102 
D-sedoheptulose-1/7-phosphate 13C1 1.65 ± 2.9 x 10
2 1.93 ± 3.3 x 103 0 ±  0.0 x 100 1.17 ± 2.0 x 103 
D-sedoheptulose-1/7-phosphate 13C2 2.39 ± 1.0 x 10
6 1.65 ± 1.5 x 104 5.75 ± 4.1 x 104 8.40 ± 8.9 x 104 
D-sedoheptulose-1/7-phosphate 13C3 4.76 ± 4.3 x 10
4 0 ±  0.0 x 100 2.03 ± 1.8 x 103 9.43 ± 16.3 x 102 
D-sedoheptulose-1/7-phosphate 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-sedoheptulose-1/7-phosphate 13C5 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-sedoheptulose-1/7-phosphate 13C6 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-sedoheptulose-1/7-phosphate 13C7 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 0 ±  0.0 x 100 











0 min 2 min 5 min 15 min 
D-erythrose-4-phosphate 13C1 2.00 ± 1.2 x 10
5 1.20 ± 0.5 x 106 1.34 ± 2.1 x 106 1.79 ± 0.2 x 106 
D-erythrose-4-phosphate 13C2 7.84 ± 0.8 x 10
4 5.30 ± 6.7 x 104 1.95 ± 6.7 x 104 7.33 ± 2.4 x 104 
D-erythrose-4-phosphate 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 3.90 ± 6.8 x 102 
D-erythrose-4-phosphate 13C4 0 ±  0.0 x 10


























Table A-12. The average ion counts plus or minus the standard deviation for the metabolites discussed and 




30 min 60 min 120 min 
glucose/fructose-6-phosphate 12C 1.91 ± 0.5 x 105 2.59 ± 1.1 x 105 4.87 ± 2.4 x 105 
glucose/fructose-6-phosphate 13C1 2.85 ± 4.9 x 10
3 1.05 ± 1.8 x 104 8.20 ± 8.8 x 103 
glucose/fructose-6-phosphate 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
glucose/fructose-6-phosphate 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
glucose/fructose-6-phosphate 13C4 2.63 ± 4.6 x 10
3 0 ±  0.0 x 100 0 ±  0.0 x 100 
glucose/fructose-6-phosphate 13C5 4.38 ± 5.9 x 10
4 
8.61 ± 14.9 x 
103 
4.00 ± 5.6 x 104 
glucose/fructose-6-phosphate 13C6 2.91 ± 2.4 x 10
5 0 ±  0.0 x 100 1.67 ± 2.4 x 105 
fructose-1-6-bisphosphate 12C 4.08 ± 6.7 x 105 1.04 ± 0.7 x 105 2.75 ± 1.9 x 105 
fructose-1-6-bisphosphate 13C1 7.28 ± 9.5 x 10
3 0 ±  0.0 x 100 1.86 ± 1.7 x 104 
fructose-1-6-bisphosphate 13C2 1.79 ± 3.1 x 10
3 0 ±  0.0 x 100 9.28 ± 10.1 x 103 
fructose-1-6-bisphosphate 13C3 1.51 ± 1.6 x 10
4 1.30 ± 1.9 x 104 1.18 ± 1.1 x 104 
fructose-1-6-bisphosphate 13C4 1.34 ± 1.7 x 10
4 2.50 ± 4.3 x 103 5.39 ± 4.9 x 103 
fructose-1-6-bisphosphate 13C5 2.23 ± 3.9 x 10
5 4.10 ± 5.6 x 104 1.15 ± 1.7 x 105 
fructose-1-6-bisphosphate 13C6 1.86 ± 3.2 x 10
6 
7.41 ± 11.8 x 
105 
1.00 ± 1.4 x 106 
D-glyceraldehdye-3-phosphate 12C 7.80 ± 4.4 x 105 4.24 ± 0.8 x 105 5.66 ± 2.5 x 105 
D-glyceraldehdye-3-phosphate 13C1 1.08 ± 0.5 x 10
4 1.15 ± 1.6 x 104 1.60 ± 1.4 x 104 
D-glyceraldehdye-3-phosphate 13C2 3.74 ± 5.5 x 10
3 1.40 ± 1.7 x 104 5.68 ± 4.3 x 104 
D-glyceraldehdye-3-phosphate 13C3 2.94 ± 3.9 x 10
5 1.12 ± 1.6 x 106 3.63 ± 2.8 x 106 
1,3-diphopshateglycerate 12C 1.67 ± 2.1 x 104 8.41 ± 4.9 x 103 2.42 ± 2.0 x 104 
1,3-diphopshateglycerate 13C1 0 ±  0.0 x 10
0 5.68 ± 9.9 x 102 1.82 ± 3.2 x 103 
1,3-diphopshateglycerate 13C2 2.03 ± 2.3 x 10
3 2.75 ± 3.8 x 103 4.56 ± 3.6 x 103 
1,3-diphopshateglycerate 13C3 4.90 ± 4.9 x 10
4 2.64 ± 3.6 x 104 1.19 ± 1.0 x 105 
3/2-phosphoglycerate 12C 6.13 ± 5.3 x 104 2.24 ± 0.6 x 104 3.70 ± 3.8 x 104 
3/2-phosphoglycerate 13C1 5.22 ± 1.4 x 10
6 2.42 ± 1.1 x 106 2.99 ± 0.4 x 106 
3/2-phosphoglycerate 13C2 1.93 ± 1.8 x 10
4 3.16 ± 1.3 x 104 2.40 ± 0.7 x 104 
3/2-phosphoglycerate 13C3 3.47 ± 5.8 x 10
5 
7.00 ± 12.0 x 
105 
8.19 ± 11.9 x 104 
pyruvate 12C 1.39 ± 2.0 x 107 1.74 ± 2.9 x 107 9.67 ±12.1 x 106 
pyruvate 13C1 1.94 ± 0.6 x 10
6 1.69 ± 1.2 x 106 6.66 ± 2.3 x 105 
pyruvate 13C2 1.97 ± 1.1 x 10
5 1.34 ±  0.9 x 105 5.13 ± 3.0 x 104 
pyruvate 13C3 1.67 ± 0.9 x 10
6 7.69 ± 4.0 x 105 2.63 ± 1.6 x 105 
alpha-ketoglutarate 12C 4.47 ± 0.5 x 106 2.47 ± 0.4 x 106 1.88 ± 0.3 x 106 
alpha-ketoglutarate 13C1 7.96 ± 3.4 x 10









30 min 60 min 120 min 
alpha-ketoglutarate 13C2 2.85 ± 2.7 x 10
7 3.33 ± 4.2 x 107 4.92 ± 4.5 x 107 
alpha-ketoglutarate 13C3 1.34 ± 1.5 x 10
4 4.73 ± 1.1 x 103 2.06 ± 2.9 x 104 
alpha-ketoglutarate 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
alpha-ketoglutarate 13C5 2.30 ± 2.0 x 10
3 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 12C 4.25 ± 7.4 x 103 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C1 0 ±  0.0 x 10
0 1.08 ± 1.9 x 103 0 ±  0.0 x 100 
succinyl-CoA 13C2 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C3 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C5 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C6 0 ±  0.0 x 10
0 0 ±  0.0 x 100 1.40 ± 2.4 x 103 
succinyl-CoA 13C7 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C8 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C9 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C10 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C11 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C12 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C13 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C14 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C15 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C16 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C17 0 ±  0.0 x 10
0 0 ±  0.0 x 100 1.47 ± 2.6 x 104 
succinyl-CoA 13C18 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C19 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C20 1.46 ± 2.5 x 10
3 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C21 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C22 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
succinyl-CoA 13C23 4.04 ± 2.1 x 10
6 2.30 ± 0.7 x 106 2.59 ± 0.3 x 106 
succinyl-CoA 13C24 9.52 ± 8.3 x 10
5 4.98 ± 4.3 x 105 2.26 ± 1.8 x 105 
succinyl-CoA 13C25 4.05 ± 2.1 x 10
6 2.16 ± 1.0 x 106 1.96 ± 0.1 x 106 
succinate 12C 4.92 ± 1.9 x 106 3.2 ± 1.1 x 106 4.54 ± 2.2 x 106 
succinate 13C1 2.54 ± 2.0 x 10
7 2.81 ± 3.0 x 107 5.76 ± 4.7 x 107 
succinate 13C2 3.91 ± 0.9 x 10
4 1.79 ± 0.9 x 104 8.99 ± 7.5 x 103 
succinate 13C3 2.09 ± 1.1 x 10
4 9.27 ± 6.7 x 103 1.48 ± 1.3 x 103 
succinate 13C4 1.23 ± 0.9 x 10
5 5.24 ± 2.5 x 104 1.49 ± 1.0 x 104 








30 min 60 min 120 min 
fumarate 13C1 1.22 ± 0.8 x 10
6 1.34 ± 1.2 x 106 2.14 ± 1.8 x 106 
fumarate 13C2 9.92 ± 1.2 x 10
5 8.51 ± 1.3 x 105 7.75 ± 2.1 x 105 
fumarate 13C3 3.07 ± 2.2 x 10
5 1.04 ± 1.3 x 105 2.29 ± 2.1 x 104 
fumarate 13C4 1.65 ± 0.9 x 10
6 6.05 ± 5.0 x 105 2.04 ± 1.5 x 105 
malate 12C 4.12 ± 2.0 x 106 3.81 ± 2.2 x 106 1.81 ± 0.5 x 106 
malate 13C1 1.14 ± 0.5 x 10
7 1.74 ± 2.2 x 107 1.35 ± 0.8 x 107 
malate 13C2 2.93 ± 1.4 x 10
3 4.02 ± 2.8 x 103 4.33 ± 1.3 x 103 
malate 13C3 0 ±  0.0 x 10
0 1.99 ± 3.4 x 102 0 ±  0.0 x 100 
malate 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
6-phospho-D-gluconate 12C 2.39 ± 4.1 x 102 0 ±  0.0 x 100 0 ±  0.0 x 100 
6-phospho-D-gluconate 13C1 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
6-phospho-D-gluconate 13C2 4.22 ± 5.6 x 10
5 1.53 ± 1.7 x 105 2.00 ± 1.9 x 105 
6-phospho-D-gluconate 13C3 2.38 ± 3.4 x 10
4 8.99 ± 8.7 x 103 1.02 ± 0.5 x 104 
6-phospho-D-gluconate 13C4 4.70 ± 6.7 x 10
3 
9.67 ± 10.8 x 
102 
8.50 ± 14.7 x 102 
6-phospho-D-gluconate 13C5 7.73 ± 8.6 x 10
3 7.53 ± 3.6 x 103 1.79 ± 0.9 x 103 
6-phospho-D-gluconate 13C6 1.14 ± 0.9 x 10
4 3.57 ± 4.7 x 103 5.75 ± 0.5 x 103 
ribose/ ribulose/ xyulose-
phosphate 
12C 1.45 ± 2.3 x 105 
9.75 ± 13.8 x 
104 
9.24 ± 13.1 x 104 
ribose/ ribulose/ xyulose-
phosphate 
13C1 2.67 ± 3.6 x 10
6 1.84 ± 2.6 x 106 2.18 ± 2.7 x 106 
ribose/ ribulose/ xyulose-
phosphate 
13C2 4.28 ± 1.2 x 10
4 3.20 ± 0.3 x 104 3.08 ± 2.4 x 104 
ribose/ ribulose/ xyulose-
phosphate 
13C3 2.37 ± 4.1 x 10
2 0 ±  0.0 x 100 0 ±  0.0 x 100 
ribose/ ribulose/ xyulose-
phosphate 
13C4 8.83 ± 10.1 x 10
3 8.02 ± 7.4 x 103 8.25 ± 1.9 x 103 
ribose/ ribulose/ xyulose-
phosphate 
13C5 7.45 ± 13.1 x 10
2 0 ±  0.0 x 100 9.31 ± 16.1 x 102 
D-sedoheptulose-1/7-phosphate 12C 1.61 ± 2.8 x 102 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-sedoheptulose-1/7-phosphate 13C1 0 ±  0.0 x 10
0 1.72 ± 2.5 x 103 1.60 ± 2.8 x 103 
D-sedoheptulose-1/7-phosphate 13C2 1.28 ± 1.1 x 10
5 2.30 ± 2.4 x 104 1.69 ± 1.8 x 105 
D-sedoheptulose-1/7-phosphate 13C3 9.21 ± 16.0 x 10
2 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-sedoheptulose-1/7-phosphate 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-sedoheptulose-1/7-phosphate 13C5 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-sedoheptulose-1/7-phosphate 13C6 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-sedoheptulose-1/7-phosphate 13C7 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
D-erythrose-4-phosphate 12C 3.18 ± 3.9 x 104 2.90 ± 4.0 x 104 3.10 ± 4.1 x 104 
D-erythrose-4-phosphate 13C1 1.09 ± 1.1 x 10
6 1.00 ± 1.2 x 106 1.26 ± 1.2 x 106 
D-erythrose-4-phosphate 13C2 8.29 ± 4.5 x 10








30 min 60 min 120 min 
D-erythrose-4-phosphate 13C3 9.01 ± 15.6 x 10
2 0 ±  0.0 x 100 4.32 ± 7.5 x 102 
D-erythrose-4-phosphate 13C4 0 ±  0.0 x 10
0 0 ±  0.0 x 100 0 ±  0.0 x 100 
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